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Mental health
Mental disorders are common [1-3]. In the Netherlands, lifetime prevalence of 
one or more mental disorders in adults has been found to be 42.7% [2]. Being 
affected by a mental disorder can result in a high disease burden, both for the 
affected individuals as well as for their environment and society [4-7]. For the 
patient, this burden primarily relates to the quality of life losses related to mental 
disorders, which can be substantial [8-10]. For the patients’ environment, mental 
health problems may lead to disturbed personal relationships, stress, and strain 
on caregivers [11, 12]. The societal burden related to mental disorders includes 
aspects like the high health care costs of treating mental disorders [13,14, 6], 
losses of productivity due to absenteeism and reduced working capacity [15, 16], 
as well as pressure on sectors such as social care, education and criminal justice 
[17-19]. Due to these broad impacts of mental disorders at several levels and in 
different sectors, specifying the overall burden of the disorders is a complex and 
challenging task.
Externalizing mental disorders in adolescents
The multifaceted and substantial impact of mental disorders also holds for 
externalizing mental disorders in adolescents. Externalizing disorders are mental 
disorders, like Attention-Deficit-Hyperactivity Disorder (ADHD), Conduct 
Disorder (CD) and Antisocial Personality Disorder, which are outwardly directed 
and therefore, by definition, do not only affect the patient, but also his or her 
environment. These disorders are therefore associated with a particularly wide 
variety of costs and effects. Symptoms of these disorders range from concentration 
problems and restlessness or disobedience to aggressive behavior, violence and 
substance use [20-22]. Patients may experience significant impairments in social, 
academic or occupational functioning [20, 23-25]. This can create high individual 
and societal burdens, both within and beyond the health care sector. Especially 
in younger patients, this burden will include aspects such as school performance, 
criminal activity, disturbed relationships with parents and siblings, and so forth. 
Several psychotherapeutic and psychosocial interventions for treatment of 
externalizing disorders exist, including, for example, Functional Family Therapy 
(FFT), Multisystemic Therapy (MST), Multidimensional Family Therapy (MDFT), 
Cognitive Behavioral Therapy (CGT), parent training, and community-based 
interventions [26-29]. Some of these interventions are specifically directed at 
improving patients’ interactions with the various systems around them (i.e., 
parents, siblings, peers, teachers, colleagues, neighbors, ‘society as a whole’).
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Budget limitations
The broad and diverse impacts of externalizing disorders in adolescents and 
related intervention strategies pose clear challenges for evaluating the (costs 
and) effects of such interventions. Nonetheless, such evaluations are needed. 
To date, limited information is available regarding the costs and effects of 
these interventions. Yet, this information is of high importance for medical 
and policy decisions concerning preferred treatment and the funding thereof. 
In recent years, changes in government policy, technological advances, 
increasing wealth and population ageing have contributed to increasing health 
care expenditures [30-32]. In the Netherlands, also as a result of changes in 
government policy, mental health care expenses rose more (+105%) than overall 
health care expenditures (+49%) [33] between 2000 and 2010. This raises questions 
regarding the sustainability of such expenditures and growth rates as well as 
the justification of how budgets are spent, given that resources are limited and 
more spending on (mental) health care has opportunity costs inside and outside 
the health care sector. Ideally, limited resources would be allocated in the most 
efficient way, so that they optimally contribute to improving overall health or 
welfare. However, a lack of information on costs and effects of interventions 
makes it difficult to provide evidence-based advice to policymakers on which 
interventions contribute optimally to their goals.
Health economic evaluation has become a commonly used tool to inform such 
policy and budget decisions [34]. Yet, to what extent the classical health economic 
methodology sufficiently and adequately captures the broad costs and effects 
of mental health interventions in adolescents with externalizing disorders 
remains a matter of debate. This has been previously highlighted for complex 
mental health conditions and mental disorders in general by Brazier et al. [35, 
36] and Knapp et al. [37]. The lack of information on costs and effects of mental 
interventions, together with questions concerning the suitability of the common 
methodology used in economic evaluations to assess these, is at odds with the 
societal and scientific relevance of providing more insight into these issues. 
This is especially the case when policy makers wish to stimulate effective and 
cost-effective treatments of adolescents with mental disorders (and externalizing 
disorders in particular).
Economic evaluations
In health economic analysis costs are compared to the benefits of an intervention. 
The aim of the analysis, when taking a societal perspective, is to answer the 
1
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question as to whether the benefits exceed the costs, thus demonstrating that 
intervention results in an increase in societal welfare. Several types of health 
economic evaluation exist. Classical cost-benefit analysis (CBA) compares 
costs and benefits both expressed in monetary units. It directly answers the 
question whether benefits exceed the costs of the intervention. Whereas CBA is 
more common in other sectors, it is used less often in health care. There, cost-
effectiveness analysis (CEA) is more common. CEA compares costs expressed 
in monetary units with effects expressed in a unit relevant to the outcome of the 
intervention (i.e., costs per life year gained, costs per hip fracture avoided, costs 
per point decrease on some clinical scale, etc.). The advantage of doing this is 
that such outcomes, which cannot easily be expressed in monetary terms, relate 
well to the clinical practice and can still be evaluated. Yet, a disadvantage is 
that CEA uses diverse outcomes across settings, which limits comparability of 
results and hence consistency of decision making. CEA can be quite useful in a 
clinical setting therefore, but when aiming to inform societal decision-making, 
comparability between different interventions is important in order to judge 
which intervention contributes most to health and welfare in relation to its costs. 
Cost-utility analysis (CUA) is more suitable for this goal. In CUAs, costs are 
measured in terms of monetary units and outcomes are evaluated in terms of 
quality adjusted life years (QALYs). The QALY measure comprises both length 
and quality of life, the latter expressed in quality of life weights typically based 
on preferences in the general public for different health states. These health 
states are measured using (generic or disease-specific) health-related quality of 
life measures like the EQ-5D [38]. Using the QALY, outcomes of analyses become 
comparable across interventions without (directly) monetarizing these effects. In 
the Netherlands, like in several other countries (e.g., Canada, Australia, and the 
UK), specific guidelines for the performance of economic evaluations have been 
developed. These guidelines suggest CUA as the preferred methodology [39, 40].1
Connecting economic evaluations and mental health
Performing health economic evaluations in mental health care, regardless of 
whether they take the form of a CBA, CEA or CUA, is challenging. Measuring 
outcomes of mental health interventions is not yet as common as the assessment 
of physical symptoms in medical care [41]. It is often difficult and even contentious 
to measure and value the broad benefits of mental health interventions. The 
1 The terms CEA and CUA are often used interchangeably. CEA is generally used when natural 
units are involved and CUA when outcomes are measured in terms of QALYs. In this disserta-
tion, we use the expression CEA as an overarching term unless otherwise indicated in the text.
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measurement and valuation of these broad benefits is hampered by the fact 
that standardized instruments specifically designed for this purpose and 
suitable for inclusion in economic evaluations are lacking, and that there are 
questions regarding whether conventional QALY measures are adequate in this 
context [35-37]. Similar concerns exist regarding identifying, measuring and 
valuing the broad variety of societal costs (and savings) associated with mental 
health disorders and their treatments. It has been previously suggested that the 
current methodology of CUA mainly focuses on improvements in health and 
may insufficiently capture broader effects of interventions [42]. This criticism 
seems relevant for sectors like social care and elderly care, but also for mental 
health, with broad personal and societal impacts, rendering traditional outcome 
measures like QALY instruments and included cost-categories potentially 
insufficient for a full welfare economic assessment of these interventions. Given 
these concerns, there is an ongoing debate about the suitability of the current 
methodology of economic evaluations, also in the context of mental health [35, 
43]. The discussion is wide-ranging and concerns issues such as the QALY not 
being able to capture treatment goals more broadly than the health dimension 
alone [37, 44], the inclusion of effects related to work or family functioning [35], 
and the inclusion of broader societal costs and benefits such as productivity 
losses and informal care [45, 46]. 
Performing economic evaluations of externalizing disorders in 
adolescents
CUAs of interventions to treat externalizing disorders are scarce [47]. In line 
with what was mentioned above, measuring the effects of interventions for 
externalizing disorders in adolescents can be considered particularly challenging, 
as (intended) treatment effects may be broader than health gains alone. Due 
to the interactional characteristics of both the disorders and the interventions, 
interventions may (intend to) affect the system around the patient as well (e.g., 
improvements in social interactions, school performance, reduction of violence 
or substance use, etc). Such broader impacts may result in changes in the health 
or wellbeing of patients and their families, as well as in societal costs or savings. 
Therefore, particular attention would be required to capture these broad costs and 
effects when determining the cost-effectiveness of an intervention. Furthermore, 
long-term effects play an important role in this patient population as treatment 
during adolescence may prevent problems later on in life, such as delinquency or 
the need for more intensive and complex treatments (for the patient, the system 
or victims). These issues need particular attention when evaluating the costs and 
1
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effects of interventions for externalizing disorders in adolescents. Within the 
current health economic methodology this long-term horizon can be taken into 
consideration using health economic modeling techniques, which may however 
be complex in light of the above-mentioned contextual costs and effects of mental 
disorders in adolescents with externalizing disorders. 
Objective
The overall aim of this dissertation is therefore to explore different ways of 
improving the methodology of economic evaluations of interventions for 
externalizing disorders in adolescents. This thesis takes first (explorative) 
steps in addressing this issue and bridging the gap between the specific goals 
of interventions for adolescents with externalizing behavioral disorders and 
conventional health economic methodology. We investigate this by first applying 
conventional methodology (using health economic modeling techniques, value 
of information analysis and the QALY as outcome measure), then using a simple 
one-dimensional alternative outcome measure, and finally developing a broader, 
preference based outcome measure.  Ultimately, this thesis aims to contribute 
to the improvement of health economic evaluations of interventions targeted 
at externalizing mental disorders, making such evaluations more valuable for 
policymaking. 
In this thesis, a number of steps will be taken in designing a comprehensive 
outcome measure, potentially useful in evaluations of interventions aimed 
at treating externalizing disorders. We note upfront that having a separate 
measure for this context necessarily compromises comparability of results of 
economic evaluations across different settings. However, it also improves the 
comprehensiveness of the captured benefits deemed important in the context of 
mental health. Hence, in this search, we may sacrifice part of the comparability 
between interventions in exchange for a more comprehensive and meaningful 
outcome measure.
Outline
This thesis consists of different chapters, which are all based on independently 
readable papers. Each of the chapters addresses a specific research question, 
related to the overall aim of this thesis. These research questions are listed below. 
Chapter 2: How can a cost-effectiveness analysis for pharmacological treatment 
  of an externalizing disorder (ADHD) be performed, including 
Binnenwerk werkbestand Saskia.indd   12 28-10-2019   12:38:52
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  consideration of relevant broader societal impacts while using 
  conventional health economic methodology? 
Chapter 3:  What do we know about the cost-effectiveness of systemic interventions 
  for delinquency and substance use?
Chapter 4:  Can we perform a cost-effectiveness analysis of a systemic intervention 
  for delinquency in adolescents using Criminal Activity Free Years as 
  outcome measure?
Chapter 5:  Can we perform a Value of Information analysis based on the cost- 
  effectiveness analysis using Criminal Activity Free Years as outcome  
  measure, to inform future research?
Chapter 6:  Which treatment effects should be captured in economic evaluations 
  of systemic interventions in adolescents according to clinicians and do 
  existing QALY measures capture these?
Chapter 7:  Which outcome measures are currently used to measure the effects of 
  systemic interventions in clinical research and could these be used in  
  cost-utility analyses?
Chapter 8: Is it possible to obtain societal preference-weights for a comprehensive 
  multidimensional outcome measure to be used in economic evaluations 
  of systemic interventions targeted at adolescents with problems of 
  substance use and delinquency?
The thesis outline is as follows. Chapter 1 provided a background on economic 
evaluations in relation to specific characteristics and challenges of externalizing 
disorders and interventions aimed at these. It also introduced the goal of this 
dissertation.
In chapters 2 and 3 the ‘standard approach’ of economic evaluation in health 
care is applied in the context of interventions in the field of mental health, and 
the literature is reviewed to learn more about the outcomes of such applications 
for interventions for externalizing behavioral disorders. Specifically, chapter 
2 reports the results of a classical probabilistic CUA, investigating treatment 
of children and adolescents with ADHD with short-acting or long-acting 
methylphenidate. The analysis applies commonly used health-related outcomes, 
but includes some relevant broader societal aspects. Chapter 3 provides an 
overview of what is known regarding cost-effectiveness of interventions for 
externalizing behavioral disorders, based on a systematic literature review.
1
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In chapters 4 and 5, we highlight how economic evaluations of mental health 
interventions could be performed using a tailored, yet very simple, outcome 
measure: Criminal Activity Free Years (CAFY). In chapter 4, a classical 
probabilistic CEA model is used to evaluate Functional Family Therapy (FFT), 
a systemic intervention, compared to treatment as usual, using the CAFY. 
Chapter 5 builds on the results from chapter 4 by investigating the value of 
future research on specific parameters of this classical CEA model, using value of 
information analysis. Obviously, while showing that standard methodology can 
be applied using a context specific outcome measure, the measure used in these 
two chapters is crude, narrow and (too) simple. For instance, it only considers 
criminal activity as a relevant outcome and assigns the same weight to different 
delinquent activities (i.e., the same weight for stealing a bike as for murder).
Given these limitations, chapters 6, 7 and 8 further investigate how the 
existing CUA methodology could be improved in the context of mental health 
interventions. Ideally, a comprehensive multidimensional outcome measure 
with societal preference-weights would exist that could be used in this context. 
Chapter 6 first examines, based on interviews with clinicians, which effects 
according to these professionals should be captured in cost-effectiveness 
analyses of systemic interventions, also given the envisioned therapeutic 
goals, and whether current generic QALY measures capture these. Chapter 7 
summarizes the results of a systematic literature review of outcome measures 
used in evaluations of systemic interventions. We also investigate whether one 
of the existing measures found in the review captures all relevant outcomes of 
systemic interventions and can be considered suitable for use in CUA. Chapter 
8 determines societal preference-weights for a (shortened) multidimensional 
instrument that was labeled as being promising in chapter 7, as to make it 
suitable for use in CUA of systemic interventions.
Chapter 9 presents the main conclusions of this thesis, reflects on the results and 
provides suggestions for further research.
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Introduction
An increasing incidence of attention deficit hyperactivity disorder (ADHD) in 
children [1] and high use of pharmacological treatments [2] have become relevant 
issues for policymakers and mental health professionals. It is yet unclear whether 
the increase in incidence is due to changes in true numbers of patients or whether 
numbers appear higher as a consequence of differences in diagnosis or recall 
of parents [3]. The high number of young ADHD patients results in significant 
societal costs [4]. Evidence from literature suggests that 50-70% of those suffering 
from ADHD in childhood also experience ADHD as an adult [5, 6]. Hence costs 
are not limited to the short term; ADHD may also result in lower household 
income, mental and physical dysfunction, comorbidities and increased health 
consumption later on in life [6, 7] as well as increased health care consumption 
and productivity losses of household members [8]. 
First-choice medication for treatment of ADHD in the Netherlands is the 
stimulant methylphenidate (MPH) [9]. MPH is available as a short-acting as well 
as a more costly long-acting formulation. Different formulations are available 
from a wide selection of brands and in different strengths. Short-acting MPH 
requires accurate medication intake 2-5 times a day [9]. Consequently, medication 
intake may require high effort and impose practical difficulties, for example, 
on children attending school. The long-acting formula has been developed to 
overcome those practical problems of medication intake and compliance by 
using a once-a-day treatment scheme [10]. Existing clinical studies suggest 
no significant difference between the efficacy of short-acting and long-acting 
MPH under the assumption of full therapy compliance [10-12]. However, it 
has been shown that lower frequency of medication intake is correlated with 
better treatment compliance [13]. Long-acting MPH has shown to be associated 
with better treatment continuity [14, 15]. Kemner and Lage [14] found patients 
treated with long-acting MPH to be subject to less breaks in medication use, 
fewer medication switches and a longer period on intended therapy. Marcus et 
al. [15] stated that the treatment duration of patients with long-acting MPH was 
on average longer than for patients treated with short-acting MPH. Long-acting 
formulations of MPH have also been proven to result in superior compliance in 
patients when compared to the short-acting formulation [16-18], hence, possibly 
leading to better effectiveness than the short-acting formulation. 
However, it is not evident whether the effect of long-acting formulations of 
MPH can justify the higher costs. Given the scarce financial resources in health 
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care, cost-effectiveness analyses have become essential to inform policymakers’ 
choices between competing treatments and to provide founded recommendations 
to clinicians within clinical guidelines. However, evidence in the form of recent 
state-of-the-art health economic evaluations of ADHD treatment in children is 
limited. Furthermore, there is increasing debate on whether it is sufficient to 
purely evaluate interventions on the basis of costs and effects in the domain of 
health care and limit these to the patient alone [19]. Authors of recent publications 
emphasized the lack of economic studies on ADHD in children and adolescents 
with a broader societal perspective [20-22]. Bernfort et al. [21] found that most 
often societal costs were not included in economic evaluations of ADHD. Wu et 
al. [22] performed a systematic literature review on health care costs of family 
members of children with ADHD and found those costs to be higher than those 
of families without a child with ADHD. Beecham [20] stated that “economic 
evaluation of interventions for child and adolescent psychiatric disorders has 
lagged some way behind its adult counterpart.” She expressed the need for a 
broader perspective as to reflect the various effects of psychiatric disorders in 
children and adolescents [20]. Evidence from the literature on meningitis [23] 
suggests that ‘spillover’ health effects on family may constitute as much as 48% of 
the health effects on the patient. As ADHD can be considered especially stressful 
on the direct environment of the patient, such as parents, siblings, friends or 
schoolmates, this percentage may even be larger for patients with ADHD. Hence, 
the inclusion of broader societal effects and costs is considered necessary [22]. 
Bernfort et al. [21] recommended the use of a health economic Markov model to 
determine the long-term costs and effects of ADHD. However, the authors stated 
that sufficiently detailed data (especially on long-term consequences of ADHD) 
was scarce or unavailable [21]. King et al. [24] expressed their concerns on the 
limited availability of effectiveness estimates and utility values, possibly due 
to scarcity of clinical data. Among the health economic evaluations that have 
been performed to evaluate various pharmacological treatments of ADHD are 
analyses based on decision analytic trees [25] and cost-of-illness calculations 
[26]. A small number of evaluations have been performed based on more 
advanced health economic (Markov) models [24, 27, 28]. However, there is a lack 
of more recent studies in the field. An economic evaluation on long-acting MPH 
osmotic release systems (OROS) versus short-acting MPH immediate release 
(IR) suggested better cost-effectiveness of OROS (hereafter referred to as the 
Faber model) [29]. However, that evaluation was limited compared with the 
current standard of HE modeling as a deterministic model was employed and 
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only effects limited to the patient were included. Hence, clear health economic 
recommendations on the cost-effectiveness of OROS compared to IR based on a 
broad societal perspective are still lacking. 
Knowledge of the cost effectiveness of treatment options for children with 
ADHD is essential in order to inform policymakers and enable the formulation 
of specific recommendations in clinical guidelines. In the case of MPH, it would 
be desirable to provide clear recommendations on which formulation is to be 
preferred under which circumstances, founded on sound and comprehensive 
health economic evidence. This study aims to contribute to this goal. We perform 
a cost-effectiveness evaluation of OROS versus IR in line with current health 
economic methodology, based on the Faber model [29], but with a probabilistic 
model update, enhanced model structure, updated input parameters (including 
utility values) and a broader societal perspective (i.e. we considered criminal 
justice costs, educational costs, employment disadvantages, out-of-pocket-
expenses, medical and productivity costs and utility values of the caregiver). 
Additionally, we provide specific recommendations for future data collection, 
which would be valuable to further increase the validity of the model outcomes.
Methods
We evaluated the cost-effectiveness of OROS compared with IR for patients 
with suboptimal response to IR. The structure of the probabilistic Markov 
model and its parameters were defined according to the Dutch guidelines for 
pharmacoeconomic evaluation [30]. 
According to health economic standards, a societal perspective was taken to 
reflect costs and effects on patients, their parents and society as a whole [31]. 
We searched literature on a broad range of cost categories for relevance and 
feasibility of inclusion in the model (i.e. criminal justice costs, lower income, 
out-of pocket expenses of the patient as well as health care costs and productivity 
costs of caregivers). Direct medical and non-medical costs as well as spillover 
effects on caregivers were included in the model. 
Consultation of experts
As part of this study, a panel of experienced psychiatrics from various regions 
in the Netherlands was consulted (table 1). These experts were asked to provide 
feedback on the model structure, input and model assumptions as well as 
estimates of transition probabilities. Transition probabilities were retrieved 
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in accordance with the Delphi panel requirements [30], and other issues were 
discussed individually. After discussion with the expert panel on, among others, 
the definition of health states and the cycle length of the probabilistic model, 
the cycle length was chosen to remain unchanged and the model states were 
slightly adapted as opposed to the Faber model [29] to better match patient 
characteristics, illness and treatment approach.
Table 1 | Consulted experts 
Expert Gender Age 
(years)
Specialism Sub specialism Years 
experience 
in mental 
health
Average 
number of 
patients 
with ADHD 
from 6 to 18 
yrs seen per 
month
Years 
experience 
with 
ADHD 
medication
Average 
number 
of 
patients 
seen/
month
1 M 55 Child- and 
youth 
psychiatrist
None 24 90 16 105
2 M 52 Child- and 
youth 
psychiatrist
Hospital, child 
psychiatry and 
ADHD
22 >30 16 >100
3 F 43 Child- and 
youth 
psychiatrist
ADHD/ODD/ticks 13 45 10 50
4 M 55 Child 
psychiatrist
Neuropsychiatry 29 50 22 80
ADHD attention deficit hyperactivity disorder, ODD oppositional defiant disorder 
2
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General model characteristics
The probabilistic model was based on the existing deterministic model by Faber 
et al. [29]. Model type, model state definitions, time horizon, model parameters 
and model input (including utility values) were updated to enhance the existing 
model and to comply with current health economic methodology. 
Table 2 | Current model vs. Faber model
Current model Faber model [29]
General model type: Markov model
Perspective: societal
Cycle length: 1 day
Resource use estimates: expert panel (Faber et al. [29])
Outcomes: expressed as cost/QALY
Utility estimates:
Patient and caregiver
Reference of utility estimates:
van der Kolk et al. [57]
Specific model type: 
probabilistic
Model states OROS/IR: 
optimal, suboptimal, treatment stopped, remission
Patient age when entering model: 
6 years
Time horizon: 
12 years
Transition rate estimates: 
Delphi panel of experts
Cost categories:
Patient: Medication costs, consultation costs, 
intervention costs, special education costs 
Caregiver: Medical costs, production losses
Cost parameter values:
2014 EUR
Utility estimates:
Patient
Reference of utility estimates:
Secnik et al. [32]
Specific model type: 
deterministic
Model states OROS: 
optimal, non compliance, treatment stopped, 
functional remission 
Model states IR:
optimal, suboptimal, treatment stopped, functional 
remission
Patient age when entering model: 
8 years
Time horizon: 
10 years
Transition rate estimates: 
various sources (literature and expert opinion)
Cost categories:
Patient: Medication costs, consultation costs, 
intervention costs, special education costs 
Cost parameter values:
2005 EUR 
As the Faber model was limited to a deterministic decision-analytic model with 
sensitivity analyses, we chose a more advanced probabilistic approach. The 
consideration of uncertainty increasingly gains importance, as shown in several 
guidelines, of which one explicitly suggests the use of probabilistic sensitivity 
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analysis [33]. Therefore, input parameters were set to vary according to prior 
distributions as to introduce parameter uncertainty in the model.
Furthermore, we refined and improved model state definitions. Where Faber et 
al. [29] considered five model states (optimal, suboptimal, treatment stopped, 
functional remission and non-compliance), with different states applicable for 
different treatment conditions, the current model defined four model states 
(optimal, suboptimal, treatment stopped and remission) consistent across 
treatment conditions.
The time horizon of the model was slightly adjusted in the current model. 
Patients entered the Faber model [29] at 8 years of age and remained in the 
model for 10 years. In the current model, we redefined the starting age of patients 
entering the model to 6 years and extended the time horizon to 12 years in 
order to be in line with the treatment guidelines for ADHD [9]. The relevant 
patient population was defined as patients within this age group who initially 
had responded suboptimally to IR because of incorrect intake of medication 
(i.e. missing doses of medication due to administrative burden). To simulate a 
randomized population, it was assumed that half of the initial patient population 
continued to receive IR and the other half switched to treatment with OROS 
when entering the model. 
Within the current model, the assumed cycle length was one day and was 
consistent with the set-up of the Faber model. The panel of experts (table 1) 
indicated that a cycle length in line with the prescription regimen of a day would 
be most appropriate and consistent as non-compliance to medication would, on 
average, result in a change in behavior on the same day for almost all children, 
with only few exceptions. This cycle length implies that an improvement or 
worsening of compliance can occur on a daily basis and symptoms and costs 
change accordingly after one day. In reality, costs may adjust less quickly than 
effects, resulting in less volatility in costs than assumed in the model.
The prescribed dosage of medication was assumed optimal for all patients based 
on age and metabolism. In line with the Multimodel Treatment of attention deficit 
hyperactivity disorder (MTA) study [34] and expert comments, a mean of three 
doses IR per day and one dose OROS per day were assumed.
2
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Costs and effects were discounted at 4% and 1.5% respectively, according to the 
Dutch guidelines for pharmacoeconomic research [30].
Model states
The effect of medication was evaluated in terms of ADHD symptoms and 
behavioral change. The model distinguished four different health states (table 
3). The definition of the health states was based on the Faber model [29] and 
enhanced with feedback from the expert panel. Where Faber et al. [29] made a 
distinction between a suboptimal state for treatment with IR and the state of 
non-compliance for treatment with OROS, the updated model made use of a 
consistent health state definition over treatments. The non-compliance state was 
replaced by the suboptimal state, now defined as a state in which medication 
was skipped and exposure to medication was insufficient for either IR or OROS.
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Table 3 | Definition of model states
Health 
state
Definition Medication intake per day:
OROS IR
Optimal 
(A)a
Optimala daily exposure to medication; remissionb of 
ADHD symptoms; the child functions well with this 
treatment; no significant problems at home, at school, with 
peers or during leisure time; the child receives additional 
care such as visits to a specialist, behavioral therapy, extra 
attention at school, etc
1x 3x
Suboptimal 
(B)c
Insufficient daily exposure to medication; ADHD 
symptoms present but reduced; different from normal 
functioning; the child functions considerably well with 
this treatment; during short periods the child experiences 
problems at home, at school, with peers or during leisure 
time; the child receives additional care such as visits to a 
specialist, behavioral therapy, extra attention at school, etc
None 0-2x
Treatment 
stopped (C)
Treatment stopped in spite of remaining symptoms of 
ADHD; noticeable problems at home, at school, with peers 
and/or during leisure time; the child experiences more 
persistent hinder of those problems; the child receives 
additional care such as visits to a specialist, behavioral 
therapy, extra attention at school, etc
None None
Remission 
(D)
No medication used; behavioral problems are no more 
different from normal; no more additional care needed 
related to ADHD such as visits to a specialist, behavioral 
therapy, extra attention at school, etc
None None
ADHD attention deficit hyperactivity disorder, IR immediate-release, OROS osmotic-release oral system
aOptimal intake is defined as follows: good compliance with intake of 1x/day for OROS and 3x/day for IR.
bRemission=not different from normal, symptoms of ADHD are at the most sometimes present, but not often 
or always.
cSuboptimal intake: insufficient compliance. Medication is not taken as prescribed, which means no intake for 
OROS and average intake of 1x/day for IR.
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In the optimal state, patients were assumed to adhere to the prescribed 
medication and consequently not experience any symptoms of ADHD. Symptoms 
not directly related to ADHD but to comorbidity may still be present in this state. 
In a suboptimal state, in contrast, patients were assumed not to adhere properly 
to their prescribed medication, resulting in symptoms of ADHD and behavior 
diff erent from normal behavior for their age group. As a single dose of OROS 
was required per day, skipping medication meant no medication at all in that 
state. For patients treated with IR, non-adherence at a mean of three prescribed 
doses per day [9] was assumed as either missing one, two or three doses per day 
yielding a mean of two missed doses per day in the suboptimal state. 
 Patients who stopped treatment entirely in spite of remaining symptoms of 
ADHD entered the state ‘treatment stopped’. Patients with functional remission 
not needing medication for treatment of ADHD entered the state ‘remission’. 
In line with the study performed by Faber et al. [29], we assumed that once 
in remission, patients remained in that state, which acted as an absorbing 
state (fi gure 1). The consulted psychiatrists indicated that reaching the state of 
remission would be exceptional. According to the experts the assumption of 
remission as an absorbing state could reasonably be made. However, the experts 
noted that there may be exceptions where patients experience a relapse after 
having reached the state of remission.
Patients in an ‘optimal’, ‘suboptimal’ or ‘treatment stopped’ state either remained 
in that state or transferred to one of the other states.
Figure 1 | Graphical representation of the model
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Transition rates
Variation in effect was modeled based on compliance and resulting symptom 
and behavior change (table 3). Data on transition rates between model states 
had to comply with our specific target population (i.e. children or adolescents 
with ADHD who initially had responded suboptimally to IR due to incorrect 
intake of medication). Furthermore, to guarantee the validity of model results, 
we preferred transition rates departing from one states to different states 
to all originate from the same source (and refer to the same definition of an 
optimal and suboptimal state). We considered transition rates from the Faber 
model [29] suboptimal as some of the transition rates were counterintuitive 
and the rates were based on multiple sources (i.e. literature and expert 
opinion). Hence, we performed a systematic literature review in the PubMed, 
PsycInfo and ERIC databases as to identify data to determine the transitions. 
First, we searched for reviews for the period from January 1, 2008 (the year 
of publication of the Faber model [29]) onwards. This search was performed 
on November 9, 2014. Then, we performed an additional search in the same 
databases directed at recent clinical trials from the publication date of the 
most recent identified review onwards. This second search was performed 
on December 8, 2104. Search terms for both searches were as follows: ADHD 
OR “attention deficit hyperactivity disorder“ [title] AND methylphenidate OR MPH 
OR MPH-IR OR MPH-ER OR pharmaco* [title] AND effect* OR efficacy OR cost-
effectiveness OR cost-utility [title]
The searches resulted in a total of 121 hits after duplicates were removed. The 
records were screened by two researchers independently, in a first round on 
title and in a second round on abstract. Where there was conflict, a decision was 
reached through consensus. The screening and selection process is summarized 
in a PRISMA flow diagram in figure 2.
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Figure 2 | PRISMA fl ow diagram of systematic literature review
The selections based on title and abstract resulted in 16 studies to be included, 
among which were seven reviews and nine clinical trials. We were specifi cally 
interested in data from which transition rates for OROS and/or IR could be 
derived. Consultation of the reviews yielded several conclusions. Five reviews 
presented only mean scores on specifi c outcome measures [35, 36] or eff ect sizes 
[37-39]. Confi dence intervals of eff ect sizes may be used to calculate transition 
rates based on a minimal meaningful improvement (i.e. defi ning a certain 
point on the distribution at which a patient moves from an optimal towards 
a suboptimal model state). However, as diff erent underlying studies used 
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different outcomes as the basis for the stated effect sizes, minimal meaningful 
improvements (and hence, definition of the suboptimal model state) would differ 
per outcome measure and per study. Hence, we did not consider this approach 
a feasible option within the scope of this study. Another review presented 
information on pharmacokinetics [40]. One other study concerned a review of 
cost-effectiveness outcomes, not presenting specific data on state transitions 
[41]. None of the reviews specifically addressed the targeted patient population 
(i.e. children or adolescents who had initially responded suboptimally to IR 
due to incorrect intake of medication). Hence we considered the option to base 
transition estimates on a single study and examined the recent articles for further 
informative data. 
From consultation of these articles we noted that seven of the nine articles did 
not contain suitable information. Two articles concerned letters to the editor 
[42, 43], one article was written in Iranian language [44], one articles concerned 
an explanatory study on effect sizes [45], one article presented mean scores [46] 
and one article referred to differences in scores [47]. Another article presented 
percentages of patients who improved (a potentially suitable measure for the 
calculation of transition probabilities). However, the study considered patients 
treated with specific extended-release MPH with 50% short-acting and 50% 
long-acting components [48]. Two remaining articles presented data potentially 
useful for calculation of transition rates [49, 50]. Garg et al. [49] found a treatment 
response of 90.7% in patients receiving IR (n=33) in Northern India. Soutullo et al. 
[50] stated that 51% (95% CI 31.1-60.6) of European patients (n=111) responded to 
treatment with OROS. The trial was performed in 48 centers across 10 European 
countries. However, both articles did not consider the specific patient population 
of this study and only one broad rate of response for the entire treatment period 
was provided, whereas our model included more specific transitions between 
the optimal and suboptimal states (back and forth) and accounted separately 
for patients staying in a specific state. Furthermore, Garg et al. [49] and Soutullo 
et al. [50] used different outcome measures to define response and the studies 
were performed in two different treatment populations. Hence, we considered 
the information available from these single clinical trials insufficient to use in the 
model. Consequently, we considered the consultation of an expert panel (from 
within the Dutch context) superior to using data from multiple international 
trials.
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Hence, transition rate estimates were attained from consultation with a Delphi 
panel of experts (table 1). We retrieved all transition rate estimates from one 
consistent source (i.e. the expert panel). 
The consulted psychiatrists suggested that the group of patients suboptimally 
treated with IR would, in particular, experience practical problems with accurate 
medication intake schemes during the day or at school. These patients would 
need to put more effort into adherence to the administration scheme compared 
with OROS, for which administration is limited to once a day. These differences 
in effect and effort were reflected in the transition rates between states.
Transition estimates were attained by blind questionnaires in two rounds, 
according to Dutch guidelines for pharmacoeconomic research [30] and 
consistent with the Delphi panel method [51, 52]. The experts were consulted 
independently and were not aware of the identity of the other experts joining 
the panel. Before distributing the questions to the experts, it was decided that 
consensus was supposed to be reached after two rounds of answers when (a) 
feedback of the experts was clear and (b) when experts did not all change their 
answers on the basis of the mean of the feedback of the first round. The questions 
for the panel were sent and returned by email. One of the researchers registered 
the replies anonymously. After all experts had returned the questionnaires, their 
answers were combined. The mean value for each question constituted the basis 
for the final answer to each question. The proposals for the final answers as well 
as the anonymized individual answers of the participants were reported to the 
experts after round 1. In the second round, experts were asked whether they 
intended to change their previous answers on the basis of the proposal for the 
final answer. 
Utility values
ADHD is associated with reduced health-related quality of life [53-56]. The 
present model was built to assess the cost utility of OROS versus IR in children 
and adolescents with ADHD. Effects were expressed in terms of quality-adjusted 
life-years (QALYs). Several members of our research team were involved in a 
recent Dutch study that measured the quality of life of children with ADHD and 
their parents [57]. The study of van der Kolk et al. [57] was a cross-sectional study 
among member of a Dutch ADHD parent association. Data collection occurred 
via online questionnaires. The quality of life of the children (n=618) was based on 
parent proxy ratings, and the quality of life of the caregivers (n=590) was based 
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on self-report of the Euroqol (EQ-5D) questionnaire [57, 58]. The available quality 
of life data were highly suitable for inclusion in the current model as the state 
definitions of responders and non-responders closely matched the definition 
within the current model. 
Utility of the patient
We found a significant difference in quality of life of patients compliant with 
prescribed medication compared with non-compliant patients [57]. Compliant 
patients reported a quality of life of 0.84 (ages 8-12 years 0.82; ages 13-18 years 
0.86) whereas non-compliant patients reported a quality of life of 0.75 (ages 
8-12 years 0.74; ages 13-18 years 0.77) [57]. In the current model, we included 
the quality of life values of the compliant group for the state ‘optimal’ and the 
utilities of the non-compliant group for the state of ‘suboptimal’ functioning. 
As there was no utility available for patients who had stopped treatment, we 
considered it reasonable to assign to those patients the same utility as patients 
in the suboptimal state, as this would constitute a conservative estimate. Based 
on the available data, utility was modeled to differ per model state but not per 
treatment type.
Spillover effects on caregiver
Family effects [8, 59-62] and negative effects of ADHD on families in particular 
[26, 63] have been addressed several times in the literature. Le et al. [8] suggest 
that benefits of ADHD treatment may also extend further than the individual 
patient. Brouwer et al. [19] proposed that when taking a societal perspective, these 
effects may be added to the effects experienced by patients. Hence, we considered 
it valuable to include spillover effects on the utility of a parent in the model. In 
our recent study on quality of life [57] we found a significant correlation between 
the quality of life of the child and the caregiver. No significant difference was 
found between the quality of life of parents of compliant or non-compliant 
children. 
The literature on ADHD is very limited on this aspect, and our study [57] was 
the first study to report utilities of patients with ADHD and caregivers in one 
study. Further studies on the specific effect of ADHD on caregiver utility could 
not be retrieved from the literature. However, there is evidence available on the 
effect of a child with ADHD on health expenditures of caregivers. Hakkaart et 
al. [4] stated that 25% of health care expenditures of the caregiver of a child with 
ADHD can be attributed to the behavioral problems of the child. This suggests a 
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considerable influence of child health on caregiver health. In the absence of more 
specific data on the caregiver effects of ADHD, we searched for publications on 
caregiver effects in other diseases. Evidence from the literature on meningitis 
[23] suggests that ‘spillover’ health effects on family may constitute as much 
as 48% of the health effects on the patient. In the case of ADHD, this may be a 
conservative estimate as ADHD has been found to be especially stressful on the 
direct environment of the patient. Hence, as an estimate, we included 48% of 
caregiver utility in the model.
Cost parameters
Categories of direct medical and non-medical costs were kept consistent with 
the Faber model [29]. These categories were medication costs, costs of medical 
consultations, costs of medical and non-medical interventions, and costs of 
special education. Costs differed per state and in remission, we assumed no 
costs associated with ADHD. We assumed all costs except drug costs to be only 
dependent on the state and not on the type of medication (IR or OROS) received 
by the patient. This assumption was based on evidence from the literature 
on comparable efficacy of IR and OROS under the provision of full therapy 
compliance [10-12] and was confirmed by the expert panel of psychiatrists (table 
1). We considered different costs for patients when below the age of 12 years and 
at and above the age of 12 years. This modeled difference in costs according to 
current age was based on consultation of the expert panel (table 1). The experts 
suggested differences in cost when switching schools (i.e. from primary to 
secondary education), which corresponds to the age of 12 years in the Dutch 
setting. Health care consumption (i.e., frequencies of consultations and non-
pharmacological interventions) were extracted from the study performed by 
Faber et al. [29]. All costs were valued in Euros (2014). Cost prices were updated 
based on Hakkaart et al. [64], costs of special education were updated as reported 
by the Dutch Ministry of Education [65] and all costs were adjusted to 2014 
values.
Next to the cost categories consistent with the Faber model [29], literature and 
available data of additional cost categories were searched to determine relevance 
and feasibility of inclusion in the model. Considered categories were: criminal 
justice costs, costs of lower-proficiency work and low income, out-of pocket 
expenses and spillover effects on caregivers (i.e., health care costs and production 
losses).
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Costs of medication
Individuals in the OROS arm of the model used a full daily dose of OROS per 
day in the optimal state and no medication in all other states. In the IR arm of 
the study, participants were assumed to take the full daily dose of IR a day in 
the optimal state and on average 1/3 of the daily dose in the suboptimal state. 
The daily dose of both OROS and IR was determined on the basis of the average 
daily dose of two age groups (6-12 and 13-18 years) and was based on IMS data 
[66]. Cost of medication was based on the Dutch pricelist [67].
Costs of medical consultations
Consultation costs concerned contacts with psychiatrists, other medical 
specialists, general practitioners, and crisis contacts. The number of visits per 
year was dependent on age and based on the Faber model [29]. Unit prices were 
retrieved from the Dutch manual for costing research [64] and applied to the 
number of contacts.
Costs of medical and non-medical interventions
Intervention costs included costs of psychosocial and psychotherapeutic 
interventions as well as interventions for educational support (i.e., psycho 
education, parent training, behavior child therapy, social skills training, teacher 
training, remedial teaching, physical therapy, home training/care, outpatients’ 
treatment and institutionalization). These categories were in line with the Dutch 
clinical guidelines for ADHD [9]. Interventions that are provided on a limited 
scale in the Netherlands (i.e., neurofeedback, cognitive training, mindfulness, 
diet) have not been included. The number of contacts was based on the Faber 
model [29]. Intervention costs were assumed to occur at age 6 and at age 12 
for one year each as experts from the panel of consulted psychiatrists (table 1) 
indicated that those costs mainly occurred at the moment of switching between 
schools. Unit prices were retrieved from the Dutch manual for costing research 
[64] and applied to the number of contacts.
Costs of special education
Costs for special education were additional costs per day in special education. 
Advice for placement in special education was assumed dependent on age. 
Costs for special education were considered continuous from age 6 to age 18 in 
accordance with the experts’ opinion. Probability of placement was based on 
the Faber model [29], and unit prices were based on the Ministry of Education, 
Culture and Science [65].
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Criminal justice costs
Several authors have found a positive relationship between ADHD in childhood 
and antisocial behavior and drug use in (young) adults [68-70]. However, it 
has to be taken into account that the high degree of antisocial activity may be 
attributed to comorbid conduct disorder [71]. A recent study by Lichtenstein 
et al. [72] suggested that criminal behavior of ADHD patients decreases when 
medication is taken consistently. Evidence from the literature suggests that data 
on criminal justice costs related to ADHD are scarce [20] and especially limited 
in the European context [8]. Though these costs are considered highly relevant 
especially in the light of a possible relation with medication intake, the lack of 
available data resulted in the exclusion of these costs from the current model.
Costs for educational support, cost of lower-proficiency work and low 
income
Evidence from literature suggests that the impact of ADHD may exceed the age 
of school-going children and that it may result in poor educational performance 
[4, 8, 63, 73, 74], work achievements [75, 76] and household income [20, 70, 77, 78]. 
However, it is not yet clear whether medical treatment necessarily improves 
academic performance or income, as it may have an effect on some aspects 
of academic functioning and not on others [73]. Children with ADHD often 
require additional support within the educational setting [20]. As this study 
focused on children between 6 and 18 years, the costs of additional educational 
support within the education system up to age 18 were included within the cost 
categories ‘costs of medical and non-medical interventions’ and ‘costs of special 
education’ in the model (i.e., costs for teacher training, remedial teaching and 
costs of special education). When expanding current projections to a lifetime 
perspective, long-term consequences of educational effects (i.e., on work and 
income) should be included as well.
Out-of-pocket expenses
In a Dutch study on out-of-pocket expenses of children and adolescents with 
ADHD, Hakkaart et al. [4] presented data from parents of children with ADHD 
treated by a pediatrician. The authors found out-of-pocket expenses of 23.13 
EUR (standard deviation EUR 150.35; adjusted to 2014 EUR) per annum in the 
Dutch setting. As the amount of out-of-pocket expenses is negligible (i.e., not 
significantly different from zero) in the study by Hakkaart et al. [4], we did not 
include these expenses in the current model.
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Spill-over on caregivers (medical costs and production losses)
Hakkaart et al. [4] found that mean health care costs of mothers of children 
with ADHD were significantly higher than those of mothers of healthy children. 
Mean medical costs per year were 841.93 EUR (adjusted to 2014 EUR) for mothers 
of children with ADHD compared with 178.10 EUR of mothers of a healthy 
child. The authors stated that 25% of mothers noted that their use of health care 
services was related to the behavioral problems of their child [4]. Consequently, 
we assumed health care costs for a caregiver of 0,25 x (841.93 EUR-178.10 EUR) 
in the suboptimal and treatment stopped states and included these costs in the 
model. In the optimal state, no additional costs were assigned.
Hakkaart et al. [4] also collected data on production losses of mothers of patients 
with ADHD. The authors found significantly higher production losses in mothers 
of children with ADHD compared to mothers of healthy controls. Mean annual 
production losses of mothers (reduced efficiency and absence from work) were 
2,594.03 EUR (adjusted to 2014 EUR) compared to 779.48 EUR for mothers of 
healthy children. As noted above, Hakkaart et al. [4] found that 25% of health 
care costs of the mother were related to behavioral problems of the child. It 
seems reasonable to assume that also 25% of production losses can be attributed 
to the behavioral problems of the child. Hence, in the model, we included mean 
annual production losses of 0.25 x (2,594.03 - 779.48 EUR) in the suboptimal and 
treatment stopped states. In the optimal state, no additional costs were assigned.
Model validation
Face validity was ascertained by consulting experts in the field of ADHD in the 
Netherlands on clinical aspects of model structure, model parameters and model 
input. Furthermore, verification of transition rates was attempted. Because of 
the scarce available data, we could only globally verify the number of patients 
in an optimal state after one year with response percentages from the literature 
identified from the systematic review [48-50], which we performed as part 
of the search for suitable transition rates. Though the estimates within these 
studies were based on different definitions of response or improvement and 
studies were performed in different countries, this constituted the best available 
data. As our study was performed in the population of patients who had in the 
past been treated with IR and reacted suboptimally because of problems with 
medication intake, it was expected that overall response within the existing 
literature would be higher than in our model. This rationale was supported, 
as Garg et al. [49] reported a 91% treatment response in patients treated with 
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MPH, Sobanski et al. [48] found 78% of patients receiving combined short- and 
long-acting MPH treatment had reduced symptoms and, according to Soutullo 
et al. [50], 51% of patients responded to treatment with OROS. On the basis of the 
expert panel estimates within the current model, 22% of patients treated with IR 
and 36% of patients treated with OROS achieved a transition from a suboptimal 
to an optimal state after one year. Hence, the transition estimates in our model 
appear to be in line with expectations and may even be conservative. We further 
performed scenario analyses to examine the sensitivity of model results to these 
parameters. 
Sensitivity analyses
Sensitivity analyses were performed for four scenarios: one scenario assuming 
equal transition rates for IR and OROS; a second scenario including an augmented 
daily dose of exposure to medication; a third scenario excluding medical costs 
and production losses of the caregiver; and a forth scenario excluding the utility 
of caregivers. As transition rates were based on expert opinion (table 4), we 
performed a scenario to estimate the impact of these parameters on the results. 
Furthermore, due to issues of noncompliance, the daily dose data may provide 
an underestimation of optimal exposure. To measure the effect of this potential 
bias, a scenario was estimated which corrected for noncompliance. Studies by 
Adler and Nierenberg [16] and Swanson [79] have estimated noncompliance to 
amount to 13-64% and 20-65%, respectively. On the basis of these findings, the 
scenario considered an average of 40% noncompliance in daily dose data used 
(implying augmentation of the daily dose by 67% for both treatment arms). Two 
additional scenarios were performed to estimate the effect of the caregiver costs 
and effects on the model outcomes. As the underlying data for the inclusion of 
these model components was limited, the outcomes of the scenario analysis 
may provide further incentive for future data collections. One scenario was 
performed excluding medical costs and production losses of caregivers, and 
another scenario was performed where utilities of caregivers were excluded. 
Monte Carlo results were simulated per scenario, allowing for uncertainty 
around all parameter estimates while analyzing the specific effect of changes of 
the parameters of interest. Detailed model parameters are provided in table 4.
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Table 4 | Detailed model parameters and assumptions [in EUR (2014)]
Parameter Description Source
General parameters
Discount rate Costs discounted at constant 
discount rate of 4%, effects at 
constant discount rate of 1,5%
College voor Zorgverzekeringen [30]
Patient age All patients assumed to enter 
the model at age 6
Indicatie Concerta, Landelijke 
Stuurgroep Multidisciplinaire 
Richtlijnontwikkeling in de GGZ [9]
Monte Carlo random 
sampling
N=1000 Briggs et al. [33]
Transition probabilities
IR: A to A Dirichlet, mean 8.97 Expert panel data 
IR: A to B Dirichlet, mean 90.20 Expert panel data 
IR: A to C Dirichlet, mean 1.01 Expert panel data 
IR: A to D 0 Expert panel data 
IR: B to A Dirichlet, mean 22.47 Expert panel data 
IR: B to B Dirichlet, mean 54.25 Expert panel data 
IR: B to C Dirichlet, mean 23.28 Expert panel data 
IR: B to D 0 Expert panel data 
IR: C to A Dirichlet, mean 16.58 Expert panel data 
IR: C to B Dirichlet, mean 10.26 Expert panel data 
IR: C to C Dirichlet, mean 73.16 Expert panel data 
IR: C to D 0 Expert panel data 
OROS: A to A Dirichlet, mean 6.25 Expert panel data 
OROS: A to B Dirichlet, mean 93.75 Expert panel data 
OROS: A to C 0 Expert panel data 
OROS: A to D 0 Expert panel data 
OROS: B to A Dirichlet, mean 58.91 Expert panel data 
OROS: B to B Dirichlet, mean 23.81 Expert panel data 
OROS: B to C Dirichlet, mean 17.27 Expert panel data 
OROS: B to D 0 Expert panel data 
OROS: C to A Dirichlet, mean 24.21 Expert panel data 
OROS: C to B Dirichlet, mean 14.21 Expert panel data 
OROS: C to C Dirichlet, mean 61.58 Expert panel data 
OROS: C to D 0 Expert panel data 
Utility – patient (8-12 years)
Optimal Beta, mean 0.82, se 0.0979 van der Kolk et al. [57]
Suboptimal Beta, mean 0.74, se 0.01588 van der Kolk et al. [57]
Treatment stopped Beta, mean 0.74, se 0.01588 van der Kolk et al. [57]
Utility – patient (13-18 years)
Optimal Beta, mean 0.86, se 0.01097 van der Kolk et al. [57]
Suboptimal Beta, mean 0.77, se 0.02645 van der Kolk et al. [57]
Treatment stopped Beta, mean 0.77, se 0.02645 van der Kolk et al. [57]
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Parameter Description Source
Utility - caregiver
Optimal Beta, mean 0.85, se 0.00897 van der Kolk et al. [57]
Suboptimal Beta, mean 0.83, se 0.01499 van der Kolk et al. [57]
Treatment stopped Beta, mean 0.83, se 0.01499 van der Kolk et al. [57]
Drug costs
Daily dose OROS – child 
6-12 years (mg)
31.70 IMS Health BV [66]
Daily dose OROS – child 
13-18 years (mg)
39.10 IMS Health BV [66]
Daily dose IR – child 6-12 
years (mg)
22.00 IMS Health BV [66]
Daily dose IR – child 
13-18 years (mg)
29.20 IMS Health BV [66]
Costs/ mg OROS 0.05 Zorginstituut Nederland [67]
Costs/ mg IR 0.01 Zorginstituut Nederland [67]
Pharmacy fee/ 3 months 7.0 Zorginstituut Nederland [67]
Consultation costs Incurred by children between 6 and 18 years
Number of visits per year – 
child < =12
State A State B State C
Psychiatrist 2.28 3.42 5.00 Faber et al. [29]
Other specialist 0 0 1.38 Faber et al. [29]
General Practitioner 0 0 0.58 Faber et al. [29]
Crisis contacts 0.57 1.49 2.71 Faber et al. [29]
Number of visits per year – 
child > 12
State A State B State C
Psychiatrist 2.43 3.57 5.00 Faber et al. [29]
Other specialist 0 0 0.11 Faber et al. [29]
General Practitioner 0 0.29 0.43 Faber et al. [29]
Crisis contacts 0.35 1.28 3.00 Faber et al. [29]
Costs per visit
Psychiatrist 113.53 Hakkaart et al. [64]
Other specialist 75.15 Weighted average psychiatrist and 
medical specialist: 46:34 [29, 64]
General Practitioner 31.22 Hakkaart et al. [64]
Crisis contacts 256.20 Based on Tariffs AWBZ-institutions 
2005 [88]
Intervention costs Incurred by children of age 6 and of age 12.
Transferred % of patients – 
child < =12
State A State B State C
Psycho education 0.89 0.93 1.00 Faber et al. [29]
Parent training 0.49 0.76 0.79 Faber et al. [29]
Behavior therapy child 0.07 0.23 0.57 Faber et al. [29]
Table 4 | Continued
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Parameter Description Source
Social skills training 
(SOVA)
0.19 0.28 0.38 Faber et al. [29]
Teacher training 0.43 0.57 0.66 Faber et al. [29]
Remedial teaching 0.37 0.51 0.77 Faber et al. [29]
Physical therapy 0 0 0 Faber et al. [29]
Home training/care 0.04 0.13 0.33 Faber et al. [29]
Outpatients’ treatment 0 0 0.25 Faber et al. [29]
Institutionalization 0 0 0.03 Faber et al. [29]
Transferred % of patients – 
child >12
State A State B State C
Psycho education 0.94 0.90 0.89 Faber et al. [29]
Parent training 0.31 0.44 0.74 Faber et al. [29]
Behavior therapy child 0.09 0.28 0.56 Faber et al. [29]
Social skills training 
(SOVA)
0.07 0.26 0.53 Faber et al. [29]
Teacher training 0.10 0.33 0.32 Faber et al. [29]
Remedial teaching 0.02 0.39 0.47 Faber et al. [29]
Physical therapy 0 0 0 Faber et al. [29]
Home training/care 0 0.1 0.13 Faber et al. [29]
Outpatients’ treatment 0 0 0.26 Faber et al. [29]
Institutionalization 0 0 0.04 Faber et al. [29]
Number of visits per year – 
child < =12
State A State B State C
Psycho education 2.64 3.64 3.86 Faber et al. [29]
Parent training 8.34 7.92 14.01 Faber et al. [29]
Behavior therapy child 13.18 11.80 13.15 Faber et al. [29]
Social skills training 
(SOVA)
9.15 9.79 9.15 Faber et al. [29]
Teacher training 1.75 3.73 3.94 Faber et al. [29]
Remedial teaching 20.00 20.00 20.00 Faber et al. [29]
Physical therapy 6.00 0 0 Faber et al. [29]
Home training/care 10.00 11.15 14.31 Faber et al. [29]
Outpatients’ treatment 0 0 51.75 Faber et al. [29]
Institutionalization 0 0 90.00 Faber et al. [29]
Number of visits per year – 
child > 12
State A State B State C
Psycho education 2.78 3.57 5.42 Faber et al. [29]
Parent training 5.91 8.24 13.74 Faber et al. [29]
Behavior therapy child 10.00 11.44 12.88 Faber et al. [29]
Social skills training 
(SOVA)
9.15 11.44 10.59 Faber et al. [29]
Teacher training 2.00 2.50 3.73 Faber et al. [29]
Remedial teaching 20.00 20.00 20.00 Faber et al. [29]
Physical therapy 0 0 0 Faber et al. [29]
Table 4 | Continued
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Parameter Description Source
Home training/care 0 10.00 10.06 Faber et al. [29]
Outpatients’ treatment 0 0 51.75 Faber et al. [29]
Institutionalization 0 0 135.00 Faber et al. [29]
Costs per visit
Psycho education 111.17 Based on Tariffs AWBZ-institutions 
2005 [88]
Parent training 104.15 Based on Tariffs AWBZ-institutions 
2005 [88]
Behavior therapy child 111.17 Based on Tariffs AWBZ-institutions 
2005 [88]
Social skills training 
(SOVA)
111.17 Based on Tariffs AWBZ-institutions 
2005 [88]
Teacher training 76.05 Based on Tariffs AWBZ-institutions 
2005 [88]
Remedial teaching 58.49 Based on Dutch Society of Remedial 
Teachers [89]
Physical therapy 39.84 Hakkaart et al. [64]  
Home training/care 114.52 Based on Health care insurance board 
[90]
Outpatients’ treatment 150.57 Hakkaart et al. [64]
Institutionalization 301.09 Hakkaart et al. [64]
Special education costs Incurred by children between 6 and 18 years
State A State B State C
Advice placement special 
education (%) – child< =12
0.015 0.1224 0.4356 Faber et al. [29]
Advice placement special 
education (%) – child> 12
0.0007 0.0863 0.3711 Faber et al. [29]
Additional costs special 
education/day
13.63 Based on Ministry of Education, Culture 
and Science [65] 
IR immediate-release, OROS osmotic-release oral system, SE standard error 
Table 4 | Continued
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Results
Transition estimates
In accordance with the model population, the expert panel of psychiatrists (table 
1) estimated transition rates for a patient population initially treated with IR with 
suboptimal result because of incorrect intake of medication.
Table 5 displays mean transition percentages per day as estimated by the expert 
panel. 
Table 5 | Mean (standard deviation) transitions per day (in %) as estimated by expert panel 
From/to optimal suboptimal treatment stopped remission
IR
optimal 8.79 (6.34) 90.20 (7.84) 1.01 (2.02) 0 (0)
suboptimal 22.47 (21.41) 54.25 (14.21) 23.28 (11.74) 0 (0)
treatment stopped 16.58 (8.02) 10.26 (8.60) 73.16 (15.94) 0 (0)
OROS
optimal 6.25 (9.46) 93.75 (9.46) 0 (0) 0 (0)
suboptimal 58.91 (21.03) 23.81 (12.51) 17.27 (9.82) 0 (0)
treatment stopped 24.21 (11.73) 14.21 (15.81) 61.58 (23.98) 0 (0)
IR immediate-release, OROS osmotic-release oral system 
 
Variability in cost parameters was captured by gamma distributions around 
the mean, and variability in transition probabilities entered the model through 
Dirichlet distributions [33]. Samples from these prior distributions were drawn 
by Monte Carlo simulation. For illustrative purposes and in the absence of trial 
data, as a common simplifying assumption, the standard errors of the cost 
parameters were assumed 20% of the mean. As is common in probabilistic 
models, a total of 1000 Monte Carlo simulations were performed to generate the 
model results.
Different estimates were attained for patients receiving OROS and for patients 
receiving IR. Experts estimated the probability to transfer from a suboptimal or 
treatment stopped state to an optimal state to be higher for patients receiving 
OROS than for patients receiving IR. However, they predicted patients receiving 
OROS to have a lower chance of staying in an optimal state than patients 
receiving IR. Furthermore, the experts estimated patients receiving OROS to 
have a lower chance than patients receiving IR to stop treatment and a higher 
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chance to go back to an optimal or suboptimal state when having stopped 
the treatment. Transitions from the suboptimal state to the remaining states 
appear to differ most between treatments. All experts considered the transition 
to a state of remission to be 0% per day. This means that the state ‘remission’ 
becomes redundant. In line with earlier critical comments on possible relapse 
after remission, it becomes clear that remission is seen as an exceptionally rare 
state (Figure 3) such that patients are expected to keep moving between the 
optimal, suboptimal and treatment stopped states instead of reaching a stable 
state of remission.
Figure 3 | Expert comments on state of remission
Model results and sensitivity analyses
Model results indicate dominance of OROS compared with IR in this population. 
OROS results in incremental QALY gains while saving costs. The number of 
QALYs for OROS exceeds the number of QALYs for IR by 0.22 (95% CI -0.206, 
0.228), and the total costs of OROS are estimated to be lower than IR with 
incremental cost savings of 5,815 EUR (95% CI 5,661 EUR, 5,969 EUR) (table 6). 
These results suggest that, for this patient group, OROS produces better effects 
at lower cost compared with IR. The detailed probabilistic model results of 
1000 Monte Carlo simulations are presented on a cost-effectiveness (C/E) plane 
and as a cost-effectiveness acceptability curve (CEAC) [80] in figures 4 and 
5, respectively. Figure 4 provides details on the uncertainty around the costs 
and effect of OROS compared with IR. The 1000 points in the scatter plot each 
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represent one simulation result. The x-axis displays the amount of incremental 
QALY gains or losses and the y-axis shows the incremental costs expressed in 
Euros (EUR).
Figure 4 | Scatt er plot: incremental costs and eff ects based on 1000 Monte Carlo simulations
The results of the C/E plane show that the majority of data points appear in the 
southeast quadrant, with lower costs and higher eff ects of OROS compared with 
IR, which indicates dominance of OROS versus IR.
Figure 5 shows a graphical presentation of the CEAC, displaying the probability 
that OROS is cost-eff ective compared to IR given diff erent values of maximum 
threshold for society. The threshold values in terms of Euros are shown on the 
x-axis and the probability of OROS being cost-eff ective is displayed on the y-axis.
2
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Figure 5 | CEAC: probability of OROS being cost-effective compared with IR
The CEAC displays data points within all four quadrants, with the majority of 
data points in the southeast quadrant [81]. The probability of OROS being cost-
effective ranges between 93 and 99%. The CEAC does not cross the y-axis at 0 
as some data points in the C/E plane display cost savings of OROS compared 
with IR. Furthermore, the CEAC does not asymptote to 1 because a part of the 
observed data points on the C/E plane show negative incremental effects. 
Sensitivity analyses indicate that when transition rates of OROS are equal to the 
transitions of IR (scenario 1), the incremental QALYs gained for OROS compared 
to IR amount to 0.00 and costs of treatment with OROS appear slightly higher 
than treatment with IR, with additional incremental costs of 800 EUR (table 6). 
These results in terms of incremental costs are close to the results of the Faber 
model [29] and the incremental effects are reduced to zero. Model results, thus, 
are strongly dependent on accurate estimates of transition probabilities as these 
determine how fast patients move between model states and, hence how often 
they stay in more or less ‘expensive’ states.
The scenario with an augmented daily dose of exposure to medication (scenario 
2) resulted in slightly lower savings compared with the base scenario (savings 
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of 4,502 EUR and QALY gains of 0.21).Exclusion of medical costs and production 
losses of caregivers from the model results in incremental cost savings of 4,930 
EUR and incremental QALY gains of 0.22. 
When utility of caregivers is excluded, there are insignificant changes in 
incremental costs (5,900 EUR) and a decrease in incremental QALY gains to 
0.15. This incremental QALY decrease is entirely explained by the fact that 48% 
of the QALYs of the patient have been added to account for effect on a caregiver.
Table 6 | Mean model results and sensitivity analyses of Monte Carlo simulations (n=1000)
Description Incremental costs Incremental QALYs
Base case -5,815 0.22
Scenario 1 Transition rates of OROS equal to transition rates of IR 800 0.00
Scenario 2 Daily dose of medication +66% -4,502 0.21
Scenario 3
Medical costs and production 
losses caregiver excluded
-4,930 0.22
Scenario 4 Utility of caregivers excluded -5,900 0.15
2
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Discussion and Conclusions
Policymakers increasingly use cost-effectiveness analyses to inform decision-
making on competing health care interventions. Health economic models 
facilitate these analyses by providing a framework to combine information 
from different sources and enable probabilistic estimations. Within health care 
there has been debate on which perspective to be taken in such models. In the 
Netherlands, a societal perspective is common according to the health economic 
guidelines. Lately, there have been voices to even include broader effects (i.e., 
exceeding the patient and exceeding health care) [19]. This may be especially 
relevant to illness in children and disorders, which have a high impact on third 
parties (such as in the setting of ADHD). The presented model adds to the current 
movement towards broader considerations in cost-effectiveness analyses. We 
have presented a model compliant with the current health economic guidelines 
and at the same time considered, and where possible included, broader societal 
aspects to increase the comprehensiveness of the model results. Hence, the results 
of this study can be used as direct input to policymakers’ decision making.
Model results indicate that, for children responding suboptimally to treatment 
with IR, the beneficial effect of OROS on compliance may be worth the additional 
medication costs. The current model was based on the Faber model [29] but 
model structure and input were improved and the model was enhanced with 
additional broader societal parameters. Transition rates consistent with our 
model structure could not be obtained from one source of literature. Therefore, 
we chose to consult an expert panel to provide transition rate estimates for all 
model states. Guidelines for health economic analysis state that in case where 
data are not available, the use of input from an expert panel is accepted, provided 
that a scientific method is used. The experts were consulted using a Delphi 
method as described in the Dutch guidelines for pharmacoeconomic analyses 
[30]. In case of transition probabilities, the use of an expert panel was crucial 
and far from ideal. However, it was necessary since data were not available from 
literature. We attempted to validate the expert transitions; however, because of 
the scarce literature, this was only partly possible. Hence, a scenario analysis 
was performed to examine sensitivity of model results to these parameters. This 
analysis showed that model results are very sensitive to estimated transitions. 
Hence, empirical data to improve these estimates are strongly needed. As 
elaborated in the “Methods” section, we adhered to the formal requirements 
of the Delphi method and present our results with caution as the focus of this 
study was to build an up-to-date model for evaluation of OROS compared with 
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IR rather than to gather comprehensive input to the model. One should note that 
participating experts received a small compensation, which was strictly limited 
to compensation for their invested time. The authors consider the collection of 
empirical data the necessary next step for further research.
In the current model, important societal costs and effect have been included (i.e., 
health care costs of caregiver, production losses of the caregiver and utilities of 
the caregiver). However, several aspects could not be covered, because of limited 
availability of data. Estimates of justice costs (i.e., incarceration costs, victim 
costs, etc.) could not be included, because of a lack of data in the considered age 
group and in the European context. Out-of-pocket expenses were not included 
as there was evidence from the Dutch literature that these costs were negligible 
[4]. However, when applying the current model to a different setting, country 
adaptation may be necessary, as a Belgian study [63] suggests differences in 
amounts of out-of-pocket expenses. These differences may be attributed to 
differences in sampling methods between the studies, but differences in health 
care systems may also play a role and necessitate model adaptation. Long-
term effects on work and income have not been included in the model but are 
considered relevant. When taking a long-term perspective, these costs should be 
included in the model. Furthermore, in the current model, health care costs and 
production losses of the caregiver, which should be attributed to the behavioral 
problems of the child, were estimated at 25% of the total production losses. 
Mothers of children with ADHD had indicated that this percentage of their 
health care expenditures was related to the behavioral problems of their child. 
As it might be ethically difficult for a mother to blame her child for her medical 
problems, this estimate may be conservative. On the other hand, heritability 
of ADHD may point towards high medical expenditures of mothers for their 
own medical needs. Hence, in total the chosen percentage might be a good 
estimate. Concerning the utilities of caregivers, the literature was especially 
limited. Hence, additional data are necessary to provide a better basis for future 
analyses. So, especially, concerning societal costs, available data were extremely 
scarce, and we emphasize the necessity for additional studies to close this gap.
Earlier cost-effectiveness results of the Faber model [29] resulted in incremental 
costs of 276 EUR and incremental QALY gains of 0.13 of OROS compared to IR. 
The calculations in the current study resulted in mean incremental cost savings 
of 5,018 EUR and mean incremental QALY gains of 0.22. The differences in costs 
can be explained by substantial revision of transition rates based on expert panel 
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estimates, differences in model structure (e.g., consistent model states over 
treatment alternatives and omission of the state of remission because of experts’ 
opinion), update of cost parameters to 2014 values (including a slight price 
deflation on drug costs of OROS) and difference in time horizon. Compared to 
the transition rates presented by Faber et al. [29], which were based on a collection 
of different sources, the experts’ transition rates based on the expert panel 
presented in this study showed significant differences. In the Faber model [29] no 
differentiation was made between the probability of patients in an optimal or in a 
suboptimal state to stop treatment (IR treatment arm). The same was true for the 
probability of patients in the optimal or suboptimal state to achieve functional 
remission or to transfer to a non-compliant/suboptimal state (OROS treatment 
arm). With respect to these probabilities, the Faber model [29] treated patients 
in an optimal and suboptimal state as being equal. These assumptions appear 
rather strong as they a priori prevented differences in compliance affecting the 
chance of functional remission or termination of treatment. In this study, on 
the contrary, the experts indicated clear differences between these transition 
probabilities (table 5). Faber et al. [29] furthermore assumed a chance of moving 
from an optimal to a suboptimal state in the IR treatment arm to be 0 and the 
chance to stop treatment when non-compliant as 0 in the OROS arm. Both these 
assumptions appear counter-intuitive as they imply that a patient treated with IR 
may not miss a dose once he has achieved an optimal state and a non-compliant 
patient receiving OROS may not stop treatment at all. In the current study, the 
expert panel estimated all transition rates without assumptions beforehand to 
achieve a consistent framework of transition probabilities. As the transitions 
have a direct effect on how long patients remain in a state, these estimates have 
a strong influence on both incremental costs and effects and mainly explain the 
difference between the current model outcomes and those of the Faber model 
[29]. The transition estimates by the expert panel showed that patients receiving 
OROS were expected to be less likely to stop treatment, which corresponds to 
the findings from the literature on treatment duration and continuity [14, 15]. 
Furthermore, more patients receiving OROS were expected to move from a 
suboptimal state or a state were treatment was stopped back to an optimal state 
compared to patients receiving IR. These results are in line with the literature, 
as this suggests improved compliance of patients receiving OROS compared 
with those receiving IR [16-18]. However, the expert panel predicted the patients 
treated with OROS to have a lower probability to remain in an optimal state 
than patients receiving IR. This constitutes an unexpected finding given the 
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literature on better compliance of patients receiving OROS [16-18]; hence, we 
consider collection of additional empirical data necessary.
The treatment effects in terms of quality of life were based on parental 
preferences. These were taken from an existing study by van der Kolk et al. 
[57]. It has been shown that the value of quality of life valuation by children 
themselves may be questionable, particularly because of lack of language, 
cognitive limitations, long-term perspective [82, 83] and conceptual difficulty 
of the standard gamble task [84]. Therefore, parental preferences were considered 
most appropriate for the young population of the current study. However, we 
are aware of the shortcomings of this approach, namely the inability of parents 
to accurately estimate invisible and subjective aspects of their child’s quality of 
life, such as social and emotional functioning [82-85]. This limitation may lead 
to inaccurate estimates and a possible overestimation of the child’s disability 
[86]. Besides the utility of the patient, we also included caregiver utility in the 
model. The proportion included was based on very limited evidence from the 
literature. As a scenario analysis showed, model results are sensitive to these 
utilities. Hence, additional data are needed. As economic cost-utility analysis 
and expressing outcomes in terms of QALYs is not yet common in the field of 
child adolescent mental health [87], it may remain relevant for further studies 
to investigate results based both on costs/QALY and on costs per different (more 
clinically focused) outcome measures.
Severity of ADHD was not specified, but average severity was assumed in 
the model. One could, for instance, specify severity of ADHD in the model 
by distinguishing between the following categories of severity: 1) severe: no 
remission achievable; 2) moderate: 50% remission achievable; and 3) mild: 100% 
remission achievable. Furthermore, taking account of co-morbidities may affect 
the costs entered in the model in such a way that part of the costs, e.g., special 
education, may not be attributed to ADHD alone but to behaviors which arise 
from a combination of co-morbidities. In addition, long-term learning delay and 
emotional development problems were not taken into account in the current 
model. Hence, it should be noted that the current methodology is yet incomplete 
and that consideration of additions for long-term effects or consideration of 
different types of outcome measures to better account for the specific effects 
of mental health interventions may be necessary to improve the existing 
methodology.
2
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Finally, as the focus of the study was the construction and demonstration of 
a broad and up-to-date probabilistic model compliant with current health 
economic methodology in this population rather than the provision of extensive 
input to the model, the model results should be interpreted with care. As can 
be seen from our results, future research should especially be directed at the 
collection of empirical data on transition estimates. We specifically suggest the 
collection of data from observational studies with large numbers of ADHD 
patients receiving (different types of) pharmaceutical treatment(s) compared 
with a control group of ADHD patients not treated with medication. It would be 
especially valuable to obtain data on treatment response (i.e., transition rates), 
health care use, school absence and performance, criminal activities and quality 
of life for these groups. To better cover the broad societal aspects, a very valuable 
and relevant addition would be data on the medical consumption, absence from 
work and utility of the caregivers and siblings as well. This information would 
be a valuable and necessary addition to the current model as it would lead to 
an increase in accuracy of the results and form a valuable basis for clinical and 
policy recommendations. 
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Chapter 3
The cost-eff ectiveness of family/family-based therapy 
for treatment of externalizing disorders, substance use 
disorders and delinquency: A Systematic review
Based on Goorden, M.*, Schawo, S.*, Bouwmans-Frijters, C., van der Schee, E., 
Hendriiks, V., Hakkaart-van Roijen, L.
BMC Psychiatry; 2016:16(1), 237.
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Introduction
Family therapy and family-based treatment is considered an evidence-based 
practice treatment for children and adolescents with externalizing disorders, 
symptoms of delinquency and/or substance use disorder [1, 2]. Familial and 
extra-familial systems are known to influence the individual [3-7], and therefore 
family/family-based therapy is not only aimed at the individual youth but also 
at systems surrounding the individual. For instance, delinquency and substance 
abuse in adolescents have been shown to be influenced by family factors, like 
parenting style and attachment [3-7]. In addition, a recent review indicated that 
problems within the extra-familial system, like delinquent peers, problems with 
bonding at school and in the neighborhood are risk factors for delinquency 
and problem drinking [7]. As the individual, familial and extrafamilial systems 
are interconnected, family/family-based therapy not only positively affects the 
adolescent but also the family (family cohesion) and the extra-familial systems 
[8].
For the purpose of the present paper, family therapy and family-based treatment 
is broadly defined as treatments in which primarily family members and/or 
members of the families’ wider networks are involved in the treatment process 
of resolving problems for young people [9] as opposed to treatments that mainly 
or solely focus on the individual youth, or treatments that do not focus on youths’ 
problem behavior, like marital therapy.
Well-known forms of family/family-based treatments are Multisystemic 
therapy (MST) [10], Functional Family Therapy (FFT) [11] and Multidimensional 
Family therapy (MDFT) [12]. Although there is a large overlap between these 
types of therapies, there are also some differences [13]. For instance, in FFT 
and MST there is more focus on antisocial behavior. However, the degree of 
severity of the disorder is often higher in MST compared to FFT. More details 
of these differences are described in Appendix 3.1. Recently, Von Sydow et al. 
[1] systematically reviewed studies on the effectiveness of family/family-based 
therapy for the treatment of children and adolescents who have externalizing 
disorders. Their study included disorders like substance abuse, attention deficit 
hyperactivity disorder, conduct disorder and symptoms of delinquency. They 
concluded that there is sound evidence that family/family-based therapy is 
effective with particularly large effect sizes for delinquency and substance abuse 
measures. However, in the meta analyses that were included in Von Sydow’s 
systematic review, more cautious conclusions regarding the effectiveness of 
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systemic therapy were drawn. Current health care policy in the Netherlands and 
elsewhere places emphasis on the provision of effective mental health services 
in a cost effective way. Family/ family-based interventions are intensive as they 
consist of a relatively high number of sessions per week and subsequently are 
relatively expensive [14-16]. Therefore, there is a need for economic evaluations 
to assess whether additional effects gained through family/family-based therapy 
in comparison to alternative treatments – if observed – justify the additional 
costs. Morgan et al. [17] described eight studies, analyzing the cost-effectiveness 
of family-based treatments for substance abusing adults and adolescents and 
concluded that some of these treatments could be considered as cost-effective. 
However, family based therapies like marital therapy, were also included in 
this study. In addition, the literature search in this study was not systematically 
conducted and was only considering patients with substance use disorders. To 
our knowledge, no systematic review of economic evaluations of family/family-
based therapy in externalizing, delinquent or substance-abusing adolescents has 
yet been performed. Hence, this paper presents a systematic review of economic 
evaluations of systemic interventions in adolescents with externalizing disorders, 
substance abuse or delinquency.
The aim of the present study was to assess the evidence on cost-effectiveness 
of family/family-based therapy for adolescents with externalizing disorders, 
substance use disorders or delinquency, and to evaluate the quality of the 
existing studies, and the generalizability of the study findings.
Methods
The review was performed according to the Cochrane handbook for systematic 
reviews of interventions [18] and adopted the Preferred Reporting for Systematic 
reviews and Meta-Analyses (PRISMA) statement [19].
Search strategy
A systematic literature search was performed in Pubmed, ERIC, Psycinfo and 
Cochrane reviews (including economic trials and clinical trials). These different 
search engines were used because of their high quality, coverage of large databases 
and their focus on economic trials. Search terms encompassed the different 
types of systemic therapy (Functional Family Therapy, Multidimensional Family 
therapy, Multidimensional Foster Care, Multisystemic Therapy, Family Behavior 
Therapy and Brief Strategic Therapy) but also more general classifications 
(systemic therapy, substance abuse treatment, family based therapy, Family 
3
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based intervention, Family system intervention, Family intervention program). 
These terms were searched for in title and abstract and were then combined with 
terms referring to economic evaluations searched for in title and abstract or a 
Medical Subject Headings (MeSH) term (economic evaluation, cost-effectiveness, 
cost-utility, cost benefit, cost analysis, cost measure) and in the title (costs). Costs 
were searched for only in the title, and not in the abstract, because the latter 
resulted in many irrelevant studies. This search term was included as we noticed 
that although in some studies both costs and effects were evaluated, the main 
focus of these studies was to evaluate the costs and a smaller part was referring 
to the effects. Consequently, when only terms referring to both the costs and 
effects were included, these studies would have been missed. The search term 
“Economic modeling” was not explicitly incorporated into the search strategy 
as the modeling should be part of a cost-effectiveness, cost utility, cost benefit or 
cost analysis (corresponding with our aim). Abbreviations were also included. To 
improve our search, MeSH terms were used, see Appendix 3.2 for more details.
Selection strategy
In Fig. 3.1 the selection criteria are described and numbered. The criteria were 
applied to the studies in chronological order and when a study was excluded 
based on a criterion the number as shown in Fig. 3.1 was noted. We considered 
studies from January 1990 until January 2016. The selected study types were 
clinical/randomized controlled trials (RCT), reviews, systematic reviews and 
meta-analyses. The treatment needed to consist of a family/family-based 
intervention, targeted at adolescents (10–20 years old) with a substance use 
disorder, externalizing disorder or delinquent behavior. The method needed 
to be a cost or cost- effectiveness/benefit/ utility analysis. When studies were 
assessed for eligibility based on their abstracts and it was likely that they only 
contained cost-outcomes and no effect-outcomes, they were also included. To 
determine the eligibility of the full text articles, the same selection criteria 
were used, except that accessibility of the study was a requirement (full text 
available) and studies that only contained costs-outcomes and no effect-outcomes 
were excluded. The selection of the articles was performed by two researchers 
independently. Differences in selections were discussed until consensus was 
reached.
Data extraction and risk of bias
The quality of the studies was assessed with the British Medical Journal Checklist 
for authors and peer reviewers of economic submissions [20] and the Consensus 
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on Health Economic Criteria (CHEC) list for assessment of methodological 
quality of economic evaluations [21] as recommended by the Cochrane reviews 
handbook [18]. We also consulted the critical appraisal of the studies by the 
NHS Economic Evaluation Database (NHS EED) structured abstract 195. This is 
a database from Cochrane library consisting of structured abstracts of economic 
evaluations of health care interventions. Full economic evaluations were 
identifi ed from a variety of sources and assessed according to a set of quality 
criteria. Subsequently, detailed structured abstracts were produced. In addition 
to the checklists, information about the economic perspective of the study (health 
care, societal etc.), design, country, follow-up, type of disorder, sample size, study 
dropout, age, gender, type, duration and intensity of intervention, time horizon, 
currency and price year, key features of sensitivity analyses and the included 
cost types were collected for the economic evaluation described in the studies. 
In accordance with the suggestions in the Cochrane handbook [18] fi ve diff erent 
biases of the individual studies were addressed: selection bias, performance 
bias, detection bias, att rition bias and reporting bias [18]. They were respectively 
addressed by assessing if patients were properly balanced at baseline, patients 
and therapists were blinded, outcome assessors were blinded, the amount of 
dropout in the studies and by reading the protocols of the studies.
Results
A total of 731 articles met the search criteria. After removal of duplicates and a 
fi rst selection based on the abstracts, 51 studies matched the inclusion criteria. 
After assessment for eligibility, 11 studies were selected (see Fig. 3.1).
Figure 1 | PRISMA fl ow diagram [19]
3
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*NA=Not available; Two studies were not available
Characteristics of the studies
An overview of the characteristics of the studies, participants and the 
interventions is shown in Table 3.1. Ten of the eleven selected studies were 
published between 2003 and 2015 [22-31] and one study was published in 1996 
207. Eight of the studies originated from the United States (USA) [22-24, 27, 29-32]. 
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Remaining studies were initiated in Sweden [26] ,England [28] and Mexico [25]. 
All studies were (based upon) randomized controlled trials. Two pairs of studies 
[22, 24, 27, 29] were each based on one sample. Most of the studies compared 
a family/family-based intervention with care as usual [23, 26, 28, 30-32]. MST 
was the most researched intervention as it was investigated in eight studies [23, 
24, 26-28, 30-32]. In the Study of Borduin et al. [31] Multisystemic Therapy for 
Problem Sexual Behavior (MST-PSB) was investigated. MST-PSB is an adaptation 
to MST aimed at the treatment of juvenile sexual offenders. A description of the 
(non- family/family-based) comparator interventions is shown in Table 3.2. The 
mean number of sessions of the family/family-based interventions was between 
1 and 3 times a week and the mean duration of treatment was between 12 and 
31 weeks. The average follow-up time was between 6 and 300 months (25 years); 
only four studies followed patients for more than 1 year [26, 28, 30, 31]. Two 
studies were outliers in respect to the time horizon they used (8 years and 25 
years) [30,31].
Six studies were aimed at adolescents with substance use disorder [22, 24, 25, 27, 
29, 32], one study investigated adolescents with a conduct disorder [26], one study 
adolescents at risk for continuing criminal activity [26], one study adolescents 
who had experienced a psychiatric crisis [23], another study adolescents who 
were serious juvenile offenders [30] and one study aimed to investigate juvenile 
sexual offenders [31]. The average sample size of the 9 studies (with separate 
samples) was 178 (SD = 163) with a variation between 48 and 600 patients. 
Follow-up attrition, when registered, was low (not more than 30%). Average 
age at baseline was 15 (Standard Deviation (SD) = 1) years and between 61 
and 96% of the individuals were males. Types of economic analyses included 
cost-effectiveness analyses [23, 25, 27, 29], cost-benefit analyses [22, 26, 30, 31] 
and cost offset analyses [28]. The difference between a cost-offset and a cost-
benefit analysis is often not well-explained. A cost-offset analysis compares the 
monetary value of resource use with the monetary value of costs reduced by 
the intervention (usually health care costs). In contrast to a cost-benefit analysis 
which also focuses on other outcomes that are translated in monetary outcomes 
(like translating number of life years gained to a monetary value). In reality, 
cost-offset analysis is a partial cost-benefit analysis because it compares the cost 
of a program with the monetary value of a single outcome (i.e., avoided future 
health care costs). In two studies, the economic evaluation was not explicitly 
classified [24, 32].
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Legend: I =intervention, C=comparator, NS=not stated,NS1=reference to non-accessible article, NA=not applicable, 
USA=United States of America, SW=Sweden, ENG= England, MEX=Mexico,SUD=substance use disorder, CD=conduct 
disorder, PC=psychiatric crisis, MST=multisystemic therapy, Joint=combination of individual and family therapy, 
group=skill-focused psycho-education group intervention, IT= individual treatment, MST-PSB=MST for Problem 
Sexual Behavior, CAU=care as usual, FSN=family support network, MDFT=multidimensional family treatment, 
MET/CBT12=motivational enhancement treatment/cognitive behavior therapy, 12 sessions;MET/CBT5=motivational 
enhancement treatment/cognitive behavior therapy, 5 sessions, ACRA= adolescent community reinforcement approach, 
DC=drug court with community services, DC +MST=drug court with multisystemic therapy, DC +MST + CM=drug 
court with mst and enhanced with a contingency management programs, FFT=functional family therapy, FC=family 
court with community services, a Cost data was only collected only during 3–9 months, b The intensity of the treatment 
was between 2 and 3 times a week; AT=after treatment
Table 2| Descriptions of comparator interventions
FSN Cognitive behavioral sessions and motivation treatment in combination with a family 
component
MET/CBT5 Motivational component and a cognitive behavioral component, to enhance motivation to 
change drug abuse and to grow the skills to maintain and regulate abstinence
MET/CBT12 MET/CBT5+ 7 sessions of CBT are added to the therapy.
FC Family court treatment with community services/ Appearance court 2 times a year/ outpatient 
alcohol and drug abuse service from the local center of the state’s substance abuse commission
DC Drug court treatment with community services/ Appearance court 1 time a week/ outpatient 
alcohol and drug abuse service from the local center of the state’s substance abuse commission 
and monitoring drug abuse
CM Frequent in home screens for drug use, voucher system contingent on clean screens, and 
drug refusal training.
ACRA Identifying reinforces that are incompatible with the drug use and to strengthen those
CAU Sheidow et al. 198 admission to a psychiatric unit and aftercare
Schoenwald et al. 207 outpatient substance abuse services
Olsson et al. 201 Not described
Cary at al. 203 Youth Offending Team (YOT)
Dopp et al. 205 Individual Therapy (IT)
Borduin et al. 206 Cognitive behavioral group therapy and individual services (from local 
juvenile court)
FSN family support network, MET/CBT5 motivational enhancement treatment/ cognitive behavior therapy, 5 
sessions, MET/CBT12 motivational enhancement treatment/cognitive behavior therapy, 12 sessions; ACRA adolescent 
community reinforcement approach, FC family court with community services, DC drug court with community services, 
CM contingency management programs, CAU care as usual
Outcomes of the studies
Details of the interventions and outcomes of our analyses are described in Tables 
3.3 and 3.4. Costs were indexed until 2014.
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d
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Substance abuse
Six studies were identified which included adolescents that were treated for 
substance abuse [22, 24, 25, 27, 29, 32]. Three of these studies considered costs 
and effects [25, 27, 29] and three considered both costs and benefits [22, 24, 32].
Studies considering costs and effects
In the study of French et al. [25] FFT was shown to be more cost-effective than 
a skill-focused psycho-education group intervention for treating substance use 
disorders and delinquency after the first 4 months. After 12 months no such 
effect was observed. Therefore, after 12 months the cost-effectiveness analysis 
reduced to a simple cost minimization analysis. As only treatment costs were 
considered (narrow perspective), the intervention with the lowest intervention 
costs, in this case group therapy, was considered to be economically beneficial. 
In another study, Dennis et al. [29] computed cost-effectiveness ratios and 
these ratios indicated that overall, the most cost-effective interventions were 
Motivational Enhancement Treatment/ Cognitive Behavior Therapy, 5 sessions 
(MET/CBT5) and Motivational enhancement treatment/ Cognitive Behavior 
Therapy, 12 sessions (MET/CBT12) when compared to Family Support Network 
(FSN) in Trial 1 and Adolescent Community Reinforcement Approach (ACRA) 
and MET/CBT5 when compared to MDFT in Trial 2. Sheidow et al. [27], computed 
Average Cost-Effectiveness Ratios (ACERS). ACERS only incorporate the pre-post 
treatment effect of one single treatment so treatments are not directly compared. 
Although this study showed that Drug Court with community services (DC) was 
more cost effective compared to FC regarding substance use disorders and that 
the addition of multi-systemic therapy (MST) resulted in an economically more 
beneficial treatment, the treatments were not directly compared [27].
Studies considering costs and benefits
Three of the studies that considered adolescents with substance use disorders, 
considered costs and benefits [22, 24, 32]. The study of French et al. [22] indicated 
that MET/CBT-5, MET/CBT-12 and FSN generated significant economic benefits 
to society for substance abusing adolescents, MDFT and ACRA did not generate 
these benefits. McCollister et al. [24] showed that the savings in costs offset 
the treatment costs of DC, especially for DC/MST/ CM, in juvenile drug court 
participants when compared to FC (Family court with community services). 
Schoenwald [32] showed that the monetary benefits of MST compared to CAU 
for substance use disorder almost offset the higher costs of MDFT. Over time 
the difference between benefits and costs may be reduced to a complete offset.
3
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Delinquency/externalizing disorders
Five studies considered adolescents with delinquency or externalizing disorders; 
the study of Sheidow et al. [23], Olsson [26], Cary et al. [28], Dopp et al. [30] and 
Borduin et al. [31] respectively included patients with a psychiatric crisis, patients 
with a conduct disorder, delinquent adolescents, serious juvenile offenders and 
juvenile sexual offenders. One study, Sheidow et al. [23], considered both costs 
and effects and four studies [26, 28, 30, 31] considered both costs and benefits.
Studies considering costs and effects
In the study of Sheidow et al. [23], MST was effective in the short term (4 months) 
in terms of externalizing behavior compared to care as usual for patients with 
psychiatric emergencies. But MST appeared equally effective on the cost measure 
over the long term (12 months).
Studies considering costs and benefits
Olsson [26] showed that for adolescents with conduct disorder MST’s benefits did 
not offset the costs and that MST was subsequently associated with a net loss to 
society. The study of Cary et al. [28] showed that MST in combination with CAU 
has a scope to generate cost savings when compared to providing CAU alone. 
The cost-benefit study of Dopp et al. [30] indicated that MST, when delivered 
to serious juvenile offenders, produces economic benefits well into adulthood. 
Borduin et al. [31] showed that when juvenile sexual offenders are treated with 
MST-PSB; this treatment can produce lasting economic benefits.
Quality of the studies
Only for one study [23] commentary was available from the NHS-EED. We 
compared the commentary on the study with our quality assessment checklists 
to evaluate if all issues were addressed. The quality of the studies was not only 
assessed for the 7 unique studies but for the 9 studies. The argument for including 
all studies was to differentiate between methods (e.g. analysis), display of results 
and discussion even though they were based on the same study. The quality 
assessed with the BMJ checklist was between 52 and 86% (Table 3.5). The quality 
assessed with the CHEC list was between 50 and 79% (Table 3.5). Up to date, there 
are no thresholds (minimum number of criteria satisfied) for these checklists to 
determine the difference between bad and good quality economic evaluations 
[18]. Overall, the outcomes on the checklists matched although quality assessed 
with the CHEC list was consequently lower. The largest difference in quality 
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percentages was 20%. All studies clearly stated their primary outcome measures. 
Most studies did not report all relevant costs and effects.
3
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Table 5 | Assessments of the quality of the studies with the Drummond checklist and the CHEC list
British Medical Journal Checklist 1* 2* 3* 4* 5* 6* 7* 8* 9* 10* 11*
1. The research question is stated. - -      -   
2. The economic importance of the research question is stated.  -   -      
3. The viewpoint(s) of the analysis are clearly stated and justified. -  -  - -   - - -
4. The rationale for choosing alternative programmes or interventions compared is stated.  - - - - -  -  - -
5. The alternatives being compared are clearly described     - - - -   
6. The form of economic evaluation used is stated. -    -      
7. The choice of form of economic evaluation is justified in relation to the questions addressed. NC    -      
8. The source(s) of effectiveness estimates used are stated.           
9. Details of the design and results of effectiveness study are given (if based on a single study).  NA       -  
10. Details of the methods of synthesis or meta-analysis of estimates are given (if based on a synthesis of a
number of effectiveness studies).
NA NA NA NA NA NA NA NA NA NA NA
11. The primary outcome measure(s) for the economic evaluation are clearly stated.           
12. Methods to value benefits are stated.   NA   NA  NA   
13. Details of the subjects from whom valuations were obtained were given.           
14. Productivity changes (if included) are reported separately. NA  NA NA NA NA NA NA NA - -
15. The relevance of productivity changes to the study question is discussed. - - - - - -  - - - -
16. Quantities of resource use are reported separately from their unit costs.   - - - - - -   
17. Methods for the estimation of quantities and unit costs are described. - - - -  -     
18. Currency and price data are recorded.   -  - - -    
19. Details of currency of price adjustments for inflation or currency conversion are given.   - - - -  -   
20. Details of any model used are given NA      NA NA  NA NA
21. The choice of model used and the key parameters on which it is based are justified. NA - -  - - NA NA - NA NA
22. Time horizon of costs and benefits is stated.           
23. The discount rate(s) is stated. NA NA NA NA NA NA  NA   
24. The choice of discount rate(s) is justified. NA NA NA NA NA NA  NA   
25. An explanation is given if costs and benefits are not discounted. NA NA NA NA NA NA NA NA NA NA NA
26. Details of statistical tests and confidence intervals are given for stochastic data. - -  -  -    - -
27. The approach to sensitivity analysis is given.  -  - - -  NC   
28. The choice of variables for sensitivity analysis is justified.  NA NA NA NA NA  NA   
29. The ranges over which the variables are varied are justified. NC NA NA NA NA NA  NA   
30. Relevant alternatives are compared.  NC - NC  NS     
31. Incremental analysis is reported.   -   -  -   
32. Major outcomes are presented in a disaggregated as well as aggregated form    -       
33. The answer to the study question is given.  NC         
34. Conclusions follow from the data reported.          - -
35. Conclusions are accompanied by the appropriate caveats. - -   -    -  -
Total score British medical journal checklist (%) 68 61 63 68 54 52 86 70 83 81 77
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CHEC list
1. Is the study population clearly described?           
2. Are competing alternatives clearly described?     - - - -   
3. Is a well-defined research question posed in answerable form? - -      -   
4. Is the economic study design appropriate to the stated objective?           
5. Is the chosen time horizon appropriate to include relevant costs and consequences? NS NS  NS NS NS  NS NS  
6. Is the actual perspective chosen appropriate? -  - - - -  - - - -
7. Are all important and relevant costs for each alternative identified? - - NS - - - - - -  
8. Are all costs measured appropriately in physical units?   - - - -  -   
9. Are costs valued appropriately?   -   NS     
10. Are all important and relevant outcomes for each alternative identified? - -   -      
11. Are all outcomes measured appropriately?           
12. Are outcomes valued appropriately? -      -    
13. Is an incremental analysis of costs and outcomes of alternatives performed?   -   -  -   
14. Are all future costs and outcomes discounted appropriately? NA NA NA NA NA NA  NA   
15. Are all important variables, whose values are uncertain, appropriately subjected to sensitivity analysis?  - - - - -  -   
16. Do the conclusions follow from the data reported?          - -
17. Does the study discuss the generalizability of the results to other settings and patient/client groups? - -  - -    - - -
18.Does the article indicate that there is no potential conflict of interest of study researcher(s) and funder(s)? -  - - - - - - - - -
19.Are ethical and distributional issues discussed appropriately?           
Total score CHEC** (%) 56 67 61 61 50 50 79 50 79 74 74
 
*Studies: Schoenwald et al., 1996; 2 French et al., 2003; 3 Sheidow et al., 2004; 4 Dennis et al., 2004); 5 
McCollister et al., 2009; 6 French et al., 2008; 7 Olsson, 2010; 8 Sheidow et al., 2012; 9 Cary et al., 2013; 10 Dopp 
et al., 2014; 11. Borduin et al., 2015. NS: Not stated; NA: Not applicable; NC: Not clear. Explanation criteria 
checklist: British medical journal checklist: 1.A specific question is not necessary, as long as the goal of 
the research is clearly stated; 5. The competing alternatives may also be described in a different accessible 
paper from the RCT in more detail 10. The presentation of the results is clearly given and discussions of 
the study contain generalizability and comparison with other studies. CHEC list: 5: Chosen time horizon is 
appropriate when after a certain time no additional effects are attained. **Scores were calculated by dividing 
the positively checked items on the quality checklist by the total minus items on the checklist that were not 
applicable (NA) to the study
Table 5 | Assessments of the quality of the studies with the Drummond checklist and the CHEC list. Continued.
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CHEC list
1. Is the study population clearly described?           
2. Are competing alternatives clearly described?     - - - -   
3. Is a well-defined research question posed in answerable form? - -      -   
4. Is the economic study design appropriate to the stated objective?           
5. Is the chosen time horizon appropriate to include relevant costs and consequences? NS NS  NS NS NS  NS NS  
6. Is the actual perspective chosen appropriate? -  - - - -  - - - -
7. Are all important and relevant costs for each alternative identified? - - NS - - - - - -  
8. Are all costs measured appropriately in physical units?   - - - -  -   
9. Are costs valued appropriately?   -   NS     
10. Are all important and relevant outcomes for each alternative identified? - -   -      
11. Are all outcomes measured appropriately?           
12. Are outcomes valued appropriately? -      -    
13. Is an incremental analysis of costs and outcomes of alternatives performed?   -   -  -   
14. Are all future costs and outcomes discounted appropriately? NA NA NA NA NA NA  NA   
15. Are all important variables, whose values are uncertain, appropriately subjected to sensitivity analysis?  - - - - -  -   
16. Do the conclusions follow from the data reported?          - -
17. Does the study discuss the generalizability of the results to other settings and patient/client groups? - -  - -    - - -
18.Does the article indicate that there is no potential conflict of interest of study researcher(s) and funder(s)? -  - - - - - - - - -
19.Are ethical and distributional issues discussed appropriately?           
Total score CHEC** (%) 56 67 61 61 50 50 79 50 79 74 74
 
*Studies: Schoenwald et al., 1996; 2 French et al., 2003; 3 Sheidow et al., 2004; 4 Dennis et al., 2004); 5 
McCollister et al., 2009; 6 French et al., 2008; 7 Olsson, 2010; 8 Sheidow et al., 2012; 9 Cary et al., 2013; 10 Dopp 
et al., 2014; 11. Borduin et al., 2015. NS: Not stated; NA: Not applicable; NC: Not clear. Explanation criteria 
checklist: British medical journal checklist: 1.A specific question is not necessary, as long as the goal of 
the research is clearly stated; 5. The competing alternatives may also be described in a different accessible 
paper from the RCT in more detail 10. The presentation of the results is clearly given and discussions of 
the study contain generalizability and comparison with other studies. CHEC list: 5: Chosen time horizon is 
appropriate when after a certain time no additional effects are attained. **Scores were calculated by dividing 
the positively checked items on the quality checklist by the total minus items on the checklist that were not 
applicable (NA) to the study
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Risk of bias
All studies were RCTs [22-32]. Two of these studies [23, 32] only included patients 
receiving Medicaid (an aid program regarding insurances for low income 
families in the United States). For these studies, the RCT of the effect study 
contained (due to randomization) balanced samples. However, these samples 
were not checked for balance after the selection of participants who received 
medicaid, so they were at risk for selection bias. All studies had a high risk of 
performance bias, as blinding of both therapist and patient is impossible. For 
two studies [23, 32] blinding was not necessary as both the cost and outcome 
data were extracted from existing data systems (The medicaid billing records). 
Although blinding of outcome assessors is possible to reduce detection bias, no 
study reported to have done so. Blinding is also necessary for pre-allocation 
assessment. All studies were based on randomized controlled trials where 
allocation concealment is necessary. The studies included in this review, did 
not explicitly refer to the allocation concealment. Three studies were at risk 
of attrition bias. These three studies did not describe the number of patients 
that dropped out from the study [24, 27, 32]. Two studies only described the 
overall attrition rate [22, 25]. For one study [29] however, overall attrition rate 
could be extracted by using the study of French et al. [22] as it was based on 
the same participants. Dropout in the effect-study of Sheidow et al. [23] was 
low and although no dropout was described for the economic evaluation, as 
the economic evaluation is based on the same participants, this is expected to 
be low. Overall, dropout rate (when measured) seemed low. Reporting bias was 
assessed by reading protocols from the studies and no bias was reported. Only 
for two studies [22, 29] a protocol existed. Other studies did not have such a 
protocol, although for three studies trial registrations were present [24, 27, 28]. 
There were no indications of deviations from the original design. The economic 
evaluations did not always include all clinical outcomes that were available [23-
26, 32] as there was often only interest in specific outcomes. One study [25] 
excluded clinical outcomes as there was no difference between treatments in 
terms of outcomes and so only costs were considered (costs minimization). The 
exclusion of outcomes was not related to possible negative impact on the results 
as effects in the studies were equally or more beneficial when compared to the 
effects of the comparator.
Methodological summary
Uncertainty around treatment costs was not presented in four studies as 
averages of these costs were used [24, 27, 30, 31]. In six studies [22, 23, 25, 29-32] 
Binnenwerk werkbestand Saskia.indd   94 28-10-2019   12:38:56
95
Cost effectiveness - a systematic review
uncertainty around the (other) estimates was not (fully) addressed. In seven 
studies, a simple one-way sensitivity analysis was used to assess the impact 
that changes in a certain parameter will have on the conclusions [22, 23, 26, 28, 
30-32]. In two studies, sensitivity analysis was applied by imputing missing data 
in different ways. Outcomes proved to be robust [27, 28]. Two studies performed 
scenario analyses meaning that cost estimates (surrounded by uncertainty) were 
increased or decreased. Data proved to be robust [26, 32]. In another study a 
sensitivity analysis was carried out to assess the effect, which outliers in each 
therapy group had on outcomes, but this did not have an effect the results. 
In the studies of Dopp et al. [31] and Borduin et al. [31] a sensitivity analysis 
was applied by using plausible minimum and maximum values (obtained from 
other studies) for offense categories, arrest rates and discount rates. French et 
al. [22] used different models, which assessed the effect on using more or less 
covariates in the models but it did not affect the results. In six of the studies 
cost-effectiveness/utility/benefits were assessed based on models [22-25, 28, 32]. 
Four of these studies used simple regression models [23-25, 28] and two used a 
more advanced least squares random effect model [19, 26]. The remaining three 
studies did not integrate any model in the analysis. Three studies did not report 
their price year (the year to which costs are indexed) [23, 24, 32]. Authors of 
three studies indicated that a societal perspective was adopted, where not only 
health care costs but also other costs, for example those associated with lost or 
impaired ability to work, were taken into account [22, 26, 29]. However, this was 
only true for the study of Olsson [26], as this was the only study to assess costs 
outside the health care sector. In the studies of Dennis et al. [29] and French 
et al. [22], the societal part was defined as using market values for calculating 
the costs of goods and services used. Dopp et al. [30] and Borduin et al. [31] 
conducted cost-benefit analyses and did not explicitly mention their perspective. 
Both studies focused on taxpayer benefits and expressed intangible benefits in 
monetary values. Cary et al. [28] used a narrow perspective as only services 
that were recorded by a specific data-system were included (appointments with 
social workers, connexion workers (a United Kingdom (UK) governmental 
information, advice, guidance and support service for young people aged 
thirteen to nineteen), reparation workers (coordinates and supports a range of 
interventions and community reparation projects that young people will have 
to undertake as part of their Referral or Community Order), parenting workers, 
group workers and psychologists). Sheidow [23] adopted the perspective of 
an institution. Other studies did not explicitly state their perspective. Most of 
the studies only reported treatment costs. A summary of the costs and clinical 
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outcomes measured in the studies is provided in Table 3.6. Following Drummond 
et al. [33], full economic evaluations should not only report costs, but also health 
outcomes. Four studies were classified as cost-effectiveness analyses [23, 25, 27, 
29]. Only one of these studies compared treatments using an incremental cost-
effectiveness ratio [29] as described for instance by Drummond et al. [33]. The 
cost-effectiveness analysis of French et al. [25] was reduced to a simple cost 
minimization analysis as the effects of both treatments after analysis proved to 
be similar. Sheidow et al. [27] calculated average cost-effectiveness ratios (ACER), 
which means that there was no direct comparison between treatments but only 
between the before- and after treatment costs and effects of every participant. In 
four studies it was explicitly stated that cost-benefit analyses [22, 26, 30,31] were 
performed. Olsson [26] considered psychosocial and behavioral effects, but as no 
difference was observed regarding these clinical measures between treatments, 
these effects were excluded from the analysis. French et al. [22] did not value the 
health outcomes on which the intervention was focused (like reduction in days of 
substance use) but did value the effects of treatment on education, employment 
and criminal activity. Dopp et al. [30] and Borduin et al. [31] conducted a cost-
benefit analysis; the cost outcome were the treatment costs and the benefits 
were defined as taypayer benefits, tangible benefits and intangible benefits were 
expressed in monetary values. Cary et al. [28] classified his study as a cost-offset 
evaluation. He calculated the net-benefit, but stated that his study cannot be 
viewed as a cost-effectiveness study as he did not measure health outcome. Two 
studies did not state the type of economic analyses they performed [24, 32], but 
did consider both costs and benefits. Mcollister [24] indicated that her study was 
not a full economic evaluation, as she only considered treatment costs. This is 
also the case concerning the study of Sheidow et al. [27], however, this study 
was stated to be a cost-effectiveness analysis. Furthermore, Schoenwald et al. 
[32] did not classify their study explicitly but considered both costs of different 
health care services and monetary benefits so it can be considered a cost-benefit 
analysis.
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Table 6 | Overview of costs and clinical outcome measures used in studies
Treatment 
costs
Other health-
care costs
Costs outside health 
care sector
Perspective used in the 
economic evaluations
Clinical 
outcome 
measure
(Schoenwald
et al., 1996)
  Healthcare -
(French
et al., 2003)
 Institution -
(Sheidow
et al., 2004)
  Healthcare CBCL/GSI
(Dennis
et al., 2004)
 Institution -
(McCollister
et al., 2009)
 Institution SRD
(French
et al., 2008)
 Institution YSR/days of 
marijuana 
use
(Olsson,
2010)
  Societal -
(Sheidow
et al., 2012)
 Institution TLFB/SRD
(Cary
et al., 2013)
 Institution -
(Dopp
et al. 2014)
  Societal -
(Borduin et 
al. 2015)
  Societal -
CBCL=Child Behavior Checklist; GSI: Global severity index; SRD=Self-Report Delinquency Scale; TLFB=Timeline 
Follow-back Form; YSR=Youth Self Report
Limitation/generalizability summary
Four studies commented on their generalizability [23, 25-27]. Sheidow et al. [23] 
reported that as their sample only consisted of youths enrolled in Medicaid, which 
are generally economically less advantaged, findings cannot be generalized to 
a more economically advantaged population. The same is true, although not 
stated, for the study of Schoenwald et al. [32] who also analyzed Medicaid data. 
The study of Olsson [26] was conducted in Sweden, where MST is twice more 
expensive than in the USA and may play a different role in society. MST in 
Sweden may be used as an alternative to nonplacement interventions as opposed 
to an alternative to placement interventions as found in other studies. Also in the 
study of French et al. [25], which was conducted in Mexico, location and small 
sample size were indicated as limitations for generalizability. The same was true, 
although not stated, for the study of Cary et al. [28] which was conducted in the 
United Kingdom. Also an important limitation (but not mentioned as such) were 
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the omissions of uncertainty around the estimates in the studies of Dopp et al. 
[30] and Borduin et al. [31], so the results should be interpreted with caution. 
Furthermore, the study of Borduin et al. [31] was based on a very small (the 
smallest one in this review) sample size (only 48 patients) so uncertainty around 
the estimates (not reported) is expected to be high. Sensitivity analysis is not a 
solution for this problem as significance of the results cannot be determined (as 
the estimates in the sensitivity analysis are also subjected to uncertainty). The 
juvenile drug court programs, analyzed in the study of Sheidow et al. [27] are not 
easily generalized to other settings as they show great variation due to absence 
of a strict format. In addition, other settings may have different populations and 
salaries implying differences in costs. Almost all studies were cautious with 
drawing conclusions on their data. They not only recognized limitations within 
their research but also recognized that the number of economic evaluations is 
very limited and more research is needed before being able to draw conclusions 
[22-28, 32].
Meta analysis
The data from the economic evaluations were not pooled as the population, 
setting, outcomes, costs and interventions were not comparable across studies.
Discussion
This systematic review summarized and evaluated the cost-effectiveness of 
family/family-based therapy for adolescents with externalizing disorders, 
substance use disorder and delinquency. The overall quality of these studies was 
low; they produced mixed results. Research should consider a wider perspective 
and take into account all relevant costs and effects using sophisticated models. 
Studies evaluating family/family-based therapy concerned various outcomes 
and costs, and investigated a variety of treatments in various populations in 
different settings. Therefore it was not possible to conduct a meta-analysis. As 
expected, most of the studies were conducted in the United States where family/
family-based treatments originate from [10, 11, 34]. The findings cannot be easily 
generalized to other health care systems as they differ between countries. The 
quality assessments showed that overall studies scored between 50 and 86% 
and only two studies scored higher than 80% [26, 28, 30, 31]. Studies that were 
conducted more recently, were in general higher of quality. When the two most 
recent studies [30, 31] were not considered, the quality of the studies overall was 
slightly higher for those studies originating from Europe. The quality of the two 
most recent studies was high when using the quality checklists, however, they 
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also contained some important limitations. Firstly, although quality checklists 
only contain one question with respect to uncertainty around the estimates, it can 
be of paramount importance, especially when the sample size is low. Secondly, 
these studies are not easily generalized to a European setting as they conducted 
cost-benefit analyses, opposed to cost-effectiveness analyses that are commonly 
applied in European studies. Although the checklists used to assess quality of 
the studies depend on the subjective evaluation of the researchers and have yet 
not been validated, these two checklists have received much scrutiny and are 
therefore recommended [18]. Recommendations that follow from the quality 
assessment of the studies that were included in the review, are the following. 
Different treatments that are included in the study should be described more 
clearly so the differences and similarities between treatments are understandable. 
In many of the studies included in the review, the perspective taken was not 
mentioned or did not match with the categories of the costs that were included. 
In line with guidelines for economic evaluations the perspective should be stated 
[33]. A more broad perspective (societal versus healthcare) is recommended. The 
unit costs and resource use should be reported separately and a source of the 
references for the unit costs should be given. It is also important to explicitly 
mention whether a study is considered a cost-effectiveness/cost-benefit or cost-
utility analysis. Most studies included in the review used no model or simple 
models (regression). More complex models, like multilevel analysis, should be 
used. In this way covariates can be included, correlation between measurements 
over time can be addressed, missing data is accounted for and skewness in the 
costs and effects is considered. Uncertainty around costs should also be presented 
by using for instance bootstrapped costs/effects confidence intervals and can be 
visualized in a cost-effectiveness plane. Sensitivity analysis should be applied 
to variables that are uncertain (the rationale behind it should be explained). A 
one way sensitivity analysis is not always sufficient and a sensitivity analysis 
also taking into account interactions between variables should be considered. 
A common discount rate should be applied for all costs and effects. Summary 
measures of the cost-benefit, cost-effectiveness or cost utility should be given. In 
case of a cost effectiveness analysis incremental cost-effectiveness ratio (ICERS) 
should be calculated. For conducting economic evaluations it is advised to 
consult a health economist.
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Conclusions
Although family/family-based treatments are widely used and can be considered 
as effective for the treatment of a wide range of disorders [17], cost-effectiveness 
also needs to be addressed. Taking cost-effectiveness into account may have 
a large impact as family/family-based treatments are expensive. This review 
has summarized the economic evidence of family/family-based therapy for 
substance use disorders and delinquency in adolescents in a systematic and 
transparent way by using state of the art guidelines [18, 19]. As there are few 
studies evaluating the cost-effectiveness of family/family-based therapy and 
the quality of the existing studies is limited, new studies using higher quality 
standards are necessary. Large-scale implementation of these treatment models 
should be held back, until more evidence is available.
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Appendix 1
Table 7 | Description family/family-based interventions
Family/Family based interventions
MST Target family interaction and the extended social systems in youths with substance abuse problems, 
delinquency or antisocial behavior / Permits separate meetings adolescent but preference for family 
/More focus on antisocial behavior/ focused both on family functioning and on extra familial 
functioning / Treatment team not actively involved as observers and actors but team is only self-
reflexive/ Treatment team actively involved as observers and actors /degree of severity higher and 
combination of more problems
FFT Target family interaction and the extended social systems in youths with substance abuse problems, 
delinquency or antisocial behavior/ Almost no separate meetings adolescent /More focus on antisocial 
behavior/More focused on family functioning less on extra familial functioning/ Treatment team not 
actively involved as observers and actors but team is only self-reflexive/ explicitly emphasizes therapist 
is integral part of the system/degree of severity lower
MDFT Target family interaction and the extended social systems in youths with substance abuse problems, 
delinquency or antisocial behavior/ Separate meetings adolescent/ Focus on substance abuse / focused 
both on family functioning and on extra familial functioning /Treatment team not actively involved 
as observers and actors but team is only self-reflexive/degree of severity higher
Sources: Leukehof et al, 2008 ; Oudhof et al, 2009; 
Legend: MST=multisystemic therapy; FFT= functional family therapy; MDFT= multidimensional family 
treatment
Appendix 2
Search terms Pubmed
“family therapy”[MESH]
“Functional family therapy”
 (FFT NOT (“fast Fourier transform” OR “freedom-from-transfusion” OR “fast Fourier 
transforms” OR “fast Fourier transformation” OR “Far-Field Transform”))
 “Multisystemic Therapy”
(MST NOT (“microbial source tracking” OR “minimum spanning tree”))
 “Multidimensional Treatment Foster Care”
 “MTFC”
“multidimensional family therapy”
 “MDFT”
“family behavior therapy”
“FBT”
brief strategic family therapy”
“BSFT”
“family based therapy”[Title/Abstract]
“family based interventions”[Title/Abstract]
“family based intervention”[Title/Abstract]
“family systems intervention” [Title/Abstract]
“family systems interventions” [Title/Abstract]
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“family system intervention” [Title/Abstract]
“family system interventions” [Title/Abstract]
“family intervention program”[Title/Abstract]
“family intervention programs”[Title/Abstract]
“systemic Therapy” [Title/Abstract]
OR 1-23
“economic evaluation” [title/Abstract]
“economic evaluations” [title/Abstract]
“cost effective” [title/Abstract]
“cost effectiveness” [title/Abstract]
“cost utility analysis” [title/Abstract]
 “costs” [Title/Abstract] AND “effect”[Title/Abstract]
 “cost” [Title/Abstract] AND “effect”[Title/Abstract]
“cost” [Title/Abstract] AND “effects”[Title/Abstract]
“costs” [Title/Abstract] AND “effects”[Title/Abstract]
“costs”[Title/Abstract] AND “benefits”[Title/Abstract]
“cost” [Title/Abstract] AND “benefit”[Title/Abstract]
“costs” [Title/Abstract] AND “benefit”[Title/Abstract]
“cost” [Title/Abstract] AND “benefits”[Title/Abstract]
“costs” [Title/Abstract] AND “utility”[Title/Abstract])
 “cost” [Title/Abstract] AND “utility”[Title/Abstract])
“cost” [Title/Abstract] AND “utilities”[Title/Abstract]
“costs” [Title/Abstract] AND “utilities”[Title/Abstract])
“Cost Analysis” [title/Abstract]
“Cost Measures” [title/Abstract]
“cost benefit analysis”[title/Abstract]
“cost measure” [title/Abstract]
“cost” [title]
“costs” [title]
“cost benefit analysis” [MESH]
OR 25-48
NOT (cancer[Title/Abstract]OR psoriasis[Title/Abstract]OR “radiation therapy”[Title/
Abstract] OR diabetes[Title/Abstract] OR diabetic[Title/Abstract] OR obesity [Title/
Abstract] OR aids[Title/Abstract] OR HIV[Title/Abstract] OR sarcomas[Title/Abstract] 
OR chemotherapy[title/Abstract]))
24 AND 49 AND 50
Search terms Eric, Psycinfo and Cochrane
3
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In Eric, the same search terms were used except for the MESH terms. In psycinfo, the 
MESH terms were replaced with APA’s thesaurus of Psychological index Terms and in 
cochrane, the same terms were used.
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Framework for Modeling the Cost-eff ectiveness 
of Systemic Interventions Aimed to Reduce Youth 
Delinquency
Based on Schawo, S., van Eeren, H., Soeteman, D., van der Veldt, M.-C., Noom, 
M., Brouwer, W., Van Busschbach, J., Hakkaart-van Roijen, L. 
The Journal of Mental Health Policy and Economics. 2012;15: 187-196.
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Introduction
Child delinquency poses a high economic burden on society [1] Therefore, 
crime prevention and treatment of youth delinquents is of great importance 
to governments, in particular for Justice Departments. Systemic interventions, 
for instance Multisystemic Therapy (MST), Functional Family Therapy (FFT) or 
Parent Management Training Oregon (PTMO), are relatively costly interventions 
in youth health care aiming to reduce delinquent behavior [2]. Cost-effectiveness 
studies are still limited in the field of youth health care. However, these costly 
systemic family interventions compete with medical treatments and other 
interventions for health care budgets, increasing the need for knowledge 
regarding the operationalization of economic evaluations in this context.
In the Netherlands, as part of an ongoing nationwide action plan of the Ministry 
of Justice, recently a selection was made of evidence-based treatments for 
delinquent youth [3], among which MST, FFT and PMTO were implemented 
given their apparent effectiveness in reducing criminal activity in youths. The 
aim of these systemic interventions is not primarily to produce health in the sense 
of physical health and absence of disease, as measured in the Quality Adjusted 
Life Years (QALY) outcome. These interventions attempt to improve family 
functioning and may even intervene with the peers and school environment of 
the youth [i.e. 4, 5]. Still, these treatments are reimbursed by the Dutch social 
health insurance system and, as such, part of the health care sector. Therefore, 
like other health care interventions, each intervention needs to demonstrate 
value for money since it competes for limited funds with other interventions. 
Efficiency considerations are deemed important in guiding decisions on which 
treatments to reimburse or initiate. However, given the atypical aim of these 
systemic interventions, i.e. reducing youth delinquency, an important question is 
how these types of interventions could demonstrate their efficiency or value for 
money. The conventional health economic approach of measuring improvements 
in terms of QALYs may fall short in this context.
Indeed, considering the literature on reducing youth delinquency, it becomes 
clear that important differences exist between economic evaluations performed 
in the health care sector and evaluations of crime prevention and treatment 
programs. It seems that both fields commonly perform sophisticated effect 
studies, including randomized controlled trials, meta-analyses and systematic 
reviews [6-10]. Considering economic evaluations of crime prevention and 
treatment programs the classical cost-benefit analysis is conventionally used 
Binnenwerk werkbestand Saskia.indd   110 28-10-2019   12:38:57
111
Framework for modelling cost effectiveness
[11, 12]. An extensive cost-benefit evaluation of crime prevention and intervention 
programs has been performed by Aos and colleagues [2] in the United States. 
That evaluation was based on a literature review, computation of average 
effects per treatment program, assignment of a monetary value to the effects 
and subsequently calculation of a net present value in a cost-benefit model 
structure. Furthermore, French and colleagues [13, 14], for example, conducted 
cost-benefit analyses on addiction treatment for substance abusers. These cost 
benefit analyses were deterministic models [2, 13, 14]. In addition, Aos and 
colleagues [2] assessed costs and benefits from a taxpayer perspective. In health 
economic literature, cost-effectiveness analyses are preferably conducted from a 
societal perspective. Another difference between the two fields is, that in health 
economics sophisticated methodological guidelines for economic evaluations 
have been developed, while in the field of criminal justice such guidelines do not 
(yet) appear to exist. Furthermore, in health economic literature, cost-effectiveness 
or cost-utility analyses dominate [12]. In the field of crime prevention and 
treatment, these analyses are limited. Nevertheless, McCollister and colleagues 
[15-17] and French and colleagues [18] conducted various cost-effectiveness 
analyses related to substance abuse treatment, where the effectiveness is for 
example measured as days of re-incarceration [15-17] or as a delinquency score 
[18]. These studies show clearly the use of state of the art methods developed in 
the field of health care, applied in the field of crime prevention and treatment. On 
the other hand, these cost-effectiveness analyses were relatively conventional as 
parameter uncertainty was not captured in the model and long-term estimates 
were not taken into account. A common way to assess the cost-effectiveness 
in health care is the so-called decision analytic model [19, 20]. This approach 
provides a mathematical structure, synthesizing the evidence on costs and effects 
in a treated population under a variety of treatment options and makes the 
uncertainty around estimates visible. An additional advantage of this decision 
analytic modeling approach is that long-term effects can be modeled, even 
beyond the duration of the trial. Decision-analytic modeling and in particular 
inclusion of long-term effects may be especially relevant for interventions 
aiming to reduce criminal behavior. Several authors suggested that criminal 
behavior during adulthood tends to be preceded by behavioral disorders during 
childhood. Berger and Boendermaker [21] stated that serious offenders often 
have a history of problematic behavior in their early years of life. Kim-Cohen 
and colleagues [22] mentioned that most mental disorders in adults “...should 
be reframed as extensions of juvenile disorders”. This suggests that systemic 
interventions for juvenile disorders may reduce future criminal activity later 
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on in life. Estimates of long-term effects are therefore essential to the analysis 
of these interventions.
The current study aims to build a probabilistic decision analytic model like 
common models in health care for assessing interventions primarily aimed at 
crime prevention and treatment in youth care. In developing the model the 
following requirements had to be met:
i. The model should be applicable to assess costs and effects of systemic 
 interventions primarily aimed in reducing delinquent behavior;
ii. The initial model should be fairly simple however easy to adjust to 
 sophisticated details (i.e. severity of delinquency);
iii. The model should be probabilistic, taking uncertainty into account;
iv. The model should be suitable for long-term analysis;
As an illustration an initial assessment of the cost-effectiveness of Functional 
Family Therapy (FFT) compared to treatment as usual (TAU) is presented. As the 
aim of the study is the application of the probabilistic decision analytic modeling 
to interventions aimed at reducing delinquency, the interventions compared 
could be substituted by other systemic interventions mentioned.
The article is structured as follows. The methods section provides information 
on the health economic model type and general characteristics of the model. 
The results section elaborates on the applicability of the decision analytic model 
and outcome measure to the field of systemic interventions specifying necessary 
adaptations to the health economic approach based on an initial assessment 
of cost-effectiveness of FFT. The conclusion relates our findings to the general 
objective of applying health economic methods to systemic interventions not 
primarily aimed at improving health.
Methods
Model structure
We constructed a probabilistic Markov cohort model [19]. Disease progression in 
common Markov models is described using transitions between ‘states’, where 
a subject can move between states or remain in the current state. The transition 
rates between states are typically estimated based on short run data. Long-term 
predictions are made based on repetition of transition cycles and assumptions 
based on for example literature.
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In order to keep the initial model as transparent as possible, a Markov model was 
constructed consisting of three states, i.e. A - criminal behavior, B - non criminal 
behavior and C - dead. The model structure is shown in Figure 1. All subjects in 
our study started in state A, moved to either state B or C or remained in state A 
and could then move between criminal and non-criminal states. Death acted as 
the absorbing state. Note that subjects could also remain in their present state 
(depicted by the u-turns).
Figure 1 | Markov model
nmr = natural mortality rate. 
tpA2A = transition probability of staying in state A.
tpA2B = transition probability of moving from state A to state B.
tpB2A = transition probability of moving from state B to state A.
tpB2B = transition probability of staying in state
Outcome measures and model parameters
In order to apply health economic methods meaningfully in the fi eld of crime 
prevention and treatment, we introduce a new and neutral outcome measure 
of cost-eff ectiveness modifi ed for this particular type of intervention: criminal 
activity free years (CAFYs). The CAFY was defi ned as a measure of time spent 
in a dichotomous criminal or non-criminal state. When extensive data is 
available, criminal activity can e.g. be defi ned as having had police contacts or 
committ ed crimes in the past half year. For the purpose of demonstrating the 
model functioning and in the absence of extensive clinical data, the criminal 
state in this study was based on adolescent recidivism derived from clinical trial 
fi ndings reported by Sexton and Alexander [4]. Transition probabilities diff ered 
according to the treatments off ered. Treatment costs also diff ered per treatment 
type whereas all other costs (Table 1) in the diff erent states were assumed to be 
independent of the treatment arm but dependent on the state. The cycle length 
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used in the model was six months. This corresponds to the period common for 
follow up intervals in clinical trials in the field of crime prevention [6, 7, 23].
Table 1 | Included types of costs
Cost categories Direct Indirect
Health care Medical and mental health care child
(psychologist, psychiatrist, GP, specialist, ER, 
hospital (day) care, medication, youth welfare 
agency (bureau jeugdzorg)*, foster home*, 
residential institution, centre for addiction 
treatment, social worker)
Medical and mental health care parent
(psychologist, psychiatrist, GP, specialist, 
foster care*, center for addiction treatment, 
social worker)
Outside health care Travel expenses (incl. parking) 
Time spent by child on exercises as part 
of therapy* 
Time spent by parent on exercises as part 
of therapy*
Productivity losses parent
(absence from work, inefficiency at work) 
Informal care/ support child
(community centre/ church/ mosque/ 
association, care/support by family or 
acquaintances) 
Criminal justice system child
(Council of child protection, Bureau Halt*, 
Police, Lawyer, Court, Incarceration costs) 
Informal care/ support parent
(community centre/ church/ mosque/ 
association)
* Included until age 30
 
In the developed model two treatment alternatives were compared. To provide 
an example of a cost-effectiveness analysis of systemic interventions, a group 
receiving FFT therapy and a comparison group receiving TAU were evaluated. 
TAU refers to a comparable treatment, which delinquent youth would have 
received if they had not received FFT. As institutions offer diverse types of 
alternative therapies to FFT, TAU may differ between the different institutions. In 
one institution TAU may be MST, while another institution may offer Cognitive 
Behavioral Therapy (CBT) as an alternative to FFT. In our illustration subjects 
could not switch between FFT and TAU.
For an extensive comparison between two systemic interventions, the model 
should include several types of cost categories. Table 1 depicts the common 
cost categories in health economic evaluations; direct and indirect costs inside 
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and outside the health care system adapted to the field of crime. The included 
types of costs are derived from a combination of the costs commonly included 
in health economic evaluations and literature on cost of crime [24]. These costs 
not only pertain to costs incurred by the delinquent juvenile, e.g. costs due to 
criminal activities or treatment, but also to costs falling on family, caregivers 
and the society as a whole. For reasons of comparability with other interventions 
in health care, the model included all relevant societal costs in accordance with 
the Dutch manual for costing in economic evaluations [25].
Discount rates for future costs and effects were set consistent with guidelines for 
economic evaluations in the Netherlands [26]. (Note that differential discounting 
is required in the Netherlands to account for the growth in the value of health 
over time. See for example Brouwer and colleagues [27] for the rationale behind 
this. Therefore, by using these rates it was implicitly assumed here, that the value 
of a criminal activity free year (CAFY) will also increase over time, comparable 
to the rate of a QALY.)
Data analytic procedures: Cost-effectiveness and scenario analyses
In effect studies, uncertainty is generally represented as a confidence interval, 
i.e. the magnitude of uncertainty is expressed in standard deviations of the 
measurement error. This assumes that all relevant uncertainty is measurable 
in a single outcome measure, and that the distribution of the measurement 
error is reasonably normal. As both assumptions do not apply in typical 
health economic evaluations, normal t-tests and other parametric statistics 
are not particularly useful in health economic modeling. Instead, probabilistic 
analysis was conducted to take the uncertainty of the model parameters into 
account. In this analysis uncertainty was simulated by running the Markov 
model several times using a large cohort of subjects, each time with slightly 
different parameter values. These values were obtained by randomly sampling 
from each of the parameter distributions, i.e. gamma distributions for costs, 
and Dirichlet distributions for transition parameters [19]. One thousand Monte 
Carlo simulations were performed. In each simulation a random draw from 
the parameter distributions was taken, which creates a unique set of cost and 
effect parameters. The expected costs and effects were then calculated and could 
be plotted on a cost-effectiveness plane. Four additional scenarios were run to 
demonstrate model behavior under different assumptions. As the transition 
probabilities constitute important model parameters, a scenario was created 
in which probabilities for both interventions were equal. Subsequently, the 
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intervention costs are important parameters, since systemic interventions are 
concerned to be relatively costly [2]. From a societal perspective, family costs are 
assumed to be important, therefore it was investigated how exclusion of these 
costs would influence the results in the third scenario.
Results
The resulting health economic model for systemic interventions showed that 
modelling an intervention with a primary aim of decreasing delinquency was 
feasible. Based on the illustrative comparison of FFT versus TAU, costs and 
effects could be expressed in costs per CAFY. This section elaborates on the 
specific characteristics of the resulting decision analytic model. Obviously, the 
combination using different sources for the inputs of a model is certainly not 
without problems, but we stress that the emphasis here was on building an 
illustrative model and demonstrating the model functioning.
Model structure
Estimates of long-term effects were essential to the analysis and were taken 
into account in the current model. This required some (informed) assumption 
regarding the endurance of effects of treatment also taking into account the 
influence that reaching a certain age or experiencing certain life events may 
have on criminal behaviour [28]. For the current model, information on these 
parameters was taken from the literature. Moffitt [29] roughly suggested that 
after adolescence or at approximately age 30 subjects who are criminal during 
their entire life, life-course-persistent offenders, will remain criminal and 
subjects who only show criminal behaviour during their adolescence, so-called 
adolescence-limited offenders, will have returned to non criminal behaviour. 
This implies a stable state of criminal activity among individuals of age 30 and 
older. To illustrate the option of incorporating earlier theory and evidence on 
the development of offending and antisocial behaviour we integrated parts 
of the long-term stabilising effects described by Moffitt [29] into the current 
model framework. This effect is implemented in the model by extending the 
effectiveness of the treatment till the age of 30 years. Consequently youth remain 
in their current state after that age. Thus after reaching the age of 30, youth 
reach a stable state in their criminal behaviour, which means the transition 
probabilities in the model are from then on defined by mortality rates only. The 
time horizon of the model is 50 years.
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To illustrate how long-term eff ects may infl uence model results, Figure 2 and 
Figure 3 present the percentage of youth in each model state over the time horizon 
of the model, for FFT and TAU respectively. Figure 2 and Figure 3 demonstrate 
that a stable state is already reached after about 1 year, which implies that the 
actual impact of the incorporation of a stabilising eff ect, based on the theory of 
Moffi  t [29] is minor in this model. However, as the model results are only as good 
as the available input used to fi ll the model, the current results only illustrate 
how long-term eff ects could be included in the present model, as it is mainly 
based on assumptions made and empirical data are lacking.
Figure 2 | Percentage of youth in model states over time for FFT
Figure 3 | Percentage of youth in model states over time for TAU
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Outcome measure: CAFY
In health economic evaluations, cost-effectiveness is most commonly estimated 
in cost per quality-adjusted life year (QALY). However, as the predominant effect 
of behavioral interventions for criminal youths is the reduction of criminal 
activity [30] and thus is not directly or exclusively linked to physical health and 
absence of disease, the effect measure QALY seems inadequate to capture the full 
benefit of interventions in adolescent mental health [31]. Therefore, a different 
outcome measure that sufficiently captures the goals of crime prevention and 
treatment was required. Considering the societal perspective of the policymaker, 
a broad outcome measure, directly linked to the goal of a reduction in criminal 
activity, was chosen. As a first step in this context, we chose the outcome measure 
of criminal activity free years (CAFYs), which can be used to determine the 
(incremental) costs per CAFY, i.e. the costs per criminal activity free year. Using 
CAFYs as the effect measure enables decisions based on a non-monetary value 
that is comparable between interventions and that properly reflects the goals of 
the Ministry of Justice while fitting into the health economic modelling approach. 
Existing examples of an effectiveness measure that resembles the use of the 
CAFY measure, is the use of days re-incarcerated [17].
As the model has two states defined as either being criminal or not being 
criminal, the transition from state A, criminal, to state B, not criminal, represents 
the rate of not being criminal after treatment. The transition of state B to state A 
on the other hand represents the rate becoming criminal after having been not 
criminal. It is assumed all youth enter the model as being criminal. The outcome 
of (incremental) costs per CAFY, was (as a first and rather simplified step) 
obtained by assigning different costs to individuals according to their current 
state, criminal state A or non criminal state B. Determining the net present value 
of the additional costs incurred in state A and state B over the full lifespan of 
subjects and dividing these by the amount of additional years the individual 
spends in the non criminal state B during his entire life (compared to TAU) 
yielded an estimate of incremental costs per CAFY. This process of calculating 
life-time costs and dividing these by life-time criminal-activity-free years was 
repeated 1000 times by means of simulation in order to reflect variability in 
input parameters.
Model parameters: Transition probabilities
Transition probabilities were dependent on the definition of the states reflecting 
the choice of outcome measure. In the current model, criminal behaviour was 
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chosen as most relevant outcome measure so that the states were defined as 
‘criminal’ and ‘non criminal’ and transition probabilities between the states 
could be retrieved from literature.
Several studies showed the effectiveness of FFT compared to TAU [4, 18, 32-
34]. Yet, there is no consistent outcome regarding the effectiveness of FFT in 
comparison to TAU. The results based on adolescent recidivism derived from 
clinical trial findings reported by Sexton and Alexander [4] were most applicable 
and comparable to the formulation of our model parameters and definition of the 
comparison group. So demonstrating the model, we used the effectiveness rates 
of that study [4]. As the rate of recidivism based on the clinical trial reported in 
the study of Sexton and Alexander is 33 percent [4], we assumed this rate could 
be equal to the transition from state B to state A in the model and is therefore 
supposed to be equal to 33 percent. As the sum of all transition probabilities 
related to one state in the model sums up to 100 percent, the transition rate of state 
B to state B (individuals remaining in the non criminal state) is set at 67% (100% 
minus 33%). As for illustrative purposes we assumed here that the probability 
of individuals staying non-criminal (B to B) to be equal to the probability of 
becoming non-criminal (A to B),the transition from state A to state B, was fixed 
at 67 percent as well. Again subtracting this transition rate from 100% resulted 
in a probability of 33% for individuals remaining in the criminal state (A to A). 
Sexton and Alexander [4] furthermore suggested that “FFT reduces recidivism 
and/or the onset of offending between 25 and 60 percent more effectively than 
other programs”. As TAU refers to a comparable treatment, we took the average 
of this range as a reasonable and illustrative estimate of the effectiveness of TAU. 
The model therefore was constructed under the illustrative assumption that FFT 
reduces criminal activity 42.5 percent more effectively than TAU.
Transition probabilities were assumed to be fixed over the years, as no further 
long term effectiveness is known yet.
Model parameters: Costs
To fill in the cost parameters in the model the costs in the criminal state were 
retrieved from an ongoing trial of FFT [35]. The volumes of costs in the non 
criminal state were derived from scaling volumes in the criminal state with a 
ratio of cost volumes of anti-social versus “normal” youths presented in a UK 
study on the financial costs of anti-social youths [36]. Unit prices were taken from 
the Dutch manual for costing in economic evaluations [25]. In absence of Dutch 
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unit costs, mean treatment costs of the interventions compared were derived 
from American costs presented in the study of Aos and colleagues [2]. These 
costs are not related to the states but depend on the intervention a youth received.
Cost-effectiveness
As the comparison of FFT with TAU in the current model is illustrative, the 
model results solely fulfill this objective. These illustrative cost-effectiveness 
results from the model point towards lower costs of FFT when compared to 
TAU. Taking the mean from the stochastic results, the number of CAFYs for FFT 
exceeds the number of CAFYs for TAU by 6.88 and the costs of FFT appear lower 
than TAU with incremental cost savings of 8,577EUR (Table 2), positioning the 
intervention in the South East quadrant of the cost-effectiveness plane (Figure 
4). Incremental cost-effectiveness from the illustrative model data expressed in 
costs per CAFY amounts to cost savings of 1,246 EUR/CAFY. These exemplifying 
results suggest that FFT produces better effects at lower cost when compared 
to TAU.
Table 2 | Scenario analyses
CAFY’s gained Cost savings
Base case 6.88 8,577
Scenario 1: transition rate FFT=TAU -0.02 -718
Scenario 2: TC FFT = TC TAU 6.85 9,112
Scenario 3: excl. family costs 6.88 6,307
FFT = Functional Family Therapy
TAU = Treatment As Usual
TC = Treatment Costs
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Figure 4 | Cost-eff ectiveness results - Base case analysis
Scenario analyses
Scenario analysis can reveal how the results change if certain parameters are 
changed. The scenario analysis indicates that the model is particularly sensitive 
to changes in transition rates whereas the results appear rather robust to changes 
in other input parameters (Table 2). When transition rates of TAU and FFT are 
assumed equal (Table 2, Scenario 1), cost savings and CAFY gains entirely 
vanish. Simulation then results, on average, in an incremental eff ect of zero and 
negligible diff erences in costs between the interventions. The results of the model 
thus appear to strongly depend on accurate estimates of transition probabilities. 
Variation in intervention costs does not yield signifi cant diff erences in costs or 
eff ects (Table 2, Scenario 2), whereas exclusion of family costs not only results 
in a decrease in cost savings but also decreases the variance of the incremental 
costs (Table 2, Scenario 3). 
Discussion and Conclusions
This study created a framework for the evaluation of interventions aimed at 
reducing criminal activity in delinquent youth. A probabilistic Markov model 
approach was constructed allowing the assessment of the incremental cost-
eff ectiveness of two systemic interventions. For illustrative purposes, the 
interventions considered were FFT and TAU. As the comparison of FFT with TAU 
in the current model is solely an example to demonstrate model functioning, 
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the model results are illustrative in absence of empirical data. As a first step 
to come to suitable outcome measures in this field, we introduced the outcome 
measure of Criminal Activity Free Years (CAFY) in a probabilistic decision 
analytic model. The presented methodology may provide a basis for further 
development of the model and outcome measures and, ultimately, decision-
making by both Ministries of Justice and, in particular, Health. Policymakers 
may compare cost and effects between different types of interventions aiming 
to reduce delinquency among youth. 
An advantage of using decision analytic models is that this approach enables 
calculation of hypothetical scenarios. Hence, questions of policymakers, for 
example on differences in cost-effectiveness within subgroups of youth or on 
the optimal age for intervention may be answered. Moreover, the decision 
uncertainty is represented in the model results by taking into account the 
uncertainty surrounding the input parameters of the model. The current study 
showed that it was feasible to apply health economic methodology to assess 
interventions aimed at reducing delinquency rates.  The approach was developed 
to be consistent with health economic guidelines. To our knowledge, this was the 
first economic evaluation using decision-analytic modelling in the evaluation of 
systemic interventions for crime prevention and treatment. 
However, a number of important questions remain. First of all, the outcome 
measure presented here is clearly sector-specific. While this enables choosing 
between interventions with similar aims, it does not directly allow comparisons 
with other interventions. This problem is not unique for this context. For 
instance, interventions in elderly care or social care may not be primarily aimed 
at producing health as well. Outcome measures such as the OPUS and ICECAP 
have been proposed as better capturing the benefits of such care [37, 38]. This 
does raise the question, however, of how to trade-off between interventions 
when their aim is not similar and when different outcome measures were used to 
assess cost-effectiveness. This seems to be an important area for future research. 
Secondly, we proposed the measure of CAFY as a first step to demonstrate 
how interventions aimed to reduce delinquency could be evaluated within a 
probabilistic decision model. If such interventions were to be evaluated more 
systematically using methodology like the one presented here, clearly, the 
outcome measure deserves more attention. The outcome measure of the CAFY 
is a very simple and crude one. One could compare it to ‘natural units’ used in 
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cost-effectiveness analysis like gained life years and event free life years. An 
important problem with these measures and the CAFY is that they do not reflect 
the seriousness of the events (e.g. living in a poor or good health state or, in this 
case, engaging in many and severe criminal activities or a few minor felonies). 
However, the definition of criminal activity free could be based on different 
measures, like the number of police contacts or youth self-report of committed 
crimes. Since not all committed crime, irrespective of the seriousness of the 
crime, is reported to the police, the difference in definition could give different 
effectiveness and cost-effectiveness results. Preference weighted measures (like 
the QALY) would be preferred in this context. Such measures could add a weight 
to different types of criminal activities and be more comprehensive in terms of 
the benefits they include (which could even entail a mix of health and crime-
related outcomes). 
Reducing delinquent behavior is an important outcome of systemic interventions, 
but multiple other outcomes may be relevant as well, among which for example 
the ability to live at home after treatment, school attendance or family functioning 
[31, 39]. As these multiple outcomes are not considered in the current model, it 
could be valuable to extend the model or broaden the outcome measure.
Before further use, the model would require improvement, since our analysis had 
a number of limitations. First, the model was limited to three states. Although 
a model is always a simplification of reality, and the current model even was an 
illustration, it should be investigated whether three states are sufficient to provide 
reasonable estimations of reality. Secondly, the states used now were dichotomous 
(criminal or non-criminal behaviour). The severity of criminal offenses is likely 
to be important as well, also as a predictor of future criminal activity [28]. The 
frequency or the types of crime could be an important differentiating factor to 
discriminate more detailed states [28]. Using more differentiated states would 
therefore add validity to the model. However, a necessary condition for the 
formulation of a more complex model is the availability of more and detailed 
trial data. Third, an individual’s history of offenses could be used to predict 
future behaviour and, thus, it may be useful to relax the ‘memoryless’ feature of 
the Markov model [19]. This feature encompasses that once a subject has moved 
from one state to another, the Markov model will have ‘no memory’ regarding 
which state the subject has come from or the timing of that transition. Using 
the history of earlier offences in the model could also improve the resulting 
estimates. The incorporation of long-term effects in the model was based on the 
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coarse assumption individuals reach a stable state of criminal behaviour after 
an age of 30 [29]. However, the impact of using this theory in the current model 
was minor. In future research one could consider incorporating other relevant 
theories like the one used here [29] to improve long-term effect modelling. 
Various other theories and studies about the development of offending and 
antisocial behaviour exist [28], that could be used to incorporate long-term effects 
into the model. For example, Sampson and Laub [40] suggest that offending 
depends on the strength of bonding to society, like bonding to family, peers, 
school and social institutions. In addition, an early age of onset predicts a 
relatively long criminal career [11, 28] and several risk factors for the early onset 
of offending are acknowledged [28]. Besides using studies like those mentioned, 
a stabilising effect could be modelled more smoothly over time or could be based 
on empirical, long-term follow-up data to add more detail to modelling long-term 
effects. Furthermore, Value of Information (VoI) analyses should explore the 
additional value of further research to characterize the uncertainty of the model 
inputs, including long-term effects [19]. Fourth, the cost parameters in the model 
are depicted from a combination of costs used in health economic evaluations 
and literature on cost of crime. However, victim costs and intangible costs, which 
include direct economic losses of the victims and indirect losses suffered by these 
victims, respectively, are not taken into account [41]. Addition of these costs could 
be of value. Finally, model parameters were solely based on the limited evidence 
base of available literature and where retrieved out of different literature sources. 
Ideally, these parameters would be retrieved from more comprehensive empirical 
data. For example, the transition probabilities could be linked to the presence 
or absence of police contacts, contacts with judicial institutions or committed 
crimes. Availability of additional data can refine the input data of the model 
and increase the validity of the model structure and the accuracy of the results. 
Concluding, we used the methods commonly employed in health economic 
evaluations to create a framework for determining the value for money 
of interventions targeted at reducing youth delinquency. The results are 
encouraging, but important further steps still need to be taken. A first next step 
may be the collection of empirical data to test the presented methodology. We 
further suggest the construction of a multidimensional outcome measure that 
enables researchers to capture the multiple dimensions of the treatment goals, 
in a preference-weighted manner. A final matter that deserves attention is the 
value we assign to outcomes such as reduced delinquency. Calculating cost-
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effectiveness is especially useful when the results can be judged against some 
‘threshold’ value. What this should be in this context remains unclear as yet. 
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Value of Information Analysis Applied to Systemic 
Interventions Aimed to Reduce Juvenile Delinquency
Based on van Eeren, H., Schawo, S., Hakkaart-van Roijen, L., Busschbach, J. 
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Introduction
In order to guide policy decisions, it would be helpful to know the cost-
effectiveness of interventions aimed at reducing juvenile delinquency. So 
far, cost-effectiveness analyses have informed an increasing number of 
reimbursement decisions in mental health-care [1-2]. Accordingly, the number 
of cost-effectiveness analyses in the field of crime prevention is increasing [2-10]. 
The inputs in a cost-effectiveness analysis can be uncertain, as available 
information about the costs and effects of interventions is rarely perfect. As 
a result, the decision whether or not to reimburse an intervention is marked 
by uncertainty. When a decision to reimburse an intervention turns out to be 
incorrect, it could lead to suboptimal interventions being approved. These 
interventions create costs in terms of foregone benefits and resources [11-15]. 
Further research may eliminate this uncertainty and optimize the reimbursement 
decision. 
This study aims to estimate the added value of future cost-effectiveness research. 
This type of analysis is referred to as a ‘value of information’ analysis and was 
introduced as part of statistical decision theory [16-17]. It was already applied 
in other research areas, such as engineering and environmental risk analysis 
[18], before it was introduced into health technology assessment [11-15,19], where 
the application of this analysis is now widely adopted, as well as in the field of 
mental health care [20-21].
A value of information analysis reveals the value of conducting additional 
research and identifies the type of research that would be most useful. Its 
results can inform about further research on specific parameters, and more 
precisely inform the decision about which intervention should be reimbursed 
[22]. Furthermore, a value of information analysis can be used to prioritize 
future research, for example by highlighting the merits of certain types of 
research which might add to the reduction of the parameter uncertainty in 
cost-effectiveness analysis [15,23-24]. The potential value of further research 
could then be weighed against the costs of conducting this research in order to 
determine whether it is worthwhile (i.e. [11-12]). 
Because a value of information analysis has not yet been applied in the field 
of crime prevention, we will present an example of this analysis based on an 
existing cost-effectiveness model in crime prevention and treatment [25]. We used 
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two interventions aimed at reducing juvenile delinquency in The Netherlands, 
for adolescents aged 12-18 years. These interventions can be applied to prevent 
juvenile delinquency or used to prevent juveniles committ ing crimes in the 
future, for example after an adolescent has been punished under the juvenile 
criminal laws. Juvenile law in The Netherlands applies to adolescents aged 12-17 
years [26]. Here, not only the criminal act itself is important, but there is a strong 
focus on for example the background and moral development of the adolescent 
[26]. 
Figure 1 | Markov model. 
B.
nmr = natural mortality rate. 
tpA2A = transition probability of staying in state A.
tpA2B = transition probability of moving from state A to state B.
tpB2A = transition probability of moving from state B to state A.
tpB2B = transition probability of staying in state
As the present study was set up as an illustration, data was used solely to 
demonstrate the method. We did not aim to test the superiority of one of the 
interventions that were used to illustrate the method. Therefore, this article 
merely presents a demonstration of the relevance of a value of information 
analysis in the fi eld of crime prevention and treatment. The presented input 
data and results should be interpreted in this context. We will start with a short 
summary of the earlier illustrative cost-eff ectiveness analysis [25], and then 
introduce and illustrate the value of information analysis. 
Methods
Interventions
We compared two interventions aimed at reducing juvenile delinquency. The 
‘Kursushuis’ intervention (translated and referred to as the Course House) 
consists of a domestic foster home where several adolescents live for about 10 
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months and professional care is at close hand. The treatment costs and effects were 
described by Slot et al. [27]. The second intervention is a systemic intervention 
named Functional Family Therapy (FFT), which lasts about 4 to 6 months. The 
costs and effects of this intervention were obtained from a multicentre quasi-
experimental study in The Netherlands [28]. The Medical Ethical Committee of 
the VU University Amsterdam approved this study (number 2008/152).
Cost-effectiveness model 
The Markov model that was used for the value of information analysis consists 
of three mutually exclusive model states: A) criminal behavior, B) no criminal 
behavior, and C) dead [25] (Figure 1). The time horizon of the model was 20 
years, with a cycle length of six months [25]. A societal perspective was taken 
and results were expressed as costs per Criminal Activity Free Year (CAFY) [25]. 
In line with health economic guidelines [29], the input parameters in the model 
were threefold. The first group of parameters were the transition probabilities. 
These reflect the probability that an adolescent transitions through the states. 
The measure of time an adolescent spends in a non-criminal state is used to 
estimate a CAFY. Criminal activity was based on the adolescents’ self-reported 
contact with police in connection with him/her having committed one or 
several crimes; having had no contacts was defined as criminal-activity free and 
having had one or more contacts as criminally active. Transition probabilities 
were extrapolated until the age of 30, as we integrated parts of the long-term 
stabilizing effects described by Moffitt [25, 30]. Dying because of committing 
crimes was not reflected in the CAFY. Adolescents were assumed to face a risk 
of death equivalent to the age specific mortality rates in the general population 
[31]. The second group consisted of costs of health-care use, productivity losses, 
and other societal costs such as costs of the criminal justice system. Both costs 
outside health care, and health care costs were included, such as the costs of 
visiting a psychiatrist or psychologist. As the family system is involved in the 
interventions provided, we included both the costs of the adolescent and those of 
one of the parents. The model state costs were fixed over time until the adolescent 
was 23 years. It was assumed that from that age onwards not all cost categories 
(such as a family guardian or foster care) would remain relevant. The third group 
comprised the intervention costs. The costs of one completed FFT treatment were 
calculated to be approximately €10,900 per adolescent, whereas the Course House 
was about €37,800 (retrieved from Slot et al. [27]). Both costs were extrapolated 
to 2013 Euro’s accounting for inflation based on the consumer price index [32]. 
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The costs and effects in the model were discounted [33, 34], according to the 
guidelines for economic evaluations in The Netherlands [29].
To represent the uncertainty of each model parameter, we assigned parameter 
distributions (S1 table). In a probabilistic analysis, uncertainty was simulated 
by running the model 10,000 times using a cohort of subjects and each time 
taking different parameter estimates from the parameter distributions [11-12]. 
These 10,000 unique sets of parameter values were used to estimate the mean 
expected cost-effectiveness. For further details on the cost-effectiveness model, 
we refer to Schawo et al. [25]. 
Cost-effectiveness analysis 
The stochastic model resulted in the relative cost-effectiveness outcomes of the 
Course House intervention compared with FFT, represented as incremental costs/
CAFY (Table 1; Figure 2). It showed that the Course House was more effective 
than FFT, but also produced higher costs. The cumulative number of CAFYs 
for the Course House exceeded the number of CAFYs for FFT by 0.7, while the 
incremental costs of the Course House exceeded those of FFT by €26,800, thereby 
positioning the intervention in the North East quadrant of the cost-effectiveness 
plane [35] (Figure 2). The incremental cost-effectiveness ratio (ICER) of the Course 
House compared with FFT was 39,000 €/CAFY. 
Table 1 | Cost-effectiveness results over 20 yearsa
Intervention Cost CAFY ICERb NMBc
Course House €249,000 12.4 €39,000 €641,200
FFT €222,200 11.7 - €618,700
a The results represented were averaged over the 10,000 simulations run.
b The incremental cost-effectiveness ratio (ICER) was calculated as the difference in cost divided by the 
difference in CAFYs between the Course House and FFT.
c The net monetary benefit (NMB) was calculated by multiplying CAFYs by the WTP value of €71,700 per 
CAFY and subtracting cost. The Course House is cost-effective compared with FFT, because the NMB of the 
Course House is higher than the NMB of FFT. Due to decimals, the numbers in the table multiplied do not 
give the exact NMB values represented in this table.
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Figure 2 | Incremental cost-eff ectiveness plane for Course House compared with FFT (10,000 simulations)
Parameter uncertainty 
The infl uence of parameter uncertainty on the model outcomes was shown in 
the cost-eff ectiveness-acceptability frontier (CEAF). In the CEAF, the probability 
of being cost-eff ective compared to the other intervention is shown for the 
intervention with the highest expected net monetary benefi t (NMB) for a range 
of societal willingness-to-pay (WTP) values per CAFY, and is therefore cost-
eff ective compared with the alternative intervention [36, 37]. 
Here, the overall maximum expected net benefi t guides the decision on which 
intervention is cost-eff ective compared with alternative intervention [36, 37]. The 
NMB was calculated by multiplying CAFYs by the WTP value per CAFY and 
subtracting cost [11, 12]. The CEAF is illustrated in the results’ section. 
Value of information analysis
In the value of information analysis, the parameter uncertainty in the model is 
monetarized. More precisely, we estimated the value of ‘knowing everything’: 
the ‘expected value of having perfect information’ (EVPI) [12,14]. Having 
perfect information would eliminate parameter uncertainty and optimize the 
reimbursement decision. In estimating the ‘value of knowing everything’, the 
EVPI places an upper boundary on the value of performing further research [11, 
12]. It can be interpreted as the maximum value society ‘should’ be willing to pay 
for additional evidence to reduce decision uncertainty around which intervention 
is preferred and, therefore, inform the reimbursement decision in the future ([11, 
12]). The EVPI is computed by fi rst taking the diff erence between the expected 
Binnenwerk werkbestand Saskia.indd   136 28-10-2019   12:38:59
137
Value of information analysis of systemic interventions
NMB with perfect information and the expected NMB with current information 
per simulation. This difference is equal to the expected benefits foregone when 
making the decision based on current evidence [11, 12]. Comparing the EVPI 
estimates with the costs of this future research reveals whether further research 
is worthwhile. 
As the value of further information is related to the size of the eligible population 
of adolescents to be treated, the EVPI was multiplied with the eligible population 
of adolescents in the population EVPI (pEVPI). About 825 adolescents annually 
were assumed to be eligible for FFT in The Netherlands. When we discount 
this number over five years, which is the assumed lifetime of the intervention 
for which additional research would be useful [11, 29], it resulted in an eligible 
population of 3,820 adolescents. We assumed that the eligible number of 
adolescents for the Course House was equal to that for FFT.   
In a value of information analysis one could also focus on specific groups of 
model parameters. To identify the model parameters that contribute to most 
of the uncertainty and for which future research is the most promising, we 
estimated the expected value of partial perfect information (EVPPI) [11, 12]. 
The EVPPI was estimated using the Sheffield Accelerated Value of Information 
application of Strong et al. [38]. Multiplying the EVPPI values with the eligible 
population results in the population EVPPI (pEVPPI). 
The EVPI and EVPPI not only depend on the uncertainty of the model 
parameters, but also on the WTP per CAFY. In the absence of a WTP per CAFY 
in The Netherlands, we used WTP estimates to reduce crime of Cohen et al. 
[39, 40]. These WTP values per crime indicate the value society wants to pay to 
prevent one crime, for example €32,200 per burglary (Table 2). Table 2 provides 
an overview of these estimates, adjusted for inflation and purchasing power 
parities [41]. Although WTP to prevent one crime is definitely not equal to WTP 
per CAFY, we used it to illustrate what is meant by WTP in crime prevention 
and how the concept can be used in a value of information analysis. We hereby 
implicitly assumed that one crime is committed per year, and thus exactly one 
crime per year is avoided in a CAFY. We estimated the EVPI and EVPPI for 
various WTP values, and we chose an average WTP value to illustrate the result 
in the results section, which was €71,700 (Table 2). 
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Table 2 | Willingness-to-pay values for crimes (Cohen & Piquero, 2009)
Crime WTP in 2007 dollars WTP in 2013 euro’s
Murder $140,000 €128,700
Rape $290,000 €266,600
Armed robbery $280,000 €257,400
Robbery $39,000 €35,900
Aggravated assaults $85,000 €78,100
Simple assaults $19,000 €17,4500
Burglary $35,000 €32,200
Moter vehicle theft $17,000 €15,600
Larceny $4,000 €3,700
Druk driving crash $60,000 €55,200
Arson $115,000 €105,700
Vandalism $2,000 €1,800
Fraud $5,500 €5,100
Other offenses $1,000 €900
Average $140,000 €71,700
The model parameters were grouped into the following ten subsets to indicate 
the direction of research as a result of the EVPPI analysis: research on 1) 
transition probabilities for FFT; 2) transition probabilities for the Course House; 
3) direct health-care costs of the criminal state; 4) direct health-care costs of the 
non criminal state; 5) direct non health-care costs related to the criminal state; 
6) direct non health-care costs related to the non criminal state; 7) indirect non 
health-care costs related to the criminal state; 8) indirect non health-care costs 
related to the non criminal state; 9) intervention costs of FFT; and 10) intervention 
costs of the Course House.
Results
Model uncertainty
The CEAF shows that FFT had the highest NMB for a WTP ranging from €0 - 
€39,000 (Figure 3). At a WTP of €39,000, FFT was cost-effective in 49% of the 10,000 
model simulations, or a probability of 0.49, whereas the Course House was cost-
effective in 51% of the simulations. Above the €39,000 WTP, the Course House 
had the highest NMB and thus was the optimal intervention. This switching 
point in the CEAF is where the NMB for FFT is equal to the NMB of the Course 
House. At this point, the WTP was exactly equal to the ICER value (€39,000 per 
CAFY). 
The CEAF (Figure 3) showed a large error probability. At the WTP of €71,700 
the Course House was cost-effective in 57% of the 10,000 model simulations, 
Binnenwerk werkbestand Saskia.indd   138 28-10-2019   12:38:59
139
Value of information analysis of systemic interventions
which suggests that there is an error probability of 0.43 that could be reduced 
by collecting additional evidence. 
Value of information analysis
In order to know the value of reducing the error probability and to assign a 
value to additional research, we estimated the EVPI. Table 3 illustrates the EVPI 
estimation (based on Soeteman et al. [21]). The table shows the generated NMB 
for each intervention for 6 of the 10,000 simulations, given a WTP value of €71,700 
per CAFY. The EVPI was determined as follows: First, we assumed that decision 
makers have perfect information for each simulation instead of making one 
single choice over all simulations. For example, for simulation 1 and 2, this would 
result in the choice for FFT (see Table 3). Second, we determined the choice 
based on current information. In this case, the Course House had the highest 
expected NMB (€641,200) over all simulations and hence was the preferred 
intervention. Finally, we took the diff erence between the decision based on 
perfect information per simulation and the optimal choice over all simulations. 
This diff erence resulted in the EVPI value or the benefi ts forgone per simulation. 
The expectation of all benefi ts forgone over the 10,000 simulations is the EVPI per 
adolescent, which is €46,000 at a WTP of €71,700 per CAFY. Perfect information 
for an individual adolescent was thus valued at €46,000. Multiplying this EVPI 
value by 3,820 eligible adolescents resulted in a pEVPI of €176 million. This pEVPI 
value suggests that, at a societal WTP value of €71,700 per CAFY, there is room 
to reduce the uncertainty in the model by a maximum of €176 million. 
Figure 3 | Cost-eff ectiveness Acceptability Curve (CEAC)
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Table 3 | Calculation of expected value of perfect information (EVPI) for individual adolescent
Simulation Net monetary benefitsa Maximum net benefit Benefits forgone
Course House FFT
Expectation €641,200 €618,700 € 687,200 € 46,000
1 €481,000 €650,000 € 650,000 € 169,000
2 €553,800 €710,300 € 710,300 € 156,500
3 €513,800 €768,000 € 768,000 € 254,200
4 €717,500 €562,700 € 717,500 € 0
5 €516,200 €671,000 € 671,000 € 154,800
... ... ... ... ... ...
10,000 €602,300 € 587,200 € 602,300 € 0
a Net monetary benefit (NMB) was calculated by multiplying CAFYs by the threshold value of € 71,700 per 
CAFY and subtracting cost.
Explanation:
Decision based on current information: Course House.
Decision based on perfect information: bold.
Expected net benefit with current information: € 641,200.
Expected net benefit with perfect information: € 687,200.
Expected value of perfect information (EVPI): € 687,200 - € 641,200 = € 46,000.
Perfect information can be valued at different WTP values. The extent of the 
monetarized uncertainty surrounding the decision for a range of WTP values is 
represented in the pEVPI curve. Figure 4 presents the pEVPI curve for an eligible 
population of 3,820 adolescents. As an example we consider the point where 
research costs society €50 million (i.e. the pEVPI value at the y-axis in Figure 
4). At this point further research would potentially be cost-effective if society 
were willing to pay more than €17,600 per CAFY (i.e. the value at the x-axis, if 
the pEVPI is €50 million). At lower values of the WTP per CAFY, the benefits of 
further research cannot offset the costs [11, 42]. At a WTP of €39,000 per CAFY, 
the pEVPI shows a local maximum of €127 million. At this point, the parameter 
uncertainty in the model is the highest and thus decision uncertainty is highest, 
as already shown in the CEAF curve (Figure 3). 
Perfect information of subsets of parameters was valued in the pEVPPI. This 
pEVPPI was estimated for a range of WTP values (Figure 4). At the illustrative 
WTP value of €71,700 per CAFY, future research would be most valuable for 
three subsets of parameters: the transition probabilities and the intervention 
costs of the Course House and the transition probabilities of FFT (see Figure 4). 
The pEVPPI of the transition probabilities of the Course House was €125 million 
(€32,700 per adolescent), and the pEVPPI for the transition probabilities of FFT 
was €91 million (€23,800 per adolescent). The pEVPPI for the intervention costs 
of the Course House was €28 million (€7,400 per adolescent). The pEVPPIs for 
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the direct non health-care costs of the criminal state and the non criminal state 
were respectively €8,400 and €43,300 (respectively €2 and €11 per adolescent). The 
pEVPPIs for the other parameter groups were all estimated to be zero (Figure 4), 
meaning there was no potential value of further research into these parameters. 
Given a WTP €71,700 per CAFY further research for these parameters would not 
reduce decision uncertainty. The EVPI and EVPPI values depend highly on the 
WTP value per CAFY, as can be seen in Figure 4 and Table S2. At a WTP of for 
example €40,000, there was indeed potential value of further research into all 
model states costs. Note that due to the interactions within the model structure, 
the pEVPPI for the groups of parameters do not sum up to the overall pEVPI for 
the model (see Figure 4 [11, 42].
Figure 4 | Cost-eff ectiveness Acceptability Frontier (CEAF)
Discussion
While cost-eff ectiveness analyses are increasingly being used in the fi eld of 
crime prevention, the value of further research has not yet been estimated for 
comparison between interventions aimed at reducing juvenile delinquency. 
An earlier developed cost-eff ectiveness model was used to estimate this value 
of further research. This study demonstrated that it was feasible to estimate 
this value of conducting further research in this context, using a value of 
information framework common in health economic evaluations. The results 
can be interpreted as similar to cost/QALY (quality-adjusted life year) studies in 
health care evaluation. 
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In this value of information analysis, the results indicated the parameters for 
which further research was valuable. Our findings show particular uncertainty 
in three groups of parameters: the transition probabilities of the Course House 
and of FFT, and to a lesser extent, the intervention costs of the Course House 
and the direct non health-care costs in both model states. Performing additional 
research in the suggested fields can reduce parameter uncertainty, and hence, 
can reduce decision uncertainty. 
Therefore, the results of a value of information analysis can prioritize further 
research to optimize the final reimbursement decision, thereby increasing 
the probability that adolescents will be assigned to the intervention that is 
cost-effective, compared with the alternative. Given this information, future 
interventions could be reimbursed (or not), and they could also be approved ‘only 
in research’ (OIR) (i.e. further research is required before the intervention can 
be approved) or ‘approved with research’ (AWR) (i.e. research can be conducted 
while the intervention is approved) [43, 44]. For example, from this study we 
can conclude that given a WTP of €40,000 per CAFY, the Course House could 
be ‘approved with research’. The Course House would then be reimbursed 
while further research would be required, for example on the effectiveness 
of the Course House. Current practice in adolescent care in The Netherlands 
illustrates this approval condition: the Dutch Youth Institute identifies effective 
youth interventions, while still conducting research on the effectiveness of some 
of these interventions [45]. However, approval might lead to irrecoverable costs 
when the approval is revised due to subsequent research revealing that the 
Course House was not as effective as expected. Then, approval ‘only in research’ 
might be preferred, because commitment to future costs is avoided until the 
results of further research are known. Approval might even be dependent on 
any change in the effective price of an intervention [44, 46].  
This study was a first attempt to apply a value of information framework to 
the field of crime prevention and treatment of juvenile delinquents. Therefore, 
some considerations should be kept in mind. The value of information analysis 
estimates the monetary value of eliminating all or part of the parameter 
uncertainty of the presented model. However, two other sources of uncertainty 
can influence the results: structural and methodological uncertainty [47, 48]. 
Structural uncertainty relates to structural aspects of the model [47, 49, 50], such 
as the conceptual framework or the transitions between the model states [50], 
and it can lead to different estimated model outcomes (i.e. [51]). This structural 
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uncertainty is likely to be present in our model. For example, we did not account 
for the severity of crimes in the model states or the elevated risk of death for 
adolescents in the criminal state (i.e. [52, 53]). The uncertainty of these aspects 
was not represented in the current value of information analysis. Future cost-
effectiveness models in the field of crime preventions should therefore carefully 
characterize the structural uncertainty [50], and account for it when possible, for 
example by parameterization [49, 50] or model averaging [47, 50, 54]. 
The second additional source of uncertainty is methodological uncertainty, which 
relates to the analytical method chosen [48, 49]. Our model also represents some 
methodological uncertainties, such as whether or not to include the costs of crime 
in the model (i.e. [55]). Here, three methodological uncertainties in our model 
are discussed in more detail. These uncertainties could be resolved through, for 
example, formulating guidelines (i.e.[47, 49]) to model cost-effectiveness research 
in the field of crime prevention.
The first methodological uncertainty concerns the societal perspective used 
in the model, which means that we included the costs and effects relevant to 
society. When considering this perspective in health care, the focus is merely 
on the patient, whereas this will be different in the area of crime prevention and 
treatment (i.e.[56]). In this study, we already included the direct and indirect 
costs of one parent, as well as direct non medical costs of the adolescent, such 
as the costs of contact with the police. Other costs that we did not account for, 
but are nevertheless relevant in the field of crime prevention are: the effect of the 
intervention reflected in both costs and effects, such as increased wellbeing and 
reduced productivity losses (i.e.[56]), in regard to family members (e.g. parents 
or siblings of the adolescents). Further additional categories are reduced victim 
costs and increased victim wellbeing, the reduction of the number of out-of-home 
placements, the reduction of the costs of committed crimes to society, reduced 
costs of avoided crimes to society and the value of reduced fear of crime (i.e. 
[39, 56]).
The second methodological uncertainty deals with the WTP value for a CAFY. 
Although we used the WTP values of Cohen et al. [39, 40] to illustrate the use of 
WTP in crime prevention, WTP to prevent a crime like burglary is definitely not 
equal to WTP per CAFY. Therefore, it is important to carefully estimate the WTP 
value per CAFY. In this study, for example, we could have weighted the WTP 
values of Cohen et al. [39, 40] by the frequency of the crimes as yearly committed 
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by the adolescents in this study, or by the number of yearly registered crimes 
in the Netherlands. For clarity reasons and due to a lack of more detailed data 
regarding the crimes committed, we chose not to use a weighted WTP value. 
Furthermore, for the WTP values used, it is not exactly known which components 
of crime, such as investigation, prosecution, witnesses, legal aid, prevention 
programs, the costs of victims, and the valuation of fear [39] are included in this 
valuation [39,57]. Therefore, further research is needed into which categories of 
costs of crime are included in a WTP value, before determining what society is 
willing to pay for one CAFY. The cost categories included in the cost-effectiveness 
model should also be reflected in the WTP value and vice versa. Also, other 
estimations of the societal WTP might be considered. These could, for example, 
be based on the cost of crime using a bottom-up approach or a breaking-down 
approach [58]. These methods take into account only the costs of crime, not the 
willingness to reduce crime levels. 
Third, to estimate a WTP per CAFY, it should be known what type of criminal 
activity is avoided in a CAFY. The seriousness of the crime, the number of times 
the crime is committed and the types of criminal activity van also be taken into 
account in defining criminal activity. Furthermore, it is important to decide on 
how to measure criminal activity. The CAFY used in our study was based on 
the adolescents’ self-reported contact with the police. However, criminal activity 
may as well be determined on the basis of police registries [27], contacts with 
other judicial institutions [6-8], rates of reconviction [3] or a delinquency score 
[5]. Different definitions of criminal activity can influence the model results. For 
example, not all committed crimes are recorded in police registrations, while 
self-reported measures could yield socially desirable answers. Using the CAFY 
in further research thus requires a clear definition of criminal activity. 
A final remark on this analysis concerns the interventions chosen. FFT and 
the Course House were chosen to illustrate the analysis in the field of crime 
prevention. The interventions under study, however, however could be 
replaced by other interventions aimed at reducing juvenile delinquency, 
such as Multisystemic Therapy, Multidimensional Foster Treatment Care or 
Multidimensional Family Therapy [45]. Contrary to a broader range of cost-
effectiveness studies in the UK and US (i.e. [4, 59]), in The Netherlands, to the 
best of our knowledge, the cost-effectiveness of such interventions has not yet 
been investigated, except for a cost-benefit analyses of ‘Maatregel Inrichting 
Stelstelmatige Daders’ or a case study into ‘Strafrechtelijke Opvang Verslaafden’ 
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[56, 60], which are both aimed at adults. Furthermore, in studying interventions 
in this field, the context of the interventions under study is highly important. In 
our illustration, we assumed that in practice, the interventions would be applied 
completely equivalently. However, preferences for an intervention may influence 
the choice for a certain intervention in reality, such as earlier experience with 
an intervention, specific characteristics of an adolescent, or the availability of 
the intervention itself. In our illustration, FFT may be, for example, used more 
often to avoid committing crimes, whereas the Course House could be used as 
an addition to a punishment under juvenile justice law, where the adolescent has 
already committed a crime. There may then be a higher probability of recidivism 
if the adolescents already have a history of committing crimes [61]. These non-
equivalent baseline situations may influence the measured effectiveness of the 
intervention. Moreover, the situation after treatment may also be different. 
This may affect the acceptance of possible or required further care (i.e.[61]), and 
therefore may influence the final degree of committing crimes in the future. In 
modeling the cost-effectiveness of interventions in the field of crime prevention, 
the application of interventions in practice should therefore be taken into account 
in a cost-effectiveness model, or at least, this should be clarified when modeling 
the cost-effectiveness of such interventions. 
In conclusion, an analysis to estimate the value of performing further research 
had not yet been conducted in the field of crime prevention. The findings of the 
current study illustrate how such an analysis might be estimated and interpreted 
in this field. Future investments in cost-effectiveness research on interventions 
aimed at reducing juvenile delinquency could use this value of information 
framework to efficiently conduct further cost-effectiveness research.
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Clinicians’ Views on Therapeutic Outcomes of 
Systemic Interventions and on the Ability of the 
EQ-5D to Capture these Outcomes
Based on Schawo, S., Brouwer, W., Hakkaart-van Roijen, L. 
The Journal of Mental Health Policy and Economics. 2017; 20(3): 131-136.
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Background
In the light of budget constraints on mental health care expenditures, economic 
evaluations have increasingly gained importance in mental health care. Yet, it 
is unclear whether existing methodology used in health economic evaluations 
captures effects of interventions in mental health equally well as those of purely 
medical interventions. This particularly holds for interventions, which focus 
on broader improvements rather than measurable changes in health alone [1, 
2]. The goals of these interventions may be broad, individualized and may 
not easily be assessed in dimensions of medical functioning such as those of 
a common outcome measure like the EuroQol five dimensions questionnaire 
(EQ-5D) [2]. When compared to medical interventions, effects of mental health 
interventions may be defined less clearly in medical terms but rather as more 
broad improvements of well-being. Shah and colleagues indicate, based on a 
survey among the general UK public, that mental health may not be sufficiently 
captured by the EQ-5D [3].
Systemic interventions, as a particular example of mental health interventions, 
focus on broad improvements of the client’s functioning within his environment. 
These mental health interventions are increasingly used to treat mental disorders 
in adolescents. Multidimensional Family Therapy (MDFT), Functional Family 
Therapy (FFT), Multisystemic Therapy (MST) are examples of such interventions. 
All systemic interventions have in common that they are particularly directed at 
improving the interaction between the client and his environments [4] and hence 
involve not only medical improvements of the client but also improvements 
in communication and interaction with family and often peers and school in 
the treatment process [5, 6]. Measurement of these effects may be relevant to 
the evaluation of treatment success. There are some differences as to the target 
population of the different types of systemic interventions. MDFT is in particular 
used to treat adolescents with substance use disorders and related problems 
[7]. MST is mainly used to treat violent behavior [6]. FFT is predominantly 
used to treat slightly less serious cases of juvenile delinquency [5] as it is a 
less intensive program when compared to MST. Systemic therapy in general 
is also used in internalizing disorders, for cases where involvement of the 
system around the client is of importance. As all systemic interventions involve 
the close environment of the client, effects on (interaction with) third parties 
can reasonably be expected. Also the nature of the treated disorders itself 
(i.e. substance use, delinquency) may imply broad effects and often involves 
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comorbidities [8], which make the effects of these disorders less clear-cut than 
those of other, purely medical, disorders.
In health economic evaluations, the costs of interventions are set off against 
their effects. According to the health economic guidelines [9, 10], these effects 
are commonly measured in terms of quality adjusted life years (QALY). QALYs 
capture effects in terms of health-related quality and quantity of life. Hence 
QALYs are particularly suitable to assess medical effects. QALYs are derived with 
generic instruments such as the EQ-5D [11] or the Short-Form 6-Dimension[12], 
which are completed by patients. For these instruments societal preference-
weights are available, hence it is possible to weigh different aspects of patient 
responses about their health status based on the societal judgment of the 
importance of these aspects and convert these into one single number (i.e. 
QALYs). Of the available instruments, the EQ-5D [11] is the preferred instrument 
in Europe as it has been translated in various languages, has a wide range of 
local societal value sets available and provides a single index of health-related 
quality of life [13, 14]. It contains a descriptive part and a visual analogue scale 
(VAS) and is particularly useful in measuring health-related treatment effects. 
The descriptive part, on which this paper focuses, includes five dimensions (i.e. 
mobility, pain/discomfort, self-care, usual activities, depression/anxiety) with 
three levels each (i.e. no, some or extreme problems) [11].
Studies on the suitability of the use of the EQ-5D in several mental health 
populations provide both positive and negative evidence for its use. In 
populations of schizophrenia patients, Willige [15] stated that the EQ-5D score 
did not sufficiently reflect changes in social and psychological well-being. Yet, 
Prieto [16] suggested that the EQ-5D was valid to be used to assess different 
degrees of illness in schizophrenia patients. In a population of chronic heroine-
dependent-patients van der Zanden [17] found the EQ-5D a suitable measure. 
In bipolar disorder, Hayhurst [18] considered the EQ-5D useful in measuring 
symptoms of depressions, however its ability to reflect manic symptoms could 
not be shown due to a limited sample of investigated patients. Pyne [19] presented 
evidence for the use of health-related quality of life instruments in populations 
of substance use disorders but noted that problems with legal issues and alcohol 
were not properly reflected by the measures. Coast [20] expressed more general 
criticism on the use of the QALY when assessing effects broader than health. In 
2007, Knapp [2] expressed criticism on the ability of measures like the EQ-5D 
to properly assess changes in mental health conditions. He suggested that new 
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measures were needed as to assess interventions in mental health [2] focusing 
on the specific aspects of quality of life of different mental health problems. He 
expressed the necessity to use an instrument, which properly reflects the relevant 
improvements within the treatment process [2].
Hence, though the EQ-5D is commonly used in economic evaluations it is yet 
unclear if it sufficiently captures all relevant benefits of interventions in mental 
health care. To improve this situation, several options can be distinguished, 
including the development of a new outcome measure, the adjustment of an 
existing measure to allow inclusion in economic evaluation or the extension 
of the EQ-5D measure with ‘bolt on’ dimensions [3]. The latter entails adding 
additional dimensions to the current instrument in an effort to improve 
its evaluative scope and sensitivity. For all options, it is necessary to obtain 
information on the relevant domains to be measured (additionally). Hence, this 
study is an explorative study with the goal of gaining initial information on 
relevant domains for potential development or improvement of instruments, 
which would properly capture the effects of mental health interventions in the 
future and can be used in economic evaluations. As a first step to investigate 
this issue, this paper focuses on systemic interventions, which typically aim 
to achieve goals beyond health gains alone. This is done based on the views of 
clinicians on relevant domains and on the ability of the descriptive part of the 
EQ-5D to capture these domains. We considered clinicians a reliable source to 
describe the relevant and specific aspects of treatment success and we aimed 
to find out whether, from their perspective rather than from the perspective 
of health economists, the current health economic method of measuring 
effects based on the EQ-5D captures the most relevant treatment effects. Based 
on semi-structured interviews with the clinicians we explored the effects of 
systemic interventions. Then we inquired whether the clinicians considered the 
dimensions of the EQ-5D to fit and capture the relevant therapeutic goals and 
effects, and whether according to their view, the instrument missed dimensions 
in order to properly capture the goals of systemic interventions.
Methods
We used a qualitative research design of semi-structured interviews as common 
within the context of explorative analyses. We performed these semi-structured 
interviews to attain a first impression of the domains clinicians consider 
relevant in the evaluation of systemic interventions. Individual semi-structured 
interviews were conducted with seven clinicians at the mental health institutions 
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‘Brijder’ and ‘de Viersprong’ in the Netherlands. The interviews were held 
between the 24th of November 2011 and the 2nd of February 2012 at The Hague, 
Halsteren and Etten Leur.
The aim was to at least include one clinician with knowledge of a particular type 
of systemic interventions (MST, MDFT, FFT and general systemic family therapy) 
in order to have a complete picture of relevant outcomes across these types of 
systemic interventions. All clinicians were active providers of one of the systemic 
interventions to young patients from ages 12-18. Clinicians were approached via 
the team leader of their systemic intervention unit, who was provided with a 
general introduction to the research. Individual clinicians were asked to take part 
in an interview of approximately one hour. All interviews were fully recorded.
The individual interviews were started with a general introduction on the 
research project. Participants were informed that the interviews were to be 
recorded and that no reward would be given. The interviews included three 
parts of guided open questions. The first part was aimed at retrieving general 
information about the clinicians. The second part was intended to attain a 
general idea of the therapeutic goals within a systemic therapy setting.. In the 
third part of the interviews, the EQ-5D was introduced. As we inquired on the 
suitability of the instrument to capture relevant treatment effects this part of the 
interview was most relevant and central to our research question. The structure 
of the three parts of the interview is provided in table 1 below.
Table 1 | Structure of the semi-structured interviews with clinicians
Part 1:
General characteristics of the clinician including age, gender, educational background, geographical region 
of work, type of systemic therapy that was provided, years of experience and the approximate number of 
clients seen per week;
Part 2:
Most important outcomes of systemic interventions as perceived by clinicians;
Part 3:
Clinicians’ judgment on the ability of the EQ-5D questionnaire to capture relevant therapeutic goals of 
systemic interventions and the effects which clinicians may miss when the EQ-5D was used to evaluate the 
effects of systemic interventions.
-     Per EQ-5D dimension judgment on suitability to pick up effects of systemic interventions (plus 
       necessary specifications per dimension)
-     Mention of possible missing dimensions when (solely) using the EQ-5D to measure outcomes of   
       systemic interventions
We posed explorative questions and used inductive coding [21], performed by 
one researcher, to retrieve overarching categories or domains. Terms mentioned 
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by the clinicians were translated from Dutch to English and grouped in major 
categories.
Results
Seven clinicians were interviewed. The proportion of female respondents in the 
group of interviewed clinicians was relatively high with 71.4%, which is in line 
with the higher number of females within the profession of clinicians. The age 
of the clinicians ranged from 30 to 60 years with a mean of 42.1 years. Four out 
of the seven clinicians worked for the mental health institution Brijder, which 
is specialized in treatment of substance use related problems. The remaining 
three clinicians worked for the mental health institution ‘de Viersprong’, which is 
specialized in personality disorders. Geographical regions in which the clinicians 
worked included four Dutch provinces: North Holland, South Holland, Brabant 
and Zeeland. Six of the clinicians had a Bachelor’s degree in Psychology and 
one had a Master’s degree in psychology. Six had obtained training on systemic 
interventions and one was currently following training on systemic interventions 
to learn to perform a specific type of systemic intervention or systemic treatment 
in general (i.e. MDFT, FFT, MST, and general systemic therapy). The years of 
experience with systemic therapy of the clinicians ranged from 0.1 to 23.0 years 
with a mean of 8.4 years, and a median of 4.5 years. The number of clients seen 
per week ranged from 2.5 to 9.5 per week with a mean of 5.4 per week.
The responses to the question of what would be the most important outcomes 
of systemic interventions in practice were listed. Based on inductive coding 
answers of respondents were summarized in ten major categories. Items of 
the category ‘family interaction/functioning’ were most often mentioned with 
38 sub-terms belonging to that category. Furthermore, ‘parental functioning’, 
‘criminal behavior of the youth’, ‘parental (mental) health’, ‘(mental) health and 
functioning of the youth’, ‘substance use of the youth’, ‘social competences of 
the youth’, ‘school or work attendance of the youth’ and ‘marital functioning 
of parents’ were mentioned between four and eight times. Finally, ‘financial 
problems of the parents’ were mentioned twice.
The answers to the questions on the relevance of the EQ-5D dimensions provided 
clinicians’ judgments on the ability of the current dimensions to capture relevant 
outcomes of systemic interventions and suggestions for additions per dimension. 
The interviewed clinicians considered several of the EQ-5D dimensions relevant 
for the evaluation of systemic interventions. The dimensions ‘usual activities’ 
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and ‘anxiety/depression’ were considered particularly important to measure 
the outcome of systemic interventions. Respectively seven and six respondents 
considered these relevant. The dimension ‘self-care’ was judged relevant by three 
out of the seven respondents. The dimensions ‘pain/discomfort’ and ‘mobility’ 
were considered less relevant. Five clinicians considered ‘pain/discomfort’ 
irrelevant. All clinicians judged the dimension ‘mobility’ to be irrelevant as 
well. The clinicians further suggested specific textual additions to the existing 
EQ-5D dimensions, which could make the instrument more suitable for 
assessment of systemic interventions. Clinicians suggested the dimension ‘usual 
activities’ to focus on school, leisure, and work and on meeting appointments 
or agreements. According to the clinicians, the dimension ‘anxiety/depression’ 
should explicitly include substance-related aspects of depression and anxiety 
and aspects of aggression. The ‘self-care’ dimensions should specify and include 
not only daily aspects such as being able to get up, brushing teeth and taking 
regular meals but also more general aspects such as maintaining a healthy 
pattern, adhering to medication, being able to use a bike or public transport. 
Dimensions which the clinicians considered relevant for the evaluation of 
systemic interventions and which are not captured by the EQ-5D instrument 
were aspects of family functioning, systemic relations (peer, school, other), 
addiction, parental functioning and mental health, daily functioning (useful 
activities and occupation), aggression and self-confidence. According to the 
interviewed clinicians these aspects were not sufficiently covered by the EQ-5D.
Discussion & Conclusions
Based on semi-structured interviews, this study aimed to explore clinicians’ 
views on the therapeutic goals of systemic interventions and to elicit their 
opinion on the ability of the EQ-5D to sufficiently capture and evaluate these 
goals. This study has provided a first indication of the aspects, which, from the 
view of clinicians, should be considered when evaluating the cost-effectiveness 
of systemic interventions.
The interviews revealed that clinicians considered a broad array of outcomes 
relevant to the measurement of the effect of systemic interventions. These 
outcomes not only included medical aspects, but also encompassed broader 
(societal) effects such as family functioning, parental functioning, social 
competencies, school attendance, etc. The clinicians considered several of the 
EQ-5D dimensions relevant (i.e. in particular ‘usual activities’ and ‘anxiety/
depression’) for the evaluation of systemic interventions. Nonetheless, they 
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suggested that some of the dimensions needed additional specifications in 
order to be more suitable in this context. This does imply moving away from 
the current content of those dimensions, as included in the EQ-5D. Furthermore, 
without an exception all interviewed clinicians emphasized that a number of 
broader life dimensions were missing in the EQ-5D but relevant (and required) 
when evaluating systemic interventions. Most often mentioned by the clinicians 
in this context were systemic dimensions such as family relations and relations 
with others (peer, school, etc). Also specific aspects of addiction were considered 
relevant additions by several of the clinicians.
Given these findings, one could choose different paths to attain a suitable 
instrument for evaluation of systemic interventions. One of these could be 
the use of bolt-ons to the EQ-5D or mapping specific, non-preference based 
instruments on the EQ-5D. Also one could search among existing instruments 
for an instrument more sensitive to the underlying goals of the interventions. 
Such an instrument would, besides the common medical aspects, also capture 
the systemic aspects of the interventions and aspects of addiction. There are 
several instruments available in the field of addiction and delinquency which 
assess multiple dimensions of functioning of a client within his environment 
and which may hence be suitable to be used. Examples of such instruments may 
be the Adolescent Drug Abuse Diagnosis (ADAD) [22], the Child Adolescent 
Functional Assessment Scale (CAFAS) [23], the Global Appraisal of Individual 
Needs (GAIN) [24], the Teen Addiction Severity Index (T-ASI) [25], and the 
WAJCA-RA structured interview [26]. However, none of these instruments was 
designed for use in economic evaluations. Hence, no preference weights (utilities) 
for their outcomes exist, severely limiting their use in economic evaluations. A 
possible route forward would be to derive such preference weights for more 
elaborate instruments, which would facilitate their use in the context of economic 
evaluations of systemic interventions (in a similar way as the EQ-5D, i.e., in 
cost-utility analyses). This does imply that their results are not comparable to 
common economic evaluations using a different concept of relevant outcome 
(health-related quality of life) and a different outcome measure (e.g., EQ-5D). 
An alternative would be to search for broader outcome measures that could be 
relevant in both contexts, such as wellbeing measures.
Whichever way one chooses to go forward, our overall conclusion from this 
study is that more dimensions should be included in the evaluation of systemic 
interventions than is currently done.
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The current study was an explorative analysis and has clear limitations affecting 
the generalizability of the presented results. First, the total number of therapists 
was small as we had to deal with practical issues of inclusion (such as limited 
time and availability of therapists). The selection of respondents therefore 
was partly pragmatic. However, we included at least one therapist per type of 
systemic intervention to cover all types of systemic interventions provided by 
the institutions. Furthermore, the number of interviewed therapists included 
a larger proportion of clinicians with specialization on MDFT. Hence there 
was a(n intentional) strong focus on clients with problems of substance use. A 
consequence may be that the importance of addiction-related improvements 
may have been overemphasized. Yet, we observed that, despite the small sample 
size, the dimensions we found in this study are in line with the literature on 
the goals of systemic interventions [6; 27; 28; 29]. We also observed considerable 
overlap between the answers of the different therapists, suggesting saturation 
so that additional interviews would not result in additional dimensions or 
insights. Furthermore, one of the interviewed clinicians had just started 
providing systemic interventions and, therefore, had little experience with these 
interventions. In addition, the current study was set up as a pilot study aiming 
to perform an explorative analysis of the goals of systemic interventions and of 
the ability of the EQ-5D to capture these effects in economic evaluations. Hence, 
the results need to be interpreted with this (explorative) intention in mind.
Practical implications of the current study are that enhancements of the current 
health economic methodology appear necessary when evaluating systemic 
interventions. To capture all relevant outcomes influenced by these interventions 
in economic evaluations, in particular broader outcome measures than purely 
health-related quality of life measures such as the EQ-5D seem required. A focus 
of future research could be on investigating the suitability of other available 
instruments for use in economic evaluations of systemic interventions or to make 
existing (validated) instruments like T-ASI or ADAD suitable for this purpose. 
Without appropriate outcome measures, evaluations may risk misinforming 
policy makers and funding decisions.
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Background
Systemic family interventions are psychotherapeutic treatments, which are 
increasingly used to treat children and adolescents with mental disorders. These 
interventions are based on the idea that the behavior of a patient is the result 
of interactions between himself and the different ‘systems’ he is involved in 
(i.e. family, peers, school, etc.) and of the interactions between these systems 
[1-3]. Treatment is directed at improving the disturbing aspects within these 
interactions [3] and it actively involves the systemic context of the patient. Hence, 
potential effects are broad and may range from improvements in the interactions 
with parents, other family members, peers or neighbors, to improvements in 
educational achievements and work relations, reduction of criminal activity and 
substance use and reduction of problems with the juvenile justice system [2, 4-6]. 
Systemic family interventions have shown particularly effective in the treatment 
of adolescents with substance use disorders and delinquency [7-10]. Examples 
of these interventions are Multisystemic Therapy (MST), Functional Family 
Therapy (FFT), Multidimensional Family Therapy (MDFT) and Brief Strategic 
Family Therapy (BSFT) [7-10]. 
With the increasing use of systemic family interventions, the question of 
funding and reimbursement arises. In some countries, like the Netherlands or 
the United Kingdom, systemic family interventions are reimbursed from social 
health insurance schemes and, as such, are part of collectively financed health 
care. Hence, the interventions compete for limited funds with other health care 
expenditures and, on top of proving effective, need to demonstrate value for 
money. Common practice in the economic evaluation of medical interventions 
is the use of cost-utility analysis (CUA) [11, 12] measuring effects in terms of 
Quality-Adjusted Life-Years (QALYs). QALYs combine length and quality of 
life gained. Typically, quality of life is measured through preference-based, 
generic health outcome measures (such as the EQ-5D). These outcome measures 
typically concentrate on improvements in a number of health domains. A recent 
publication of our department [13] described the results of a CUA of MDFT 
versus Cognitive Behavioral Therapy (CBT) in which the effects were measured 
with the EQ-5D. Yet, in the field of mental health, doubts have been expressed 
[14, 15] on the use of these generic quality of life measures [16] as these tools 
might be too limited to cover all relevant treatment effects. Studies on the 
applicability of these measures in mental health have presented mixed results [14, 
15]. Furthermore, there is increasing attention for the inclusion of spillover effects 
on caregivers and families in economic evaluations. Currently, these effects are 
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not yet included [17, 18], though they may be particularly important in treatment 
of younger patients. Recently, the Second Panel of Cost-Effectiveness in Health 
and Medicine has recommended further research on quality of life effects on 
family members of patients [19].
Both aspects, the assessment of effects specific to mental health treatments and 
the inclusion of (partial) effects on third parties, seem of particular relevance to 
the economic evaluation of systemic interventions in delinquency and substance 
use in adolescents. As outcomes of systemic family interventions are broad and 
transcend health gains, conventional CUA outcome measures may be too limited 
and insufficiently connected to clinical practice. This may be one of the reasons 
why economic evaluations of systemic interventions are still scarce and overall 
of low quality [20]. Existing economic evaluations of these interventions vary in 
setting, design and in outcomes measured [20] hence limiting the comparability 
of results. Furthermore, few studies consider effects on others than the patient [1].
If the aim is to perform economic evaluations of systemic family interventions 
which account for all relevant effects, a disorder-specific multidimensional 
measure that captures all relevant systemic contexts would be desirable. Ideally, 
if such a measure had societal preference-weights attached to its dimensions and 
levels, it would deviate from the common CUA methodology yet enable CUA-like 
economic evaluations. In patients with substance use disorder (one of the patient 
groups treated with systemic family interventions), the need for such a single 
comprehensive outcome measure capturing the full benefits of treatments has 
been recognized before [21]. Deas and Thomas [22] and Hogue and Liddle [23] 
emphasized the necessity of assessing various outcomes beyond effects in the 
adolescent. In an illustrative pilot study, Jofre-Bonet and Sindelar [21] presented a 
first example of a preference-based measure for adult populations with substance 
abuse. However, that measure was not based on standard preference-elicitation 
techniques but the authors attached patient preference-weights to the eight main 
domains of the Addiction Severity Index (ASI) [24] by constructing a weight 
index. 
In the current study, we take this line of research further by searching for a 
multidimensional outcome measure to evaluate systemic family interventions 
in the populations of adolescents with substance abuse disorder or problems 
of delinquency. Such a measure could facilitate CUAs of systemic family 
interventions and could either be based on existing effectiveness measures in 
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this fi eld or fully designed anew. In both cases, the use of an existing measure 
or the design of a new measure, relevant domains would need to be identifi ed. 
Based on consultation of the literature on systemic family interventions [1, 25, 26] 
the domains relating to aspects of the individual patient, family, school (or work) 
and other community environments (e.g. peers, neighbors) were considered most 
relevant to the evaluation of the interventions. Figure 1 provides a graphical 
illustration of these domains, which indicate where potential eff ects may occur. 
The strength of the impact on the diff erent systems may obviously diff er, 
depending on the exact underlying problems and other contextual factors. 
Figure 1 | Systems involved in systemic family interventions for treatment of delinquency and sub-
stance-abuse in adolescents
We perform a systematic literature review to investigate and appraise available 
instruments in the fi eld of adolescent delinquency and substance use, which 
cover the relevant domains and which are already accepted and validated in 
the fi eld. We assess which of these instruments might be most suited to serve 
as a basis for a preference-based measure in CUA, based on characteristics 
like comprehensiveness, brevity, accessibility, psychometric properties, etc. 
Advantage of using an existing instrument would be its being established, 
accepted and validated in the fi eld and known by clinicians. It would then only 
be necessary to add preference-weights to the domains to account for diff erences 
in impact of each domain. In this way we aim to contribute to the development 
of adequate outcome measures to assess the economic value of systemic family 
interventions in the treatment of delinquency and substance use.
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Methods
We conducted a systematic literature review to identify instruments within the 
effectiveness and efficacy literature of mental health interventions for adolescents 
with substance use disorder and delinquency problems. We then assessed the 
suitability of these instruments for use of preference elicitation techniques. 
The assessment was based on several characteristics relevant to attain societal 
preference weights. These characteristics were among others the coverage of the 
systems displayed in figure 1 (i.e. youth, family, peers, school, work, society and 
neighbors), brevity, practicability of use, accessibility, psychometric properties 
and acceptance in the field. The review protocol was not registered. Yet, this 
study adhered to the PRISMA reporting guidelines [27].
Criteria for inclusion
Types of participants
The target population of the systematic literature review consisted of adolescents 
between 12 and 18 years of age with symptoms of delinquency and/or substance 
use. Patients from specific sub-groups (e.g. homeless or runaway adolescents 
or adolescents with substance use disorder and comorbid depression) were 
excluded. As studies focusing on these subgroups evaluated specific outcomes, 
which were not necessarily relevant for the entire population of adolescents 
with substance use disorders and delinquent behavior, these studies were not 
considered relevant for the current study.
Types of interventions
We included studies on various mental health interventions for adolescents with 
substance use disorder or delinquency in a therapy/counseling setting in the 
systematic search to cover as many instruments as possible in the relevant target 
population. Individual interventions as well as systemic family interventions 
were included. Examples of such interventions are Cognitive Behavioral Therapy 
(CBT), Motivational Enhancement Therapy (MET), Multidimensional Family 
Therapy (MDFT), Multi Systemic Therapy (MST), Functional Family Therapy 
(FFT) and Ecologically Based Family Therapy (EBFT). Two types of interventions 
were excluded. First, interventions in mental health care that consisted of only 
pharmacotherapy were excluded since the focus of our study was specifically on 
the effect of psychosocial interventions. Second, mental health interventions for 
the prevention of criminal behavior or substance use disorder were excluded, as 
the symptoms within this group (i.e. high risk behavior or general behavioral 
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problems) were not considered severe enough to fi t the defi nition of the target 
population. 
Types of outcome measures
Our objective was to identify a wide array of instruments used to measure the 
eff ect of mental health interventions for adolescents with substance use disorders 
and delinquent behavior. Hence, we included studies with all measures of 
eff ectiveness and treatment outcome as well as effi  cacy studies.
Search methods for identifi cation of studies
Databases were selected as to cover both interventions in the medical and in the 
educational fi eld. The systematic literature review was performed in PubMed, 
Psychnet (PsycBOOKSc, PsycCRITIQUES, print), Cochrane and ERIC (Education 
Resource Information Center) to identify all eff ectiveness studies of mental 
health interventions for adolescent with substance use disorder or problems of 
delinquency. The databases were consulted between 5 March 2013 and 8 March 
2013. Additional studies were identifi ed based on reference list search. There 
were no restrictions on the type of publication. The language of publication was 
required to be English and publication date was 1990 or more recent. The search 
strategy used is displayed below.
Data analysis
Study selection
First, duplicates were removed. Then, the study selection was performed in two 
rounds. First, a selection based on title and abstract was performed, then selected 
articles were subject to a second screening based on full texts. Both rounds 
Binnenwerk werkbestand Saskia.indd   170 28-10-2019   12:39:01
171
Search for relevant outcome measures
of selection were performed by two researchers independently and were each 
followed by a round of consensus. The eligibility criteria for the fi rst selection 
based on title and abstract were the following. 
aexcluding interventions consisting of pharmacotherapy only and prevention interventions
bexcluding less severe symptoms like high-risk behavior or general behavioral problems and specifi c 
subgroups (i.e. homeless, runaway, patients with comorbid depressive disorder)
Subsequently, when abstracts or titles adhered to the above screening criteria, 
full texts were independently screened for inclusion based on the following 
(additional) criteria.
cexcluding interventions consisting of pharmacotherapy only and prevention interventions 
dexcluding less severe symptoms like high-risk behavior or general behavioral problems and specifi c 
subgroups (i.e. homeless, runaway, patients with comorbid depressive disorder)
eclear outcome domain or instrument was stated in the text; process measures such as therapy dose, therapy 
adherence or motivation to change were not considered principle outcomes and were hence excluded.
Furthermore, articles from reference lists of reviews were identifi ed. For these, 
we performed a shortened screening and selection procedure. Titles of these 
articles were screened based on the following criteria: a) >=1990; b) peer-reviewed 
article; c) randomized control trial or eff ect/eff ectiveness/effi  cacy study/treatment 
outcome; d) adolescents; e) delinquency/off enders/substance-abuse; f) mental 
health intervention (no pharmacotherapy). If this selection resulted in inclusion, 
the abstract was screened and a fi nal decision on inclusion or exclusion was 
made. Included articles were added to the database of identifi ed articles for 
further data synthesis.
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Data extraction
Data extraction was performed in MS Access with predefined fields. From all 
selected studies, general information, such as the title of the study, the name of 
the author, journal, etc., were recorded, as well as information on the sample size, 
the studied population and type of intervention (systemic, other [i.e. individual, 
group intervention], both). 
In addition to this general information, instrument-specific information was 
extracted. This information consisted of instrument names (e.g. Child Behavior 
Checklist [CBCL]) and covered domains (e.g. family functioning, adolescent 
behavior, etc.). This information was recorded in order to identify the instruments 
currently used in the field and their coverage of the different systems relevant 
for the evaluation of systemic family interventions (figure 1). 
Synthesis and evaluation of results
As a next step, domain names of the instruments were extracted from the 
identified articles and linked to the systems relevant for the evaluation of 
systemic family interventions (figure 1): youth, family, peers, school, work, 
society and neighbors. Domain names were verified with available resources 
such as guidelines, websites of the developer and other articles using the same 
instrument. After verification, the domains were translated into the systems 
mentioned in figure 1. For this purpose, domains related to the adolescents 
themselves, such as ‘substance use and abuse’, ‘physical health’ or ‘mental health’ 
were linked to the system ‘youth’ whereas domains such as ‘family relations’ 
were recoded into the system ‘family’, domains like ‘peer relations’, ‘social skills’ 
or ‘leisure/recreation’ were labeled as ‘peer’ system, domains like ‘educational 
status’ were labeled ‘school’ and ‘delinquency’ as ‘society’. Table 1 provides 
an example of the process of recoding for the Problem Oriented Screening 
Instrument for Teenagers (POSIT). Next, all instruments were classified based 
on the number of systems (presented in figure 1) covered and ranked from 
highest to lowest. Those covering five or more systems were considered most 
relevant for our purpose as those covered the majority of effects of systemic 
family interventions in adolescents with substance use disorder or problems of 
delinquency. 
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Table 1 | Example of recoding of domains into systems
Problem Oriented Screening Instrument for Teenagers (POSIT)
domain corresponding system
Substance use and abuse youth
Physical health youth
Mental health youth
Family relations family
Peer relations peers
Educational status school
Vocational status work
Social skills peers
Leisure/recreation peers,
Aggressive behavior/delinquency society
In line with our aim to identify an instrument, which captures most of the systems 
relevant to the evaluation of systemic family interventions, those instruments 
covering more than five systems were evaluated in more detail. These were then 
appraised according to necessarily arbitrary characteristics of brevity, feasibility, 
practicability, accessibility, psychometric properties and acceptance in the field. 
These characteristics were set up as to identify one or more instruments suitable 
to attain societal preference-weights for an instrument by means of preference-
elicitation techniques. Within preference-elicitation techniques, such as discrete 
choice experiments, the number of domains rarely exceeds ten [28, 29]. With 
higher numbers of domains, the decision task may become too complex and 
cognitively demanding for the respondent [28]. Hence, a suitable instrument 
should possess less than 10 domains. A second consideration was the practical 
use of the instrument itself in clients. An instrument, ideally suitable for self-
completion, should put as little strain as possible on the respondent, without loss 
of important content. Hence, we set a limit to the maximum number of items of 
the instrument at 500 and a maximum completion time of 1 hour, assuming that 
these would be reasonable amounts of items and time to ask from respondents. 
Another criterion was the accessibility of the instrument as to ascertain ease 
of use in future studies. Evaluation of this criterion included the price of use 
and availability of a (digital) version. Psychometric properties were considered 
to judge the suitability of the instrument for integration in health economic 
evaluations. Findings from existing publications on validity and reliability of 
the instruments were considered in this context. Finally, the frequency of use of 
the instrument was considered an indicator for the acceptance of the instrument 
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in the clinical fi eld. This was approximated by the number of times that an 
instrument was used in the studies identifi ed in this review. 
Results
Study selection 
The systematic search resulted in 1,060 articles. After duplicates were removed 
1,002 articles remained. Screening based on abstracts resulted in the exclusion 
of 880 articles. Full text assessment of the remaining 122 articles resulted in 
the exclusion of 2 articles not matching the defi nition of the intervention, 23 
articles not matching the disease or symptoms of the target population, 13 not 
matching the requirements for the principle outcome of the studies, and 9 due to 
unavailability of a full text version. Hence 75 articles were included. Furthermore, 
318 underlying articles from reviews were screened. From these, 166 articles 
remained after duplications with the fi rst search results were removed. The 
screening of these articles in a fi rst round by title and in a second round by title 
and abstract resulted in the exclusion of 161 articles and inclusion of 5 additional 
publications (fi gure 2).
Figure 2 | Phases of the systematic review adapted from Moher et al. [28]
Study Results 
A total of 80 articles were included in the synthesis. The aim was to identify 
clinical instruments in the fi eld suitable for integration in a health-economic 
framework based on criteria of coverage of relevant systems, feasibility to 
perform preference-elicitation techniques, practicability of use, accessibility 
for future studies, psychometric properties and acceptance in the fi eld. A 
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summary of the identified reviews and clinical trials is provided in tables 2 and 3 
respectively. From the 80 selected articles we identified a total of 102 instruments, 
differing substantially in what these intended to measure and in whom. These 
instruments measured varying (combinations of) outcomes such as substance 
use, physical health, mental health, family relations, peer relations, school and 
work status and criminal history. 
Table 2 | List of identified reviews
ID Authors Year Population
1 Armelius Bengt-Åke, Andreassen Tore Henning 2007 youth with antisocial behavior
2 Baldwin SA, Christian S, Berkeljon A, Shadish WR. 2011 adolescent delinquents and 
substance-abusers
3 Borduin CM. 1999 criminal and violent adolescents
4 Brown SA, D’Amico EJ. 2003 adolescent substance abusers
5 Cottrell D, Boston P. 2002 patients with conduct and 
attention deficit disorders, 
substance misuse, etc.
6 Curtis N, Ronan K, Borduin C M 2004 antisocial youths and youths 
with serious emotional 
disturbances
7 Deas D, Thomas SE. 2001 adolescents with substance use 
disorders
8 Deas D. 2007 adolescents with AOD disorders
9 Diamond G, Josephson A. 2005 adolescent substance use
10 Ferguson LM, Wormith JS. 2012 (adult and) young offenders
11 Henggeler SW, Sheidow AJ. 2012 conduct disorder and 
delinquency in adolescents
12 Henggeler SW, Sheidow AJ. 2003 conduct disorder and 
delinquency in adolescents
13 Hogue A, Liddle HA. 2009 adolescent substance abuse
14 Littell Julia H, Campbell Margo, Green Stacy, Toews Barbara 2005 (among others) delinquent youth
15 Randall J, Cunningham PB. 2003 violent substance-abusing and 
substance-dependent juvenile 
offenders
16 Tanner-Smith EE, Wilson SJ, Lipsey MW. 2013 adolescent substance use 
disorder
17 Tripodi SJ, Bender K, Litschge C, Vaughn MG. 2010 adolescent alcohol use
18 Waldron HB, Kaminer Y. 2004 adolescent substance use 
disorders
19 Waldron HB, Turner CW. 2008 adolescent substance abuse
20 Walker D F, McGovern S K, Poey E L, Otis K E 2004 adolescent sexual offenders
21 Woolfenden Susan, Williams Katrina J, Peat Jennifer 2001 adolescents with delinquency or 
conduct disorder
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ca
le
 (S
R
D
);
25
B
ro
w
n 
SA
, D
’A
m
ic
o 
E
J, 
M
cC
ar
th
y 
D
M
, T
ap
er
t S
F.
20
01
ad
ol
es
ce
nt
s 
tr
ea
te
d 
fo
r a
lc
oh
ol
 a
nd
 d
ru
g 
p
ro
bl
em
s
14
-1
8
16
6
C
u
st
om
ar
y 
d
ri
n
ki
ng
 a
nd
 d
ru
g 
u
se
 r
ec
or
d
 (C
D
D
R
);
H
ol
li
ng
sh
ea
d
 c
la
ss
ifi
ca
ti
on
 s
ys
te
m
;
H
ea
lt
h 
p
ro
bl
em
s 
co
m
p
os
it
e 
in
d
ex
26
B
u
rl
es
on
 JA
, K
am
in
er
 Y
, G
ol
d
st
on
 
D
B
, H
ab
er
ek
 R
20
05
A
do
le
sc
en
t A
lc
oh
ol
 
A
bu
se
 o
r 
A
lc
oh
ol
 
D
ep
en
de
nc
e 
D
is
or
de
r
12
-1
8 
ye
ar
s; 
av
er
ag
e 
15
.9
17
7
Su
ic
id
al
 Id
ea
ti
on
 Q
u
es
ti
on
n
ai
re
 (S
IQ
-J
R
);
Te
en
 A
d
d
ic
ti
on
 S
ev
er
it
y 
In
d
ex
 (
T-
A
SI
);
D
ia
g
no
st
ic
 in
te
rv
ie
w
 s
ca
le
 fo
r 
ch
il
d
re
n 
(s
el
f-
ad
m
in
is
te
re
d
 V
oi
ce
-
D
IS
C
)
27
B
u
rl
es
on
 JA
, K
am
in
er
 Y
.
20
05
ad
ol
es
ce
nt
s 
w
ith
 
su
bs
ta
nc
e 
u
se
 
di
so
rd
er
13
-1
8
88
Si
tu
at
io
n
al
 c
on
fi
d
en
ce
 q
u
es
ti
on
n
ai
re
 (S
C
Q
);
D
ia
g
no
st
ic
 in
te
rv
ie
w
 s
ch
ed
u
le
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r 
ch
il
d
re
n 
(D
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C
-C
)
28
C
or
ne
liu
s 
JR
, D
ou
ai
hy
 A
, B
uk
st
ei
n 
O
G
, D
al
ey
 D
C
, W
oo
d
 S
D
, K
el
ly
 T
M
, 
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ll
ou
m
 I
M
.
20
11
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ce
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s 
w
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ho
l u
se
 d
is
or
de
r 
(A
U
D
) a
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aj
or
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es
si
ve
 d
is
or
de
r 
(M
D
D
)
15
-2
0
75
H
am
il
to
n 
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ti
ng
 s
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le
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r 
d
ep
re
ss
io
n 
(H
A
M
-D
-2
7)
;
B
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k 
D
ep
re
ss
io
n 
In
d
ex
 (
B
D
I)
;
T
im
el
in
e 
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-b
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k 
m
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d
 (
T
L
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);
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Search for relevant outcome measures
ID
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ut
ho
rs
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ar
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A
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N
E
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t m
ea
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s
29
D
’A
m
ic
o 
E
J, 
E
ll
ic
ks
on
 P
L
, W
ag
n
er
 
E
F,
 T
u
rr
is
i R
, F
ro
m
m
e 
K
, G
ho
sh
-
D
as
ti
d
ar
 B
,L
on
gs
ho
re
 D
L
, M
cC
aff
re
y 
D
F,
 M
on
tg
om
er
y 
M
J, 
Sc
ho
n
la
u
 M
, 
W
ri
gh
t D
.
20
05
ad
ol
es
ce
nt
s 
w
ith
 
al
co
ho
l a
nd
 o
th
er
 
d
ru
g 
p
ro
bl
em
s 
(A
O
D
)
13
-1
9
28
9
Pe
rc
ei
ve
d 
st
re
ss
 s
ca
le
;
Re
vi
se
d 
w
ay
 o
f c
op
in
g 
ch
ec
kl
is
t;
30
D
em
bo
 R
, S
h
em
w
el
l M
, G
u
id
a 
J, 
Sc
h
m
ei
d
le
r 
J, 
Pa
ch
ec
o 
K
, S
ee
be
rg
er
 
W
19
98
ju
ve
n
il
e 
off
en
d
er
s
M
ea
n 
14
62
SC
L-
90
-R
;
31
D
em
bo
 R
, W
ot
h
ke
 W
, L
iv
in
gs
to
n 
S,
 
Sc
h
m
ei
d
le
r 
J
20
02
ju
ve
n
il
e 
off
en
d
er
s
11
-1
8;
 
m
ea
n 
14
.5
27
8
SC
L-
90
-R
;
32
D
en
n
is
 M
, G
od
le
y 
S 
H
, D
ia
m
on
d
 
G
, T
im
s 
F 
M
, B
ab
or
 T
, D
on
al
d
so
n 
J, 
L
id
d
le
 H
, T
it
u
s 
J C
, K
am
in
er
 Y
, W
eb
b 
C
, H
am
il
to
n 
N
, F
u
n
k 
R
20
04
ad
ol
es
ce
nt
 c
an
n
ab
is
 
us
er
s
15
-1
6
60
0
G
A
IN
;
33
D
en
n
is
 M
, T
it
u
s 
JC
, D
ia
m
on
d
 G
, 
D
on
al
d
so
n 
J, 
G
od
le
y 
SH
, T
im
s 
FM
, 
W
eb
b 
C
, K
am
in
er
Y
, B
ab
or
 T
, R
oe
bu
ck
 
M
C
, G
od
le
y 
M
D
, H
am
il
to
n 
N
, 
L
id
d
le
 H
, S
co
tt
 C
K
; C
. Y
. T
.S
te
er
in
g 
C
om
m
itt
ee
.
20
02
ca
n
n
ab
is
 d
ep
en
d
en
ce
 
or
 a
bu
se
 in
 
ad
ol
es
ce
nt
s
12
-1
8
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0
D
ru
g 
A
bu
se
 T
re
at
m
en
t C
os
t A
n
al
ys
is
 P
ro
gr
am
 (
D
A
T
C
A
P)
;
G
lo
ba
l A
p
p
ra
is
al
 o
f I
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iv
id
u
al
 N
ee
d
s 
(G
A
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);
A
d
ol
es
ce
nt
 R
ea
so
n
s 
fo
r 
Q
u
itt
in
g 
(A
R
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Fa
m
il
y 
E
nv
ir
on
m
en
t S
ca
le
 (
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S)
;
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ie
nd
s,
 F
am
il
y 
an
d
 S
el
f (
FF
S)
;
A
d
ol
es
ce
nt
 R
el
ap
se
 C
op
in
g 
Q
u
es
ti
on
n
ai
re
 (A
R
C
Q
);
SC
ID
 I
I p
er
so
n
al
it
y 
qu
es
ti
on
n
ai
re
 (S
P
Q
);
D
im
en
si
on
s 
of
 T
em
p
er
am
en
t R
ev
is
ed
 (
D
O
T
S)
;
C
h
il
d
 B
eh
av
io
ra
l C
h
ec
kl
is
t (
C
B
C
L)
34
G
il
 A
G
, W
ag
n
er
 E
F,
 T
u
bm
an
 JG
20
04
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ve
n
il
e 
off
en
d
er
s
14
-1
9
21
3
T
im
el
in
e 
fo
ll
ow
-b
ac
k 
in
te
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ie
w
 (
T
L
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);
P
ro
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em
 r
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og
n
it
io
n 
qu
es
ti
on
n
ai
re
 (
P
R
Q
)
35
G
li
ss
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, S
ch
oe
nw
al
d
 S
K
, 
H
em
m
el
ga
rn
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, G
re
en
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, D
u
ke
s 
D
, 
A
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st
ro
ng
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S,
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h
ap
m
an
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E
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en
t y
ou
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t m
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ar
n
er
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, P
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, D
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M
L,
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le
y 
M
D
.
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ce
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er
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8
32
0
G
A
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 S
u
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ta
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e 
P
ro
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em
 S
ca
le
 (S
P
S)
;
D
A
T
C
A
P;
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G
od
le
y 
SH
, H
ed
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s 
K
, H
u
nt
er
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.
20
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ad
ol
es
ce
nt
s 
w
ith
 
su
bs
ta
nc
e 
u
se
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-1
8
21
41
G
A
IN
;
38
H
al
l J
A
, S
m
it
h 
D
C
, E
as
to
n 
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, A
n 
H
, 
W
il
li
am
s 
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, G
od
le
y 
SH
, J
an
g 
M
20
08
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ut
h 
in
 o
ut
pa
tie
nt
 
tr
ea
tm
en
t f
or
 
su
bs
ta
nc
e 
ab
u
se
12
-1
8
40
4
G
A
IN
;
39
H
ar
ol
d
 G
T,
 K
er
r 
D
C
, V
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 R
yz
in
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, 
D
eg
ar
m
o 
D
S,
 R
ho
ad
es
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A
, L
ev
e 
L
D
.
20
13
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ol
es
ce
nt
 g
ir
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 in
 
ju
ve
n
il
e 
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st
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e 
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st
em
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-1
7
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6
B
ri
ef
 s
ym
p
to
m
 in
ve
nt
or
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(B
SI
);
40
H
en
de
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on
 C
E,
 D
ak
of
 G
A
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G
re
en
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u
m
 P
E
, L
id
d
le
 H
A
.
20
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ce
nt
 d
ru
g 
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u
se
 
an
d 
de
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en
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-1
7
37
8
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rs
on
al
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er
ie
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e 
In
ve
nt
or
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(P
E
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;
T
im
el
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ll
ow
-b
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k 
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ho
d
 (
T
L
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);
D
ia
g
no
st
ic
 in
te
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ie
w
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u
le
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r 
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il
d
re
n
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on
d
 e
d
it
io
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(D
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);
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m
il
y 
en
v
ir
on
m
en
t s
ca
le
 (
FE
I)
;
41
H
en
gg
el
er
 S
W
, H
al
lid
ay
-B
oy
ki
ns
 C
A
, 
C
u
n
n
in
gh
am
 P
B
, R
an
d
al
l J
, S
h
ap
ir
o 
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, C
h
ap
m
an
 J
E
.
20
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n
il
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en
d
er
s 
m
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ti
ng
 c
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a 
fo
r 
su
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ta
nc
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u
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 o
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de
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en
ce
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7
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1
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rm
 9
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ba
se
d
 o
n 
T
L
FB
;
Se
lf
 r
ep
or
te
d
 d
el
in
qu
en
cy
 s
ca
le
 (S
R
D
);
C
h
il
d
 b
eh
av
io
r 
ch
ec
kl
is
t (
C
B
C
L)
;
42
H
en
gg
el
er
 S
W
, M
cC
ar
t M
R
, 
C
u
n
n
in
gh
am
 P
B
, C
h
ap
m
an
 J
E
.
20
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u
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 s
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bs
ta
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ab
u
se
 
an
d
 c
ri
m
in
al
 b
eh
av
io
r
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7
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4
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rm
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T
L
FB
;
Se
lf
 r
ep
or
te
d
 d
el
in
qu
en
cy
 s
ca
le
 (S
R
D
);
43
H
en
gg
el
er
 S
W
, M
el
to
n 
G
B,
 B
ro
nd
in
o 
M
J, 
Sc
he
re
r D
G
, H
an
le
y 
JH
19
97
vi
ol
en
t a
nd
 c
hr
on
ic
 
ju
ve
n
il
e 
off
en
d
er
s
11
-1
7
15
5
G
lo
ba
l s
ev
er
it
y 
in
d
ex
 (G
SI
) o
f t
h
e 
B
SI
;
R
ev
is
ed
 p
ro
bl
em
 b
eh
av
io
r 
ch
ec
kl
is
t (
R
B
P
C
);
Se
lf
-r
ep
or
t d
el
in
qu
en
cy
 s
ca
le
 (S
R
D
);
Fa
m
il
y 
ad
ap
ta
bi
li
ty
 a
nd
 c
oh
es
io
n 
ev
al
u
at
io
n 
sc
al
es
 (
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C
E
S-
II
I)
;
Fa
m
il
y 
as
se
ss
m
en
t m
ea
su
re
 (
FA
M
-I
II
);
Pa
re
nt
 v
er
si
on
 m
on
it
or
in
g 
in
d
ex
;
A
d
ol
es
ce
nt
 v
er
si
on
 m
on
it
or
in
g 
in
d
ex
;
13
-i
te
m
 M
is
so
u
ri
 p
ee
r 
re
la
ti
on
s 
in
ve
nt
or
y 
(M
P
R
I)
;
14
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m
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n
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Search for relevant outcome measures
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rs
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ar
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pu
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ti
on
A
ge
N
E
ff
ec
t m
ea
su
re
s
44
H
en
gg
el
er
 S
W
, M
el
to
n 
G
B
, S
m
it
h 
L
A
19
92
se
ri
ou
s 
ju
ve
ni
le
 
off
en
d
er
s
M
ea
n 
15
,2
84
SR
D
 (S
el
f R
ep
or
t D
el
in
qu
en
cy
 S
ca
le
);
FA
C
E
S-
II
I (
T
h
e 
Fa
m
il
y 
A
d
ap
ta
bi
li
ty
 a
nd
 C
oh
es
io
n 
Ev
al
u
at
io
n 
Sc
al
es
);
M
P
R
I (
M
is
so
u
ri
 P
ee
r 
R
el
at
io
n
s 
In
ve
nt
or
y)
;
R
B
P
C
 (
R
ev
is
ed
 B
eh
av
io
r 
P
ro
bl
em
 C
h
ec
kl
is
t)
;
SC
L
-9
0 
(S
el
f R
ep
or
t S
ym
p
to
m
 C
h
ec
kl
is
t)
;
SC
S-
C
BC
;
45
H
en
gg
el
er
 S
W
, P
ic
kr
el
 S
G
, B
ro
nd
in
o 
M
J.
19
99
su
bs
ta
nc
e-
ab
u
si
ng
 
an
d 
-d
ep
en
de
nt
 
de
lin
qu
en
t 
ad
ol
es
ce
nt
s
12
-1
7
11
8
Pe
rs
on
al
 e
xp
er
ie
nc
e 
in
ve
nt
or
y 
(P
E
I)
;
Se
lf
-r
ep
or
t d
el
in
qu
en
cy
 s
ca
le
 (S
R
D
)
46
H
og
u
e 
A
, D
au
be
r 
S,
 S
ta
m
ba
u
gh
 L
F,
 
C
ec
er
o 
JJ,
 L
id
dl
e 
H
A
.
20
06
su
bs
ta
nc
e-
ab
u
si
ng
 
ad
ol
es
ce
nt
s
av
er
ag
e 
15
.5
10
0
T
L
FB
;
C
BC
L;
Y
SR
;
47
H
og
u
e 
A
, H
en
d
er
so
n 
C
E
, D
au
be
r 
S,
 
Ba
ra
ja
s 
PC
, F
ri
ed
 A
, L
id
dl
e 
H
A
.
20
08
ad
ol
es
ce
nt
 s
u
bs
ta
nc
e 
us
e 
an
d 
re
la
te
d 
be
h
av
io
r 
p
ro
bl
em
s
13
-1
7
13
6
T
im
el
in
e 
fo
ll
ow
-b
ac
k 
(T
L
FB
);
Pe
rs
on
al
 e
xp
er
ie
nc
e 
in
ve
nt
or
y 
(P
E
I)
;
C
BC
L;
Y
SR
;
48
H
u
nt
er
 S
B
, R
am
ch
an
d
 R
, G
ri
ffi
n 
BA
, 
Su
tt
or
p
 M
J, 
M
cC
aff
re
y 
D
, M
or
ra
l A
.
20
12
ad
ol
es
ce
nt
 s
u
bs
ta
nc
e 
us
e
n
/a
27
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G
A
IN
;
E
m
ot
io
n
al
 p
ro
bl
em
 s
ca
le
 (E
P
S)
;
Il
le
ga
l a
ct
iv
it
ie
s 
sc
al
e 
(I
A
S)
;
Pa
st
 m
on
th
 s
u
bs
ta
nc
e 
p
ro
bl
em
 s
ca
le
 (S
P
S-
G
A
IN
);
Su
bs
ta
nc
e 
fr
eq
u
en
cy
 s
ca
le
 (S
FS
-G
A
IN
);
49
K
am
in
er
 Y
, B
u
rl
es
on
 JA
, G
ol
d
be
rg
er
 
R
20
02
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ol
es
ce
nt
 s
u
bs
ta
nc
e-
ab
u
se
rs
13
-1
8
88
T-
A
SI
;
D
IS
C
-C
;
St
ru
ct
u
ra
l c
li
n
ic
al
 in
te
rv
ie
w
 fo
r 
th
e 
D
SM
 (S
C
ID
-I
I)
;
R
ev
is
ed
 d
im
en
si
on
s 
of
 te
m
p
er
am
en
t s
u
rv
ey
 (
D
O
T
E
S-
R
);
50
K
am
in
er
 Y
, B
u
rl
es
on
 JA
.
20
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ol
es
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nt
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w
ith
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u
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di
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rd
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8
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A
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;
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A
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Po
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A
ge
N
E
ff
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t m
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s
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K
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y 
M
K
.
20
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er
at
ed
 
ad
ol
es
ce
nt
s
13
-1
8
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C
ar
eg
iv
er
 C
BC
L;
Y
ou
th
 s
el
f-
re
p
or
t (
Y
SR
);
C
op
in
g 
in
ve
nt
or
y 
of
 s
tr
es
sf
u
l s
it
u
at
io
n
s 
(C
IS
S)
;
Pa
re
nt
al
 b
on
d
in
g 
in
st
ru
m
en
t (
P
B
I)
;
In
ve
nt
or
y 
of
 p
ar
en
t a
nd
 p
ee
r 
att
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h
m
en
t (
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);
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K
il
le
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 T
K
, M
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rk
 A
L
, 
W
al
d
ro
p
 A
E
, U
p
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a 
H
, B
ra
d
y 
K
T.
20
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ad
ol
es
ce
nt
s 
w
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m
ar
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an
a 
u
se
 
di
so
rd
er
s
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-1
8
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C
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p
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it
e 
in
te
rn
at
io
n
al
 d
ia
g
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st
ic
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rv
ie
w
 (C
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I)
;
Te
en
 A
d
d
ic
ti
on
 S
ev
er
it
y 
In
d
ex
 (
T-
A
SI
);
T
im
el
in
e 
Fo
ll
ow
-b
ac
k 
(T
L
FB
);
M
ar
iju
an
a 
cr
av
in
g 
qu
es
ti
on
n
ai
re
 (
M
C
Q
-1
2)
;
B
ar
re
tt
 I
m
p
u
ls
iv
it
y 
Sc
al
e 
(B
IS
-I
I-
A
);
53
L
at
im
er
 W
W
, W
in
te
rs
 K
C
, D
’Z
u
ri
ll
a 
T,
 N
ic
ho
ls
 M
20
03
ad
ol
es
ce
nt
 d
ru
g 
ab
u
se
rs
12
-1
8
43
D
ia
g
no
st
ic
 in
te
rv
ie
w
 fo
r 
ch
il
d
re
n 
an
d
 a
d
ol
es
ce
nt
s 
(D
IC
A
-I
V
);
A
d
ol
es
ce
nt
 d
ia
g
no
st
ic
 in
te
rv
ie
w
 r
ev
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ed
 (A
D
I-
R
)-
m
u
lt
ia
xa
l 
in
te
rv
ie
w
;
Pe
rs
on
al
 e
xp
er
ie
nc
e 
in
ve
nt
or
y 
(P
E
I)
;
Fa
m
il
y 
as
se
ss
m
en
t m
ea
su
re
 (
FA
M
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Instrument suitability for evaluation of systemic family interventions
Table 4 displays the instruments ranked according to the number of systems 
covered. 
Table 4 | Ranking of instruments according to the number of systems covered
Name instrument # systems covered
systems
youth family peers school work society neighbors
POSIT 6 ● ● ● ● ● ●
CAFAS 6 ● ● ● ● ● ●
WAJCA-RA 6 ● ● ● ● ● ●
ADAD 6 ● ● ● ● ● ●
T-ASI 6 ● ● ● ● ● ●
CTRADA 5 ● ● ● ● ●
ADI 5 ● ● ● ● ●
GAIN 5 ● ● ● ● ●
PEI 4 ● ● ● ●
MAAS 4 ● ● ● ●
FES 4 ● ● ● ●
CPHHQ 3 ● ● ●
FFS 3 ● ● ●
SCQ 3 ● ● ●
SRD 2 ● ●
SCL-90-R 2 ● ●
BSI 2 ● ●
Hollinghead 
classification system
2 ● ●
IPPA 2 ● ●
CRI 2 ● ●
MAP 2 ● ●
The majority, 81 instruments, covered just one system such as the youth or the 
family system. These one-dimensional instruments were often used in a multi-
method (i.e. a combination of self-report, parent-report, court records, urine-
analysis, etc.) assessment battery of instruments. Thirteen instruments covered 
two, three or four systems. We identified eight instruments, which covered five 
or more systems and which therefore were considered potentially suitable for 
comprehensive evaluation of systemic family interventions. 
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Search for relevant outcome measures
Detailed information on these eight instruments was searched and is highlighted 
below. It has to be noted that available information per instrument (e.g. number of 
items, example questions, domain names, most recent versions of the instrument, 
type of administration, etc) strongly differed. 
The Adolescent Drug Abuse Diagnosis (ADAD) [30] is a multidimensional 
instrument to evaluate adolescent substance use [31] administered in a structured 
interview. It covers nine problem areas: medical, school, employment, social 
relations, family and background relations, psychological, legal, alcohol use, and 
drug use [32]. Example questions are “How would you rate your overall physical 
health?”, “How many days in the past 30 have your been absent (from school)?” 
and “How many months did you work fulltime in the past six months?”. A 
patient’s treatment need is assessed by the interviewer per problem area based 
on a 10-point rating scale with scores 0-1 (no real problem), 2-3 (slight problem, 
treatment probably not necessary), 4-5 (moderate problem, some treatment 
indication), 6-7 (considerable problem, treatment necessary), and 8-9 (extreme 
problem, treatment absolutely necessary) [32]. The instrument consists of 150 
items and is based on the Addiction Severity Index (ASI) [24]. There is also 
a European version of the instrument, the European Adolescent Assessment 
Dialogue (EuroADAD). Its aim is to “describe, communicate and compare young 
clients over borders of countries and institutions.” [33]
The Adolescent Diagnostic Interview (ADI) [34] originated in the 1980’s as a 
project “to address measurement gaps in the alcohol-drug field” [35]. It is a tool 
to measure substance use disorders in adolescents “…organized around DSM–
III–R criteria for psychoactive substance use disorders.” [34]. In the literature 
a version based on DSM-IV criteria is also mentioned [36]. The instrument is 
administered in a structural interview setting. Substance use of the adolescent 
is assessed based on two main sections with each two subsections: clinical 
(sociodemographics, psychosocial stressors, substance use frequency and 
duration, alcohol symptoms, cannabis symptoms, other substance symptoms and 
level functioning) and appendix (orientation and memory screen) [34]. Example 
items are “Which drugs have you used five or more times in your life?”, “How 
many times do you think that you have used (this drug/each drug) in the past 
6 months?”, “Have you ever continuously felt like crying for several days in a 
row?” [36]. A computer-based version is available for self-assessment [34].
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The Child Adolescent Functional Assessment Scale (CAFAS) “…assesses the 
degree of impairment in functioning in children and adolescents secondary to 
emotional, behavioral, or substance use problems” [37]. The instrument originally 
included seven scales, of which five evaluated the functioning of the youth and 
two scales assessed the environment of the youth [37]. The five youth scales were 
role performance, thinking, behavior towards self and others, moods/emotions, 
and substance use [38]. The two environment scales were basic needs and family/
social support. The scales subsequently have been changed and expanded to 8 
youth and 2 caregiver scales: school, home, community, behavior towards others, 
moods, self-harm, substance use, and thinking (youth) and material needs, and 
social support (caregiver) [38]. The different subscales include items of four 
severity levels (i.e. severe, moderate, mild, and minimal or no impairment) [37]. 
The assessor determines the level of problems of the patient per subscale. He 
first considers the items of the most severe level, checks whether these items 
apply and if not progresses towards the lesser symptom levels until an item of 
the current severity level applies to the patient [37]. Then scores of 30, 20, 10 and 
0 are applied to severity levels severe, moderate, mild and minimal respectively 
such that an overall severity rating is generated. Overall ratings range from 0 to 
240 with higher scores indicating higher severity [30].
The Global Appraisal of Individual Needs (GAIN) questionnaire [39] is a 
collection of related instruments that are gathered under the umbrella of GAIN 
using an identical format. The most recent version of the questionnaire has been 
adapted for use in adults as well as adolescents. The GAIN is an assessment 
measure, which can be used in several settings and populations such as inpatient, 
outpatient short- or long-term treatment evaluation, legal programs or school-
based programs [40]. It assesses eight domains: background, substance use, 
physical health, risk behaviors, mental health, environment, legal, and vocational. 
Example items of the GAIN are “During the past 90 days, on how many days 
were you in foster care?”, “When was the last time, if ever, you used...any kind of 
alcohol?“, and “What was the most (drinks/joints/etc.) you had in one day?” [41].
The Problem Oriented Screening Instrument for Teenagers (POSIT) is a 
screening instrument for adolescents with substance use disorder, which 
was designed as a component of the Adolescent Assessment/Referral System 
(AARS) [42]. It “is designed to flag those functional areas, if any, where a problem 
MAY exist that requires further assessment and perhaps treatment.” [42]. The 
instrument addresses ten functional domains: substance use/abuse, physical 
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health status, mental health status, family relations, peer relations, educational 
status, vocational status, social skills, leisure and recreation, and aggressive 
behavior and delinquency. The POSIT includes 139 items, which can be answered 
with yes or no [42]. Per domain, items can be grouped into three categories: 
general purpose items, general purpose age-related items, and red flag items [42]. 
Each affirmative response to a general purpose item counts as one point towards 
the total functional domain score [42]. The same holds for general purpose age-
related items, but these are only relevant for specific age groups of respondents 
(below or above 16 years) [42]. Red flag items indicate the need for treatment 
once one of these items is answered positively [42]. Example items of the POSIT 
are “Do you get into trouble because you use drugs or alcohol at school?”, “Do 
your parents or guardians argue a lot?”, and “Have you ever been told you are 
hyperactive?” [42].
The Teen Addiction Severity Index (T-ASI) [43] is the adolescent version of the 
ASI [24]. The instrument assesses seven dimensions of functioning (i.e. alcohol 
and drug use, school status, employment-support status, family relationships, 
legal status, peer-social relationships, and psychiatric status) [43]. The T-ASI is 
intended for use in adolescents with substance use disorder aged between 12 and 
19 years [43]. Example items of the T-ASI are “What chemicals have you used in 
the past month?”, “School days spent in detention or any other measures taken 
for disciplinary reasons last month. (Principal’s or school counselor’s office.)“, and 
“How long was your longest period of employment during the past year?” [44]. 
Responses are rated on a 5-point scale [43]. A revised version of the T-ASI, the 
T-ASI-2 has been developed in 2008. This concerns a version of the instrument, 
which is self-administered via computer or telephone and contains additional 
domains [45]. 
The WAJCA-RA structured interview is a risk assessment tool for juvenile 
offenders developed by the Washington State Institute for Public Policy in 
collaboration with the juvenile courts [46]. It was designed to identify risk 
and protective factors in the following domains: criminal history, school, use 
of free time, employment, relationships, family, alcohol and drugs, mental 
health, attitudes, social skills, progress on community supervision, progress 
while confined [46]. Example items of the WAJCA-RA are “Violence/anger: 
Reports of displaying a weapon, fighting, threatening people, violent outbursts, 
violent temper, fire starting, animal cruelty, destructiveness, volatility, intense 
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reactions.”, “Runaways or times kicked out of home”, and “Number of weeks of 
longest period of employment” [46].
The Parent and adolescent interview CTRADA that was used by [47] was 
not considered a common instrument but institution-specific interview as 
no references could be retrieved from neither literature nor the Internet. The 
instrument therefore could not be further considered or assessed. 
Instrument suitability for use in CUA
Hence seven instruments remained for further consideration. The frequency of 
use of each of these instruments in the identified studies is presented in Table 5. 
Furthermore, Table 6 illustrates an evaluation of the instruments for suitability 
for use in CUA and use of preference elicitation techniques. When our feasibility 
characteristics were applied to the seven instruments, three instruments (POSIT, 
WAJCA, ADI) were excluded due to the number of domains exceeding ten, 
and one instrument (GAIN) was excluded due to reasons of practicability (i.e. 
number of items exceeding the maximum of 500 and completing time exceeding 
one hour). It was noted that a short version of the GAIN (Global Appraisal of 
Individual Needs Short Screener, GAIN-SS) is available as well [48]. However, 
based on its goals of screening, use for clinical staff with limited experience 
or periodic measurement [48], this instrument is considered too restricted for 
the purpose of this study. The remaining three instruments (CAFAS, T-ASI 
and Euro-ADAD) were considered candidates for use in CUA. One instrument 
(CAFAS) was considered slightly less suitable due to reasons of accessibility (i.e. 
concerning a paid instrument as opposed to freely available online versions of 
other instruments). For the remaining two instruments (T-ASI and the Euro-
ADAD) only limited information on psychometric properties could be obtained. 
It needs noting that the T-ASI and Euro-ADAD are related as they are both based 
on the ASI adult instrument [33, 43]. Psychometric properties of this ‘predecessor’ 
have been judged satisfactory [24, 49-52]. To our knowledge Euro-ADAD is more 
frequently used in Europe, whereas T-ASI is more commonly used the United 
States. 
Two psychometric studies with small sample sizes were identified for the T-ASI 
[43, 53] and one study [33] with a larger sample size was identified for the Euro-
ADAD. Frequency of use was slightly favorable for the T-ASI compared to the 
Euro-ADAD as the instrument was used four times in the studies identified 
in this systematic review, whereas the Euro-ADAD was used in no more than 
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one study. These differences were not considered sufficient to justify favoring 
either of the instruments over the other. Hence, the T-ASI and Euro-ADAD were 
considered to have equal potential suitability for the comprehensive evaluation 
of systemic family interventions in a health economic framework. 
Table 5 | Frequency of instrument use
Instrument name # of papers which used this measure
Global Appraisal of Individual Needs (GAIN) 13
Teen Addiction Severity Index (T-ASI) 4
Adolescent Diagnostic Interview (ADI) 4
Problem Oriented Screening Instrument for Teenagers (POSIT) 2
Child Adolescent Functional Assessment Scale (CAFAS) 1
Washington Association of Juvenile Court 6Administrators - Risk 
Assessment (WAJCA-RA)
1
Adolescent Drug Abuse Diagnosis (Euro-ADAD) 1
7
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Discussion and conclusions 
The objective of this systematic literature review was to identify existing 
instruments in the field of adolescent delinquency and substance use, which 
cover the relevant domains of systemic family interventions. The instruments 
were appraised based on characteristics relevant for use in economic evaluations 
such as brevity, accessibility, psychometric properties etc. Euro-ADAD and T-ASI 
showed favorable characteristics in relation to the criteria for a comprehensive 
outcome measure, covering multiple relevant systems and being suitable for 
obtaining preference weights. Both instruments lack preference weights for the 
outcomes, at present. Attaining these (as a potential next step) would facilitate 
calculating ‘utility scores’ as common in economic evaluations. Furthermore, 
the results of the current study may inform future efforts towards standardized 
and comprehensive core outcome sets as defined by the COMET initiative [54]. 
The study may be seen as a preparatory step towards a full COMET effort to 
standardizing the QALY approach to include broader effects. 
Some limitations of this study must be noted. First, given our focus on published 
research up to 2013, we may have missed out on very recent developments in 
this field. In the Netherlands, for instance, a new, comprehensive instrument 
for measuring substance abuse in adolescents is being developed, called the 
MATE-Y [55], which includes nine modules each containing several domains. 
Yet, up to today there have not yet been publications on the MATE in the field 
of youth/adolescents. But similar developments may be ongoing elsewhere. 
Second, we have not investigated the possibility of constructing a new measure 
by combining different measures into one composite measure. Though this 
may be a limitation of this paper, we considered it a necessary first step to 
identify the instruments currently available in the field for direct use. This may 
also help to highlight the relevant domains to include in a newly developed 
instrument. With our approach, we were able to identify two instruments as 
most promising candidates to use in comprehensive evaluations of systemic 
family interventions. Neither instrument is currently considered ‘gold standard’ 
in practice. Furthermore, as common for systematic reviews, the results from 
the current study are based on a limited selection of databases within a limited 
timeframe. Yet the number of screened and identified articles was extensive and 
we assume that the consultation of an even larger number of databases would not 
have yielded significant differences in results. Also, the characteristics for further 
selection of the instruments were necessarily arbitrary and guided by our goal of 
selecting one or more instruments suitable to be used to attain societal preference 
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weights and be used in economic evaluations in the long term. We realize that 
the suitability criterion of a maximum of 500 questions/1 hour of completion 
time may be rather high when considering the busy clinical practice and ongoing 
evaluation of patient progress. Furthermore, had we considered different or more 
broad characteristics, additional instruments might have been found suitable. 
For example, one could think of shortening existing longer instruments first 
and then proceeding towards steps of attaining societal preference weights. In 
the light of limited time, this was not considered feasible in the current study. 
Notwithstanding these limitations, our review revealed two promising, 
currently used instruments, which may be made suitable for inclusion in 
economic evaluations of systemic family interventions: the Euro-ADAD and 
T-ASI. To make these instruments suitable for health economic evaluations, first 
of all, more detailed investigation is necessary of their validity, feasibility and 
comprehensiveness. Current information on this is scarce, yet needed. Moreover, 
using these instruments in health economic evaluations will require important 
next steps. In particular, preference weights would need to be derived for the 
different states described by the instrument, like those available for health-
related utility measures such as the EQ-5D. This is possible through preference 
elicitation techniques, such as discrete choice experiments or time-trade-off 
techniques, ultimately leading to ‘utility scores’, which can be attached to the 
different ‘states’ described by the instrument. 
Intriguing questions in this context relate to who should indicate the state 
a person is in and who should provide the values for the different possible 
states (i.e., whose preferences count). In line with many guidelines for health-
economic evaluations [11, 56], and in line with the broad aim of systemic family 
interventions, one could ask ‘patients’ to provide self-reports based on one of 
the identified multidimensional instruments. The value attached to this state 
could then be based on preferences obtained in the general population. This 
would provide ‘societal weights’ for the broad outcomes of systemic family 
interventions. These societal weights could thus be attached to the state a 
person indicates him- or herself to be in on the multidimensional instrument, 
thus leading to an overall utility score. Given the broad range of outcomes, 
including effects incurred by others than the patient or even his family (e.g., a 
safe neighborhood), the score thus relates to a preference ordering over states 
that include the effects on more than the patient alone. This may be an additional 
reason for opting for general public preferences. However, whether the general 
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public is the appropriate source (rather than e.g. decision makers or health care 
professionals) must be further assessed and discussed, as well as their ability to 
appropriately weight such diverse outcomes. The more fundamental question is 
whether these scores would count as ‘utilities’ or rather as multi-criteria decision 
weights.
Other relevant issues in developing a multidimensional utility measure of 
systemic family interventions may be the diversity and hierarchy of treatment 
effects. As mentioned earlier, a comprehensive measure would include health 
as well as non-health effects and would also include both the effects on the 
patient himself and society as a whole. Obviously, these different effects may 
be interrelated. Moreover, some observable effects may be considered to be 
intermediate effects, whereas others may be final outcomes. Related to this point, 
there may be short-term and long-term effects, which can be important. Hence, 
in the construction of such a preference-based measure, good care needs to be 
taken of the possible interaction of the effects.
One may argue that an alternative route to finding an appropriate outcome 
measure could be to use existing measures in the field of economic evaluation, 
most notably QALY measures. To our knowledge, so far there have been only 
a few studies on the validity of preference-weighted health-related quality of 
life instruments in an adult population of substance abusers [57, 58]. There have 
been two studies on the degree to which common preference-weighted measures 
of quality of life (e.g. QWB-SA, SF-12) correlate with substance use severity [58, 
59]. Whereas the first study provides evidence for insufficient coverage of all 
disease dimensions in substance use disorder [58], the second study does suggest 
moderate to good correlation between quality of life measures and substance use 
severity measures [59]. In order to verify these results and determine whether 
the proposed instruments add value in the field of delinquency and substance 
abuse in adolescents, further research on the suitability and potential of the 
quality adjusted life year (QALY) measure in this population is recommended. 
Keeping these alternatives in mind, further research on the instruments 
highlighted in the current paper, specifically on the attachment of societal 
preference weights could bring evaluation of mental health interventions 
for delinquent and substance abusing adolescents closer to the standard 
methodology in health economic evaluations of curative medical interventions. 
Both identified instruments appear suitable and broad enough to capture the 
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effects of family interventions in substance abusing and delinquent adolescents 
in such CUA. Adding societal preference weights to one of these instruments 
will create an instrument, which combines the advantage of the specificity of 
a disorder-specific instrument with compliance with common methodology of 
health economic evaluations and captures the broad effects relevant to mental 
health interventions. CUAs of these interventions can then be performed based 
on a broad and specific measure that includes several systems/dimensions 
and at the same time acknowledges the relative value that society attaches to 
improvements in these diverse systems. Though performing CUAs in the field 
of substance abuse and delinquency in adolescents remains a challenging task, 
this paper attempted to contribute to confronting one of the major issues in that 
context: finding a suitable outcome measure. 
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Obtaining Preference Scores for an Abbreviated Self-
completion Version of the Teen-Addiction Severity 
Index (ASC T-ASI) to Value Therapy Outcomes of 
Systemic Family Interventions: a Discrete Choice 
Experiment
Based on Schawo, S., Hoefman, R., Reckers-Droog, V.T., van de Wetering, L., 
Kaminer, Y., Brouwer, W.B.F., Hakkaart-van Roijen, L. 
Submitt ed to Health and Quality of Life Outcomes.
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Introduction
Economic evaluations in health care often take the form of cost-utility analysis, 
in which outcomes are captured in terms of quality-adjusted life-years (QALYs) 
[1,2], as measured with generic instruments like the EQ-5D [3] or SF-6D [4]. This 
implicitly reflects that many curative health care interventions primarily aim 
to improve health and longevity of patients. However, in certain health care 
sectors the aim of interventions may not (primarily) be to improve health, but 
to improve broader aspects of quality of life than health alone. These outcomes 
may be captured insufficiently by existing generic health-related quality of life 
instruments used to calculate QALYs [5, 6]. This issue is gaining attention, for 
example, in the area of elderly care, where broader measures like the ICECAP-O 
and ASCOT have been developed [7, 8]. These measures capture broader life 
domains than health and are suitable for use in economic evaluations. In other 
areas, including mental healthcare and addiction-related treatments, such 
generic preference-based outcome measures are still lacking [8-12]. This issue 
of appropriate and comprehensive outcome measures, preference-based and 
suitable for use in economic evaluations, is highly relevant in the context of 
mental health interventions aimed at youths and systemic family interventions 
in particular. These interventions are intended to have broad effects (e.g. related 
to substance use, family interactions, interaction with peers, and performance at 
school) exceeding the domain of health. If not appropriately identified, measured 
and valued, such broader effects may fall outside the scope of economic 
evaluations, risking wrong conclusions about value for money of interventions 
and, potentially, undesirable (that is, welfare lowering) decisions concerning 
their reimbursement.
The relevance of this issue is emphasized by the fact that systemic family 
interventions for adolescents with problems of substance use and/or delinquency 
are increasingly subject of economic evaluations [13]. However, existing studies 
are limited in quality and comparability as settings, design and outcome 
measures vary extensively [13]. The application of economic evaluation in the 
field of systemic family interventions is hampered by the lack of preference-
based instruments that are validated, sensitive and feasible to use and capture 
all relevant benefits. Systemic family interventions are explicitly directed at 
improving interactions between the adolescent patient and surrounding systems, 
and are often used in the context of substance abuse and delinquency [14-16]. 
Aims of such interventions are diverse and include improvements in family 
relations, peer interactions, achievements at work or school, and reduction of 
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substance use and criminal activity [15; 17-19]. In a meta-analysis evaluating the 
effectiveness of outpatient substance abuse treatments for adolescents, systemic 
family interventions were found to be effective in the treatment of substance 
abuse [20]. Given that these interventions typically are intensive and costly 
[17; 21; 22], economic evaluations are important, also to inform reimbursement 
decisions. This requires validated, broad multidimensional preference-based 
instruments that capture the relevant effects of such interventions.
In order to fill this gap, a recent systematic review of the effectiveness literature 
on systemic family interventions identified existing instruments, which measure 
benefits beyond health-related quality of life [12]. While no preference-based 
instruments were found, the Teen-Addiction Severity Index (T-ASI) [23] was 
identified as a multidimensional instrument that captures the main relevant 
life domains affected by these interventions. Although preference scores for 
this instrument were lacking, it was considered suitable for adaptation into a 
preference-based measure for use in economic evaluations of systemic family 
interventions [12].
The original T-ASI is a relatively long semi-structured interview that measures 
symptoms of adolescent substance use based on seven domains and five levels of 
problem severity. The instrument is not a self-report instrument but completed 
by a therapist together with the patient. Some questions are directed at the 
patient while others ask the therapist to provide his or her judgment. In order to 
make the instrument suitable for use in economic evaluations, in which patients 
commonly report their own situation using a self-complete descriptive system, 
we created an abbreviated, patient-completed version of the T-ASI, the ASC 
T-ASI [24; see appendix A and B]. This abbreviated instrument was based on 
the main patient-reported questions from all domains of the T-ASI, reflecting the 
functioning of the patient as judged by him or herself. The ASC T-ASI is a broad 
outcome measure, suitable for self-completion. After designing the instrument, 
two studies were performed. One study validated the ASC T-ASI, with favorable 
results [24]. The second derived societal preference scores for the ASC T-ASI 
using a discrete choice experiment (DCE). This second study is presented in the 
current paper.
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Methods
Questionnaire
Data was obtained from an existing online panel. People who signed up for 
the panel were invited to participate in this study. Those who accepted the 
invitation were informed about the purpose of the study and how anonymity 
of participants was guaranteed. They were informed that participation in the 
study was voluntary and could be stopped at any time, in which case that the 
data they had provided up to that point would be discarded. By submitting their 
response at the end of the questionnaire they provided consent for the use of 
their data for the stated purposes of the study. Participants received no financial 
compensation.
The Dutch translation of the ASC T-ASI [24; Appendix B] forms the basis for the 
current study and the preference-based measure. In this study, we used a DCE 
to obtain societal preference weights for all domains and levels of the ASC T-ASI 
instrument. A professional Dutch translation agency advised us in formulating 
the instructions of the discrete choice tasks based on reading level B1.
Pilot and main data were collected with a questionnaire that was distributed 
online by a professional survey company. As the common source of health 
state valuations is the general public [1, 2], we elicited preferences for different 
outcomes described with the ASC T-ASI in a sample representative of the general 
adult population in the Netherlands in terms of age (18-65 years), gender, and 
level of education. Before respondents completed the questionnaire, they were 
informed about the background of the study, the target population of adolescents 
with problems of substance abuse and/or delinquency, and the attributes and 
levels of the DCE. Furthermore, an outline of the questionnaire, instructions on 
the type of questions and a privacy statement were provided. The questionnaire 
of pilot and main study comprised four parts. Part one included questions about 
demographics of the respondent. Part two consisted of the DCE tasks. Part three 
stated questions about the feasibility and readability of the DCE tasks. Part four 
consisted of questions on current health status of the respondent.
Discrete choice experiment
DCEs are frequently used to inform policy decisions in health care [25-27]. 
In such experiments individuals are confronted with a series of choice tasks. 
The DCE methodology is based on McFadden’s random utility theory [28] and 
assumes that an individual, when confronted with a choice task that consists of 
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n alternatives with a fixed number of attributes and attribute levels, will choose 
the option that maximizes his or her utility.
Choice task
The current study used choice tasks with two unlabeled alternatives (A and B) 
reflecting a state of an adolescent described by the seven attributes (substance 
use, school, work, family, social relationships, justice, and mental health) and 
five attribute levels (ranging from ‘no problem’ to ‘very large problem’) of the 
ASC T-ASI. Unlike the case in common outcome measures, where respondents 
are asked to value states for themselves, given the specific nature of the ASC 
T-ASI, respondents here were asked to choose between the alternatives based 
on what they believed would be best for the adolescent (hence the question was 
formulated in the third person). In this way, we obtained societal preferences 
for the different situations of the adolescent described with the ASC T-ASI 
instrument. Appendix C presents an example of one of the choice tasks, as 
presented to the respondents.
Design pilot study
 Between 11 and 16 December 2013, we collected pilot data from a sample (n=106) 
representative of the general adult population in the Netherlands in terms of 
age (18-65 years), gender, and education level. The pilot study had two main 
objectives. First, we collected information on the attributes and levels that could 
be used for the development of an efficient design for the main study. Second, we 
obtained information concerning the feasibility and readability of the DCE tasks.
A dummy-coded multinomial logit (MNL) model with fixed priors was chosen 
to build a D-efficient design in NGENE version 1.1.2. As higher problem levels 
were logically expected to be associated with lower preference scores in all seven 
attributes, priors were fixed at 0.04, 0.03, 0.02, and 0.01 for ‘no problem’ to ‘large 
problem’, respectively. ‘Very large problem’ was set as the base case attribute level 
for all attributes. The design included 50 rows and respondents were randomly 
assigned to one of five blocks, resulting in ten choice sets per respondent. In each 
of the presented choice tasks, respondents were asked to imagine an adolescent 
with problems of substance use and/or delinquency and to choose the alternative, 
which they considered to reflect the best scenario for the adolescent. To force 
respondents to choose between one of the provided alternatives, no opt-out was 
provided. To examine left-right bias in respondent choices, an alternative-specific 
constant was added to the model.
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Two control tasks were included to identify respondents who responded 
inconsistently. The first task was a dominated choice scenario, with one 
alternative indicating less problems in all domains. The second control task 
presented respondents with a mirrored version of a choice task they had already 
answered earlier on in the DCE. Respondents who answered at least one of the 
two control questions inconsistently were excluded. Expected completion time 
was 12 minutes based on the mean completion time determined by test runs by 
two independent researchers. Responders who completed the questionnaire in 
less than a third of this time (<4 minutes) were considered to be ‘speeders’ and 
were excluded from the analysis.
Design main study
Between 7 and 13 March 2014, we collected data from a sample (n=1,500) 
representative of the general adult population in the Netherlands in terms of age 
(18-65 years), gender, and education level. Based on the results of the pilot study, 
the design of the main study was slightly adapted. The number of questions per 
respondent was reduced from ten to eight and color-coding was applied to the 
choice tasks to visually emphasize the differences in problem severity between 
attribute levels. A D-efficient design with 40 rows and five blocks was created by 
applying normally distributed Bayesian priors from the pilot study and using 
1000 Halton draws. The attribute levels were dummy-coded. Respondents were 
randomly assigned to one of five blocks with eight choice tasks each plus two 
control tasks. In line with the pilot study, respondents were excluded from the 
analyses when they were considered ‘speeders’ or answered at least one of the 
two control questions incorrectly.
Model specification
The main data were analyzed by first applying an MNL model and stepwise 
extending this model towards a panel mixed multinomial logit (MMNL) model. 
Whereas for the MNL model the assumption holds that all variables need to be 
independent and identically distributed (IID assumption), this assumption does 
not apply to the panel MMNL model [29]. The panel MMNL model hence allows 
for interdependency of observations (which e.g. may occur when respondents 
answer several choice tasks) and heterogeneity in respondent preferences. 
Consequently, within the panel MMNL model, utility variation, which would 
otherwise enter into the error component of the MNL model is explicitly modeled 
and reflected in the parameter estimates [29, 30]. Model fit was evaluated based 
on log likelihood ratio (LR) tests.
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When extending the MNL model towards a panel MMNL model, several steps 
were taken. First, an unrestricted dummy-coded MNL model with an alternative-
specific constant was estimated. No evidence for left-right bias was found, 
and hence the constant was excluded from the model. Next, we investigated 
various model specifications with random parameters to allow for heterogeneity 
in respondent preferences. Making all parameters random was not feasible 
technically due to limitations on computer capacity, so stepwise parameters that 
indicated the strongest heterogeneity, i.e. with the highest standard error, were 
added as random parameters and model fit was evaluated based on LR tests. As 
a final step, we verified whether collapsing attribute levels two and three (‘fairly 
large problem’ and ‘large problem’) or three and four (‘large problem’ and ‘very 
large problem’) would improve model fit. However, these modifications did not 
lead to an improvement based on LR. Hence, a panel MMNL with fourteen 
random and fourteen fixed parameters was chosen as the final model. Standard 
deviations were derived based on Cholesky decomposition. The analyses were 
performed in NLOGIT (version 5).
ASC T-ASI preference scores
To estimate the coefficients for the fourteen random parameters, bootstrapping 
using 10,000 hypothetical individuals from a normal distribution using the 
population level estimates of the MMNL was applied and individual-specific 
parameters were derived. Individual-specific parameters for each of the attributes 
and levels were averaged. The averages of the random parameters and estimates 
of the beta coefficients of the non-random parameters from the MMNL model 
were rescaled to a 0-1 scale to provide an ASC T-ASI tariff set. A score of 0 refers 
to the worst state with very large problems in all of the ASC T-ASI domains, 
while a score of 1 refers to no problems in any of the domains.
Results
Pilot study
The pilot study included 106 respondents (after the exclusion of ‘speeders’ and 
respondents who answered at least one of the control questions inconsistently). 
The number of excluded respondents was unknown as the survey company 
directly excluded these. Analysis of the dummy-coded MNL model of the 
pilot study showed that the intercept and the five coefficients of the attributes 
‘substance use’ and ‘justice’ were significant at the 5% level; the remaining 
coefficients were not significant at the 5% level. In addition, coefficient values of 
‘substance use’ and ‘justice’ were generally larger than those of the remaining 
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attributes. Based on significance and size of the coefficients we concluded that the 
weight of the attributes ‘substance use’ and ‘justice’ could be considered higher 
than the weight of the remaining attributes in the main study. As an indication 
of these possible differences in preferences, we set the priors for the design of 
the main study at 0.8; 0.7; 0.6; 0.5 for the attributes ‘substance use’ and ‘justice’ 
and at 0.4; 0.3; 0.2; 0,1 for the remaining attributes.
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Table 1 | Results of multinomial logit regression model (pilot study)
Attribute Level β coefficient Standard error
Alternative specific constant .17213** .07364
Substance use No problem -.25458 .15787
Slight problem -.33906** .14340
Fairly large problem -.29451* .16178
Large problem -.43473** .16930
Very large problem Base
School No problem .02548 .14697
Slight problem -.01061 .14727
Fairly large problem -.00028 .13802
Large problem -.11372 .13429
Very large problem Base
Work No problem -.10070 .13417
Slight problem -.25961* .13853
Fairly large problem .11855 .15717
Large problem -.20238 .15715
Very large problem Base
Family No problem -.17069 .17254
Slight problem -.13104 .14296
Fairly large problem -.19364 .15630
Large problem -.24786 .15315
Very large problem Base
Social relationships No problem -.02810 .15607
Slight problem .00062 .15381
Fairly large problem -.26423 .18211
Large problem -.04516 .15244
Very large problem Base
Justice No problem -.37518** .15755
Slight problem -.25657 .15922
Fairly large problem -.34744*** .13473
Large problem -.34762** .15835
Very large problem Base
Mental health No problem .19324 .15250
Slight problem .03586 .14204
Fairly large problem .03471 .15899
Large problem .09234 .14292
Very large problem Base
Note: ***, **, * ==> Significance at 1%, 5%, 10% level respectively.
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Concerning the feasibility and readability of the questionnaire, 56.6% (n=60) of 
respondents of the pilot study found the DCE tasks ‘difficult’ or ‘very difficult’. 
The majority of respondents had difficulties choosing between the different 
alternatives (n=53). Some respondents had difficulties imagining the situation 
of the adolescent (n=10), or reading the descriptions provided with the choice 
tasks (n=4). To reduce complexity and enhance clarity for respondents in the 
main study, the questionnaire was slightly adapted as compared to the pilot 
study. The first adaptation referred to color-coding of the attribute levels from 
light to dark violet as to facilitate a choice by making the different levels visually 
more distinct. In addition, the number of choice sets was reduced from 10 to 8 
per respondent, to increase the feasibility of the study and quality of the data.
Main study
The main study comprised 1,500 respondents after exclusion of ‘speeders’ and 
exclusion of 853 respondents who answered at least one of the control questions 
incorrectly. General respondent characteristics are displayed in Table 2.
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Table 2 | Sample characteristics of main study (n=1,500)
Sample main study
Mean (SD) or % (n)
General Dutch population
Mean (SD) or %
Gender (Male) 50.3 (754) 50.2
Age
   Female
      18-34 16.3 (244) 16.2
      35-49 16.8 (252) 16.7
      50-65 16.7 (250) 16.9
   Male
      18-34 16.5 (248) 16.5
      35-49 16.9 (253) 16.8
      50-65 16.9 (253) 17.0
Educational levela
   Minimum Low 10.9 (164)
   Minimum Middle 58.6 (879)
   Minimum High 30.5 (457)
Completion time (min)
   Minimum 4.00
   Maximum 23.70
   Mean 8.16
Work
   Yes (>=36 hrs/wk) 29.3 (439)
   Yes (<36 hrs/wk) 27.6 (414)
   No 43.1 (647)
Children
   Yes (<12 yrs) 13.1 (196)
   Yes (12-21 yrs) 18.5 (278)
   Yes (>21 yrs) 26.3 (395)
   No 50.8 (762)
Subjective health (EQ-5D-3L VAS) 74.35 (14.78) 77.72 (15.19)b
Health-related QoL (EQ-5D-3L) .87 (0.20) .87 (0.18)b
Note. a Low = lower vocational and primary school, Middle = middle vocational and secondary school, 
High = higher vocational and academic education; b [32]
Respondents’ distribution of age and gender was in line with the general 
population in the Netherlands. Mean age was 42 years (general Dutch population: 
42 years) and the proportion of male respondents was 50.3% (general Dutch 
population: 50.2%) [31]. Completion time ranged from 4 minutes to nearly 24 
minutes, with a mean completion time of 8 minutes and 13 seconds. This shorter 
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completing time as compared to the pilot can be explained by the reduction in 
the number of choice sets and the addition of color-coding. A large proportion 
of the respondents stated not to have paid work (43.1%), 29.3% worked 36 or more 
hours a week and 27.6% worked part time with an average of 19.16 hours per week 
(SD 9.063). Slightly more than half of respondents (50.8%) had children, of which 
18.5% were between 12 and 21 years (an age group similar to the population that 
the discrete choice task referred to). Subjective health and health-related quality 
of life based on the EQ-5D and its Dutch tariffs were comparable to the values 
of the general Dutch population [32].
Preference scores for the ASC T-ASI domains and problem levels
The results of the panel MMNL model are presented in table 3. An overview of 
the coefficients for each of the attributes and attribute levels is provided.
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Table 3 | Results of panel mixed multinomial logit regression model (main study)
Attribute Level β coefficient Standard deviation
Substance use No problem 2.48564*** 1.63320***
Slight problem 1.92631*** 1.39210***
Fairly large problem .87412*** -
Large problem .33400*** -
Very large problem Base
School No problem .91027*** -
Slight problem .86616*** .37781***
Fairly large problem .33925** 1.10870***
Large problem .25556*** -
Very large problem Base
Work No problem 1.25942*** 1.08894***
Slight problem .81447*** -
Fairly large problem .58935*** -
Large problem .21731* .79275***
Very large problem Base
Family No problem 1.67697*** -
Slight problem 1.17190*** -
Fairly large problem .58164*** .85331***
Large problem .03268 .94046***
Very large problem Base
Social relationships No problem 1.26387*** .73073***
Slight problem 1.01831*** -
Fairly large problem .78538*** -
Large problem .37928*** 1.02409***
Very large problem Base
Justice No problem 2.02321*** 1.53078***
Slight problem 1.53178*** 1.09865***
Fairly large problem .68487*** -
Large problem .25052** .66371***
Very large problem Base
Mental health No problem 2.31869*** 1.06997***
Slight problem 1.95064*** -
Fairly large problem 1.21795*** -
Large problem .52154*** -
Very large problem Base
Note: ***, **, * ==> Significance at 1%, 5%, 10% level respectively; - ==>fixed parameters
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Table 3 shows that all coefficients were positive. Hence, generally, fewer problems 
than the base case level (very large problems) were preferred by the respondents. 
The coefficients of problems with substance use, family, justice and mental health 
were relatively large compared to the other coefficients indicating that changes 
in these domains had a relatively high impact on the choice between alternative 
situations. Problems in the domains school, work and social relationships had a 
relatively low impact on the choice. All but two coefficients were significant at 
the 5% level. One coefficient for ‘large’ problems was only significant at the 10% 
level (with an effect of 0.019 on the tariff), and one was not significant at the 10% 
level (with a marginal effect of 0.001 on the tariff). This suggests that in these two 
cases there was no evidence for the level of a ‘large problem’ to be significantly 
different from a ‘very large problem’ (base level). Yet, as described above, 
collapsing the problem levels ‘large’ and ‘very large’ did not yield significant 
improvements of the model (as shown by the LR).
Table 3 also shows that all standard deviations of the random parameters 
were relative large and significant at the 1% level hence providing evidence for 
preference heterogeneity amongst respondents.
Tariff set
Table 4 presents the results of the conversion of the coefficients into preference 
scores per domain and problem level with the total score ranging from 0 to 1. A 
score of 0 refers to the worst state as defined by the instrument and a score of 1 
refers to the best possible state defined by the instrument.
The use of the preference scores can be illustrated as follows. Based on table 4, 
an adolescent with a ‘slight problem’ in the domain substance use, a ‘fairly large 
problem’ in the domains school and work and ‘no problem’ in the domains 
family, social relationships, justice and mental health would be coded 2331111, 
which translates into a score of 0.161+0.028+0.050+0.141+0.106+0.168+0.194 =0.848.
Consistent with the coefficients presented in Table 3 and the above mentioned 
example it can be seen that the domains substance use, mental health, justice, 
and family were more influential and received more weight than the domains 
social relationships, work and school.
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Table 4 | ASC T-ASI tariff set
Domain Problem level Preference Scores
Substance use No problem .210
Slight problem .161
Fairly large problem .073
Large problem .028
Very large problem .000
School No problem .076
Slight problem .073
Fairly large problem .028
Large problem .022
Very large problem .000
Work No problem .105
Slight problem .068
Fairly large problem .050
Large problem .019
Very large problem .000
Family No problem .141
Slight problem .098
Fairly large problem .049
Large problem .001
Very large problem .000
Social relationships No problem .106
Slight problem .086
Fairly large problem .066
Large problem .032
Very large problem .000
Justice No problem .168
Slight problem .128
Fairly large problem .058
Large problem .022
Very large problem .000
Mental health No problem .194
Slight problem .164
Fairly large problem .102
Large problem .044
Very large problem .000
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Discussion
In this study, we obtained societal preference scores for the ASC T-ASI, creating 
a short preference-based measure suitable for use in economic evaluations of 
systemic family interventions. The scope of this measure is more in line with 
the goals of systemic interventions than currently available health-related 
quality of life measures, and hence enables a more meaningful interpretation 
of the effects of such interventions. The instrument is an adaptation of the 
frequently used T-ASI [23], which may contribute to its acceptance, validity 
and feasibility of implementation. The ASC T-ASI is a preference-based 
outcome measure with a self-contained scoring system with its own range and 
interpretation. In that respect it is similar to other recently developed broader 
outcome measures, like the ICECAP instruments [5, 6]. While the preference-
based ASC T-ASI has clear similarities with common health-related quality of 
life measures, we emphasize that they are distinct. For health-related quality 
of life measures like the EQ-5D, a preference-score of 0 corresponds to the 
state ‘dead’ and hence represents a ‘natural zero’. This is not the case for the 
ASC T-ASI, where a score of 0 simply refers to the most severe problems on all 
domains of the instrument and where 1 refers to the best situation. Combining 
ASC T-ASI scores with duration therefore requires a careful consideration and 
interpretation. Moreover, QALY tariffs represent average valuations of health 
states obtained by asking respondents to imagine being in these health states 
themselves. Here, we asked adults to value states from the perspective of the 
adolescent, not themselves, which is a fundamental difference. The resulting 
scores therefore cannot be straightforwardly transformed into or compared with 
QALYs. The use of the preference-based ASC T-ASI measure hence implies the 
loss of some of the comparability specific to CUA (as comparison is only possible 
between interventions which can be evaluated with the same quality of life 
concept or even instrument). However, it may be more informative and yield 
more meaningful results when performing economic evaluations of systemic 
family interventions where effects broader than health may be expected and 
allows comparisons of benefits of such interventions.
Sindelar and Jofre-Bonet [33] have earlier expressed the need for a preference-
weighted instrument to perform CEAs in the context of substance abuse 
treatment. They presented an index score for the ASI, the adult version of the 
T-ASI, which differs in some domains from the T-ASI. The authors obtained 
index scores by asking patients and participants from a convenience sample 
from the general public how important treatment was or how important each 
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domain was. The authors introduced their method as an “intermediate step until 
further, more sophisticated surveys become available” [33]. The current study 
may be considered such a further step, providing societal preferences for the 
actual states the ASC T-ASI describes, based on a discrete choice experiment.
Before discussing some implications and future research, we note a number 
of limitations and strengths of this study. A first limitation relates to the issue 
of completeness, i.e. whether all relevant effects of systemic interventions are 
covered in the ASC T-ASI. One might argue that more dimensions could have 
been included in the instrument. Moreover, some of the included domains may 
not be relevant for all respondents. For example, the domain ‘work’ may only 
be relevant for relatively old adolescents who work or would want to work. 
Future research may be directed at investigating this issue further, for instance 
by considering conditional questions or changes in the labeling of the domains 
or levels.
A second limitation is related to the significance of parameters. Ideally, all 
parameters would be significant. Two parameters presented in table 3 (family– 
large problems and work – large problems) were not significant at the 5% level, 
although the latter was significant at the 10% level (p-value 0.089). This may 
indicate some inefficiencies in the design, yet the impact of the non-significant 
coefficients on the tariff was limited to negligible (with values of 0.019 and 0.001, 
respectively). Non-significance of these parameters suggests that the levels 
of ‘large problems’ and ‘very large problems’ may not need to be evaluated 
separately but could be merged for these domains. Merging however resulted 
in a reduced model fit. Hence, we chose to keep the levels apart, basing the tariff 
on all available information and differentiating between problem levels in the 
same way in all domains. Sample-size may have had an influence on significance 
levels as well.
Third, interactions between attributes and attribute levels were not explicitly 
modeled due to the large number of model parameters and limitations in 
computer capacity. This may constitute a shortcoming of the current study and 
may be explored in future research.
Fourth, a more general limitation, related to the design of the study, is that 
respondents stated to have experienced the choice tasks as complex. This was 
already observed in the pilot study. In the main study, we therefore decreased 
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the number of choice tasks from ten to eight per respondent and applied 
color-coding to simplify the decision process and reduce overall demands to 
respondents. Furthermore, to increase the probability that the choice tasks were 
well understood by the included respondents, speeders and respondents who 
did not answer the control questions correctly were excluded. Nonetheless, 
more than half of the included respondents still considered questions in the 
main study to be difficult or very difficult. When provided with possible reasons 
for the difficulties, 44.1% (n=661) of respondents indicated problems with 
making a choice between the different situations. This may be related to the 
inherently difficult nature of the choices in this context. Other problems were 
less frequently mentioned, including having trouble imagining the situations of 
the adolescent, trouble reading the descriptions of the choice tasks, and possible 
interdependencies of alcohol and drug problems with other problems. Part of the 
difficulties of making a choice may have been related to the fact that respondents 
were confronted with a forced choice without an opt out option. While this was 
done intentionally to avoid disturbing the utility balance of the design, lowering 
its efficiency, and to avoid respondents opting out due to reasons other than 
preferences related to the choice task [34], the absence of such an option may 
have increased the difficulty of the task. Including an opt-out option might have 
influenced our results.
Fifth, potentially related to the previous point, we excluded a substantial amount 
of respondents who incorrectly answered one or two control questions, in 
order to achieve the highest possible quality of the data for the tariff set. One 
could argue that excluding only those respondents who answered both control 
questions incorrectly would have been sufficiently cautious. Respondents who 
were excluded due to answering one control question incorrectly (N=717) were 
significantly older (44.91 vs. 42.00 years; p=0.000) and lower educated (p=0.000) 
than included respondents. No gender difference was observed.
Sixth, very important also for the interpretation of the presented tariffs, as 
indicated above, the observed scores reflect what people in the general public 
think is ‘best’ for the adolescents involved, not an indication of a preference to be 
in a certain state oneself. This may have added to the difficulty of the task. It also 
represents a crucial difference with many other preference elicitations in health 
care in which people normally choose for themselves. This difference between 
the here presented tariffs from common ‘utility scores’ needs emphasis. We 
chose this valuation approach for several reasons. Firstly, we wanted to obtain 
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broad societal preferences from the general public, in line with Dutch guidelines 
[1]. Given that the ASC T-ASI relates to adolescents, this renders obtaining 
preferences of people for themselves meaningless. Hence, we asked them to 
opt the best option for the adolescent, which yielded preferences that may be 
somewhat ‘paternalistic’. Secondly, we assumed that preferences of adolescents 
actually being in these states arguably would be less useful for societal decision 
making, especially when ‘distorted’ by underlying problems like addiction and 
myopia (also due to the age of respondents). Moreover, such preferences would 
be influenced by coping and adaptation [35].
Future research could explore the important normative issue of ‘whose values 
count’ [35] in situations like these, but could also compare preferences of affected 
adolescents, adolescents without the specific problems described with the 
instrument, and those of the general public. Using preferences from non-affected 
adolescents may yield preferences that are more representative of those of the 
treated group. Moreover, arguably, such respondents might be more capable of 
imagining (what it means) being in the different states described with the ASC 
T-ASI than adults in the general population. However, whether their preferences 
would be (more) appropriate to use in societal decision making remains unclear. 
Domains like ’social relationships’ could for instance receive more weight in 
samples consisting of adolescents, at the expense of domains like family or 
school.
Future research may also consider the framing of the choice task. We chose 
the framing of asking which situation was ‘best for the adolescent’, reflecting 
potential treatment goals of the health system, which can be different from 
what the adolescent would prefer. The approach taken therefore can be viewed 
as being aligned with societal decision-making and collective financing of 
interventions, at the expense of not using preferences of the treated adolescents.
Seventh, duration of states was not included as an attribute. Hence, when 
applying the ASC T-ASI preference-based measure in practice in combination 
with duration linearity of scores over time needs to be assumed.
Finally, the current study was limited to the Dutch setting. Moreover, among 
our respondents there was a high percentage of individuals without paid work, 
which may have affected our results.
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A number of strengths of this study also deserve mentioning. First, we built on 
an existing instrument to come to the ASC T-ASI, and the first validation study 
of the adapted version of the instrument showed promising results [24]. This 
approach may lead to higher acceptance and feasibility when implementing 
the measure in cost-effectiveness studies or in clinical practice. The Dutch 
version of the ASC T-ASI is set up in reading level B1, which may have enhanced 
readability, facilitating self-completion also by adolescents. Second, we used a 
two stage-design, starting with an elaborate pilot, followed by a main study. 
Advantages of this approach were that adjustments to the design could be made 
in between the pilot and main study, enhancing the quality of the data obtained. 
A third strength relates to the model used in our analyses, which allowed for 
interdependency of observations and heterogeneity in preferences. The chosen 
model fits the panel data of the DCE tasks and accounts for individual differences 
in choice behavior, which is valuable as we assume that choices may differ 
between different members of society. Future research could further analyze 
the heterogeneity in the data. Our current aim was to obtain overall preference 
scores rather than to differentiate between the scores of specific groups of 
respondents.
The presented ASC T-ASI can be used in several ways. It may be used as an 
add-on instrument in future cost-effectiveness studies and clinical trials 
with low burden to patients due to its brevity. Also, it can be used as a stand-
alone self-completion instrument to weight different changes in the situation 
of adolescents. Both options would provide valuable information for use in 
economic evaluations, in combination with the here provided tariffs. When 
used in combination with other cost or benefit measures in economic evaluation, 
overlap and double counting need to be avoided. Such overlap could occur 
with common measures like the EQ-5D or with cost components of economic 
evaluations. This, as well as the validity of the ASC T-ASI in different settings, 
needs to be investigated further in future research. Furthermore, though the 
ASC T-ASI is developed in the context of systemic family interventions, future 
studies may consider its application in a broader context of youth mental health 
interventions.
Concluding, we performed a discrete choice experiment to attain preference 
scores for the ASC T-ASI. Our goal was to facilitate the use of the ASC T-ASI in 
the context of economic evaluations, by obtaining specific preference scores for 
this instrument capturing the most relevant disease-specific aspects of systemic 
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family interventions in adolescents with problems with substance use and/or 
delinquency. To our knowledge, the ASC T-ASI is the first generic preference-
based instrument in adolescent mental health care for which societal preference 
scores have been obtained that capture benefits beyond those included in the 
QALY. Many questions for further research were identified which exceed the 
scope of the current study. Nonetheless, the presented tariff hopes to provide a 
first step in including relevant disease-specific aspects in economic evaluations 
of systemic family interventions.
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Appendix A. English version of the ASC T-ASI instrument (B1 
level) [22]
Please check the answer that currently fits you best:
1. Substance use
I have no problem with the use of alcohol, drugs or medicine
I have a slight problem with the use of alcohol, drugs or medicine
I have a fairly large problem with the use of alcohol, drugs or medicine
I have a large problem with the use of alcohol, drugs or medicine
I have a very large problem with the use of alcohol, drugs or medicine
2. School
I have no problem with school
I have a slight problem with school
I have a fairly large problem with school
I have a large problem with school
I have a very large problem with school
3. Work
I have no problem with work
I have a slight problem with work
I have a fairly large problem with work
I have a large problem with work
I have a very large problem with work
4. Family
I have no problem with family
I have a slight problem with family
I have a fairly large problem with family
I have a large problem with family
I have a very large problem with family
5. Social relationships
I have no problem with friends, acquaintances and others in my environment
I have a slight problem with friends, acquaintances and others in my environment
I have a fairly large problem with friends, acquaintances and others in my 
environment























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I have a large problem with friends, acquaintances and others in my environment 
I have a very large problem with friends, acquaintances and others in my 
environment
6. Justice
I have no problem with the judicial authorities    
I have a slight problem with the judicial authorities   
I have a fairly large problem with the judicial authorities  
I have a large problem with the judicial authorities   
I have a very large problem with the judicial authorities   
7. Mental health
I have no problem with my mental health     
I have a slight problem with my mental health     
I have a fairly large problem with my mental health    
I have a large problem with my mental health    
I have a very large problem with my mental health    


 









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Appendix B. Dutch version of the ASC T-ASI instrument (B1 
level) [22]
Zet één kruisje bij het antwoord dat op dit moment het best bij jou past:
1.  Middelengebruik
Ik heb geen probleem met het gebruik van alcohol, drugs of medicijnen 
Ik heb een klein probleem met het gebruik van alcohol, drugs of medicijnen
Ik heb een redelijk groot probleem met het gebruik van alcohol, drugs of medicijnen
Ik heb een groot probleem met het gebruik van alcohol, drugs of medicijnen
Ik heb een heel groot probleem met het gebruik van alcohol, drugs of medicijnen
2.  School
Ik heb geen probleem met school     
Ik heb een klein probleem met school     
Ik heb een redelijk groot probleem met school    
Ik heb een groot probleem met school     
Ik heb een heel groot probleem met school    
3.  Werk
Ik heb geen probleem met werk      
Ik heb een klein probleem met werk     
Ik heb een redelijk groot probleem met werk    
Ik heb een groot probleem met werk     
Ik heb een heel groot probleem met werk    
4.  Familie
Ik heb geen probleem met familie     
Ik heb een klein probleem met familie     
Ik heb een redelijk groot probleem met familie    
Ik heb een groot probleem met familie     
Ik heb een heel groot probleem met familie    
5.  Sociale relaties
Ik heb geen probleem met vrienden, bekenden en anderen in mijn omgeving
Ik heb een klein probleem met vrienden, bekenden en anderen in mijn omgeving
Ik heb een redelijk probleem met vrienden, bekenden en anderen in mijn omgeving
Ik heb een groot probleem met vrienden, bekenden en anderen in mijn omgeving
























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Ik heb een heel groot probleem met vrienden, bekenden en anderen in mijn 
omgeving
6. Justitie
Ik heb geen probleem met justitie     
Ik heb een klein probleem met justitie     
Ik heb een redelijk groot probleem met justitie     
Ik heb een groot probleem met justitie     
Ik heb een heel groot probleem met justitie    
7. Geestelijke gezondheid
Ik heb geen probleem met mijn geestelijke gezondheid   
Ik heb een klein probleem met mijn geestelijke gezondheid  
Ik heb een redelijk groot probleem met mijn geestelijke gezondheid 
Ik heb een groot probleem met mijn geestelijke gezondheid  
Ik heb een heel groot probleem met mijn geestelijke gezondheid  






 





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Appendix C. Example of a choice set (English translation)
Which alternative do you consider best for the adolescent?
Below, two situations are presented in which a substance abusive and/or delinquent 
adolescent can end up: alternative A and B. Each alternative is further specified by the 
same seven problems (e.g. problems with school or within the family). However, the 
severity of these problems differs across the alternatives. The adolescent may experience 
no problem, a slight, fairly large, large, or very large problem.
What do we ask you to do? Think of a substance abusive and/or delinquent adolescent, 
whom you do not know. Then imagine that he experiences alternative A or B. Which 
alternative do you consider best for the adolescent, A or B? We will present you with 12 
of these questions. Hence, you will have to choose 12 times between alternative A or B. 
Remember that all questions refer to the same adolescent in different situations. We are 
interested in your choice. There are no good or bad answers.
In case you would like more information on the type of problem you can move your 
cursor over the problem, e.g. ‘school’ to see more details.
Question 1. Which alternative do you consider best for the adolescent?
Alternative A Alternative B
The adolescent has a slight problem with 
the use of alcohol, dugs or medicines
The adolescent has a very large problem with 
the use of alcohol, dugs or medicines
The adolescent has a fairly large problem 
with school
The adolescent has a large problem with school
The adolescent has no problem with work The adolescent has a slight problem with work
The adolescent has a very large problem 
with his family
The adolescent has no problem with his family
The adolescent has no problem with 
friends, acquaintances and others in his 
surroundings
The adolescent has a very large problem 
with friends, acquaintances and others in his 
surroundings
The adolescent has a very large problem 
with justice
The adolescent has a fairly large problem with 
justice
The adolescent has a slight problem with his 
mental health
The adolescent has a large problem with his 
mental health
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Introduction
The individual and societal impact of mental disorders is large. Effective 
treatment options can help to prevent mental disorders or reduce their 
impact. Yet, mental health treatments typically compete with other health care 
interventions for scarce financial resources. Hence, these interventions need to 
demonstrate their cost-effectiveness in order to ensure that they offer ‘value for 
money’ as compared to other treatment options. This is normally done through 
performing economic evaluations. As the results may inform funding and 
allocation decisions, it is crucial that such economic evaluations are executed 
well, fit to their precise purpose, and their results are carefully considered.
Measuring effects of mental health interventions as part of economic evaluations 
is not straightforward and much debated. The extent to which classical 
instruments to measure and value such effects (i.e., health economic outcome 
measures such as generic health-related quality of life questionnaires) adequately 
capture all relevant benefits of different mental health interventions has been 
questioned [1-3]. These concerns appear particularly relevant in the context 
of treatments for externalizing disorders in adolescents. These disorders can 
impact a broad array of life domains of the affected adolescents, and, also due 
to their life phase, strongly affect other people in their social environment. 
Patients may, for example, be acting out, pursue criminal activities, use drugs, 
or drop out of school, all of which result in costs and effects on and for the 
adolescents themselves as well as for the broader systems in which they operate 
(i.e., their family, school, neighborhood, etc.). Consequently, this may result in a 
high individual and societal burden within and beyond the health care sector. 
In assessing the impact of interventions aimed at treating adolescents with 
externalizing disorders, these broader costs and effects need to be recognized. 
Treatments for externalizing disorders in adolescents include psychotherapeutic 
and psychosocial interventions as well as pharmacological treatments. As 
part of the non-pharmacological interventions, systemic family interventions 
have shown to be effective, yet are intensive and costly. Consequently, the 
question as to whether such interventions offer value for money is relevant. 
Economic evaluations attempting to assess this need to capture all relevant 
costs and benefits, including the broader impacts described above. The current 
methodology of economic evaluations does not appear to be fully adequate for 
doing so. This dissertation seeks to increase the awareness of this fact, as well as 
taking first steps in improving the methodology of economic evaluations. Our 
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aim was to explore various ways of expanding the scope of economic evaluations 
of interventions for externalizing disorders in adolescents. In particular, 
we investigated how cost-effectiveness analyses (CEA) of interventions for 
adolescents with externalizing behavioral disorders can be performed most 
meaningfully.
In the next section, I will highlight the results of the different chapters in relation 
to the specific research questions and the overall aim of this thesis. Thereafter, 
I will highlight important limitations and implications of the studies presented 
in this thesis.   
Answering the research question
In Chapter 2, we first explored the use of existing health economic methodology 
with an extension to include broader societal outcomes. In doing so, we addressed 
the research question of how to perform a CEA for pharmacological treatment of an 
externalizing disorder (ADHD), including consideration of relevant broader societal 
impacts while using existing health economic methodology. 
ADHD is common with a prevalence of 5% in children and adolescents [4] and 
is associated with broad societal and long-term effects [5-7]. Yet, the scope of 
the few available economic evaluations of treatments for ADHD is limited 
[8-10]. We performed an economic evaluation largely applying existing CEA 
methodology. To this end, we constructed a probabilistic Markov model to 
perform an illustrative calculation of cost-effectiveness of immediate release 
methylphenidate (IR) versus extended release methylphenidate (OROS). In 
contrast to most available economic evaluations, we included long-term effects 
and broader societal costs (e.g., costs of additional educational support and 
spillover effects in terms of caregivers’ utility, medical costs and productivity 
losses). While the research presented in Chapter 2 highlighted that existing 
methodology can be used as a starting point for broader economic evaluations, 
in this particular case, available model input was limited, especially in terms 
of transition rates. Including broader elements of societal costs and benefits 
impacted the results of the economic evaluation, and arguably provided more 
relevant and disorder-specific estimates of cost-effectiveness. As such, our 
findings encourage adopting a broader perspective in CEA in the context of 
externalizing disorders. 
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In Chapter 3, we moved away from pharmacological treatments and towards 
systemic family interventions, the main focus of this dissertation. We performed 
a systematic literature review to investigate the current knowledge regarding cost-
effectiveness of systemic interventions for delinquency and substance use. 
Our final selection of papers included eleven studies. Because the results of 
those studies varied strongly – in terms of adopted perspective, which costs and 
effects were included, the treatment type and setting, and so forth – performing 
a meta-analysis was impossible. The quality of the included studies was found to 
be insufficient to draw firm conclusions about the cost-effectiveness of systemic 
interventions. As such, our exploration of the existing literature demonstrated 
that more research, of higher quality, is required. Not only do future studies 
need to clearly describe treatment types and use more sophisticated modeling 
approaches, they also need to take a broad (standardized) societal perspective 
in order to provide relevant estimates on the cost-effectiveness of systemic 
interventions. 
In Chapters 4 and 5, we explored the possibility of adjusting the methodology of 
economic evaluations to better fit the characteristics and broad impact of systemic 
interventions for adolescents with problems of delinquency in particular. As 
a first step, we developed a simple, unidimensional overall outcome measure 
capturing broad outcomes and using this in the context of a CEA. We again 
constructed a probabilistic Markov model, this time to compare Functional 
Family Therapy (FFT) with treatment as usual. To capture the broad outcomes 
of systemic interventions in adolescents, we expressed the outcomes of the 
intervention in terms of the outcome ‘Criminal Activity Free Years’ (CAFY). 
This addressed the research question of whether we can perform a CEA of a systemic 
intervention for delinquency in adolescents using Criminal Activity Free Years as an 
outcome measure. The model included long-term effects and resulted in an estimate 
of incremental costs per CAFY. Using a probabilistic model and the CAFY 
outcome measure to assess cost-effectiveness of systemic interventions aimed 
to reduce delinquency was shown to be feasible. The presented model provided a 
framework to assess the cost-effectiveness of systemic interventions, while taking 
into account parameter uncertainty and long-term effectiveness. In Chapter 5 
we took this research one step further, using Value of Information analysis to 
address the question whether we can perform a Value of Information analysis 
based on the CEA using Criminal Activity Free Years as outcome measure to 
inform future research. We found that further research to eliminate parameter 
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uncertainty had a high value (i.e., €176 million) and that reducing uncertainty 
in some specific model parameters might be more valuable than in others. Such 
insights can steer future research, making it more efficient. Importantly, chapter 
5 demonstrated that using a Value of Information framework to assess the value 
of conducting further research in the field of crime prevention, using a simple 
CAFY outcome measure, was indeed feasible. The results appeared relevant and 
well interpretable. However, notwithstanding the results from chapters 4 and 
5, it should be noted that the CAFY (like, for example, event free life years) is 
a very simple and crude outcome measure, which is not preference-based (e.g., 
does not distinguish between types of delinquency). In that sense, though being 
more specifically directed at delinquency, it is a clear step back from generic 
health-related outcome measures. Moreover, its use will be hampered in practice 
by the fact that threshold values (i.e., what a CAFY would be worth to society) 
are not available. The use of an outcome measure like CAFY therefore results in 
problems common to CEA, using natural units as outcome measure (including 
problems of comparability of outcomes). This is not the case in cost-utility 
analyses (CUA) where standardized preference-based outcomes like QALYs are 
used.    
Hence, the need for relevant, broad, yet more sophisticated, outcome measures, 
resembling some of the positive features of QALYs, is not reduced by having a 
CAFY measure. Therefore, in this thesis, attention was also paid to finding and 
developing preference-based outcome measures able to capture the relevant 
benefits of systemic mental health interventions. A logical starting point of 
course is to assert whether existing QALY measures indeed fail to sufficiently 
capture the goals and relevant effects of systemic mental health interventions. 
This can be done in a variety of ways. Here, we performed a qualitative study, 
presented in Chapter 6, in which we examined which treatment effects should be 
captured in economic evaluations of systemic interventions in adolescents according to 
clinicians and whether the existing QALY measures capture these. 
Clinicians considered several EQ-5D dimensions relevant, in particular ‘usual 
activities’ and ‘anxiety/ depression’. However, they also emphasized that the 
instrument lacked systemic dimensions such as family relations and relations 
with others, as well as addiction specific issues. These findings suggested 
that generic QALY measures like the EQ-5D instrument may not (directly) 
capture all relevant effects related to the here studied systemic interventions. 
This implies that economic evaluations using generic health-related quality of 
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life instruments as their outcome measure may omit relevant outcomes and, 
consequently, potentially lead to non-optimal policy decisions. More relevant 
outcome measures may be required, which could be either new measures or 
existing ones. 
In Chapter 7, we therefore set out to investigate which outcome measures are 
currently used to measure the effects of systemic interventions in clinical research 
and could be used in cost-utility analyses. We performed a systematic literature 
review, which revealed a large variety of outcome measures currently used 
in effectiveness research of systemic interventions. However, only eight of 
the available instruments covered five or more life domains relevant in this 
context, and thus could be called comprehensive. None of these had preference-
weights available. The T-ASI instrument was identified as promising in terms 
of comprehensiveness and potential to be transformed into a self-complete, 
preference based instrument for use in economic evaluations. 
Based on the findings of Chapter 7, we investigated the question of whether it 
is possible to obtain societal preference-weights for a comprehensive multidimensional 
outcome measure to be used in economic evaluations of systemic interventions targeted 
at adolescents with problems of substance use and delinquency. Based on the findings 
presented in Chapter 7, an abbreviated self-complete version of the T-ASI (called 
ASC T-ASI) was developed [11]. Chapter 8 describes how we derived societal 
preferences (‘tariffs’) for this instrument, which meanwhile has been validated 
with promising results [11]. We performed a discrete choice experiment (DCE) 
among a sample of the Dutch general population with the aim to obtain tariffs for 
the ASC T-ASI. Although respondents considered the choice task to be difficult, 
the results showed that the preference scores were logically ordered, with 
lower scores for worse states. All but one estimated coefficient were statistically 
significant. It turned out that problems concerning substance use, psychiatric 
status, and legal status were most influential, followed by family relations. School 
status, employment/support status, and peer/social relationships had less impact 
on overall scores. The obtained tariffs enable a preference-based assessment of 
broad effects of systemic family interventions for adolescents with problems of 
substance use and/or delinquency within economic evaluations when using the 
ASC T-ASI as outcome measure. However, given some methodological choices 
made in deriving these tariffs, more research is necessary to confirm the current 
tariffs in new and larger samples and to inform the interpretation of ASC T-ASI 
scores. 
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Concluding, we have explored various ways of expanding the scope of 
economic evaluations of interventions for externalizing disorders in adolescents 
throughout this dissertation. We started out with an exploration of classical CUA 
of pharmacological interventions extended with elements to account for broad 
societal costs. We then examined the available literature on cost-effectiveness and 
CUA of systemic family interventions. We observed a lack of state-of-the art CEAs 
as well as low quality of existing analyses of treatments for substance use and 
delinquency. In response, we performed a CEA of systemic family intervention 
and introduced a broad, yet basic outcome measure specific to delinquency. 
The evaluation was feasible, yet lacked the comparability allowed in cost utility 
analyses. Therefore, we explored next steps towards broader CUAs of systemic 
family interventions. To do this, we performed interviews among clinicians to 
establish whether the current QALY measure captures goals and relevant effects 
of systemic interventions and we investigated which outcome dimensions may be 
missing within the current methodology. The EQ-5D captured several relevant 
dimensions yet lacked others. In line with these findings we took steps towards 
developing a broader, more comprehensive outcome measure. We systematically 
searched for existing outcome measures with broad dimensions and suitable to 
be used to obtain societal preference weights. We identified a broad, established 
instrument, which is accepted in the field and covers the broader domains of 
interventions for externalizing disorders. Finally, we obtained societal preference 
weights for an abbreviated self-completion version of this instrument to facilitate 
its use in health economic evaluation. 
Strengths and Limitations
Capturing the broad and (partly) non-medical effects of interventions for 
externalizing disorders in adolescents in economic evaluations has shown to 
be multi-faceted and challenging. Yet, information on the costs and effects of 
treatments for externalizing disorders is vital to the process of decision-making 
concerning resource allocation within the health care domain. We consider it 
a strength of this dissertation that various health economic techniques were 
explored and adapted in the context of the evaluation of systemic interventions 
of externalizing disorders. We built on existing data, added societal dimensions, 
examined a simple, yet broad measure of cost-effectiveness and explored 
possibilities for CUA by identifying a more comprehensive and meaningful 
measure and obtaining societal preference-weights for it. We have attempted 
to set first steps in including the broad effects of treatments for externalizing 
disorders in economic evaluations and have shown that the existing methodology, 
9
Binnenwerk werkbestand Saskia.indd   243 28-10-2019   12:39:04
244
Chapter 9
together with extensions and a preference-based broad measure presented here, 
can be valuable in attaining this goal. 
Several of the aspects discussed in this dissertation (e.g., broad effects on patient, 
third parties and society as a whole) may be common to more or even all mental 
disorders and may play a role in economic evaluations of these disorders as 
well. Family functioning, interaction with others and the ability to take social 
responsibilities, to participate in educational activities or the ability to engage 
in meaningful work will often be affected by a mental disorder. As such, these 
considerations should be factored in when determining the cost-effectiveness 
of interventions adopting a societal perspective. One could apply the classical 
health economic methodology using the QALY as outcome measure, possibly 
extended by measures to also capture broader effects or one could include these 
effects by choosing a broader outcome measure, which captures all relevant 
domains of functioning (like we presented here for delinquency and substance 
use).  Thus, the findings from this dissertation may well be of value in thinking 
about ways to improve the health economic evaluation of these disorders in the 
future as well.
Yet, though our explorations resulted in valuable findings, many questions 
remain unanswered. We mention some, directly related to some of the studies 
performed in this thesis. 
First of all, when investigating whether the QALY sufficiently captures relevant 
outcomes, we based our conclusions on literature and on findings from a 
qualitative study, whereas quantitative studies investigating the responsiveness 
of specific generic health-related quality of life instruments may have been 
valuable additions. Yet, those were beyond the scope of this dissertation. 
Furthermore, and important also in terms of intended use of economic 
evaluations, though we and others [11] have taken several steps towards designing 
a comprehensive outcome measure for the economic evaluation of systemic 
interventions, we were not able to capture the specific outcomes of interventions 
without compromising on comparability of results. Within a clinical setting, CEA 
can be useful to compare similar interventions, yet it is limited in that outcomes 
are not comparable across interventions and across settings. Hence, CUA is more 
suitable for societal decision-making as it enables comparisons of different 
interventions to determine which intervention contributes most to health and 
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welfare compared to its costs. When using different ‘utility measures’, like the 
one investigated in this thesis, comparability is also sacrificed. In particular, 
results from the ASC T-ASI cannot be readily compared to QALY outcomes, as 
they measure different concepts and outcomes, and are expressed on different 
utility scales. (Note that this is also true for other broader outcome measures 
recently developed for economic evaluations, such as the ICECAP-O instrument 
or the ASCOT [12, 13]. This means that comparability is limited to other studies 
using the same or highly similar outcome measures. Hence, finding an adjusted 
outcome measure, like the ASC-T-ASI, which captures the broad and systemic 
effects of interventions means diminishing the comparability with outcomes of 
other economic evaluations. However, it also creates an opportunity to carefully 
and comprehensively capture the effects of the intervention, more in line with 
the intervention’s goals and the results as viewed by patients and clinicians. 
For the ASC T-ASI, an additional complication is that its tariffs are not expressed 
on an anchored scale like the QALY, so that 0 (1) simply means the worst (best) 
situation expressed with the instrument, making multiplications with duration 
less straightforward (also in terms of interpretation). In addition, no threshold 
values exist for the ASC T-ASI. Given the broad domains in the ASC T-ASI, 
specific attention needs to be paid to the possibility of double-counting items 
(on both the cost and the effect-side). Finally, even though first results on validity 
presented in [11] looked promising, to date the ASC T-ASI instrument has been 
validated only once, and so far no information is available on the sensitivity 
to change of the ASC T-ASI instrument. In that sense, the tariffs presented in 
Chapter 8, were developed soon after the first validation and do not imply that 
further validation is not encouraged. We also were not able to perform head-to-
head comparisons of the ASC T-ASI instrument in a relevant sample with for 
instance conventional health related quality of life instruments like the EQ-5D, 
or more general preference based wellbeing measures, such as the ICECAP-A 
instrument [14].
Another important methodological challenge refers to the question of who 
should value the states described with a preference based outcome measure 
like the ASC T-ASI. In this dissertation, we opted for the common source of such 
valuations, i.e. the general population. While in valuing health states this already 
implies valuing hypothetical states (as many individuals will not be experiencing 
or even will ever have experienced the health state under valuation), here we 
asked respondents to choose what they believed to be best for the (hypothetical) 
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adolescent in that state. While one may feel this to be a logical choice, also for 
paternalistic reasons, other choices could have been made [15]. Future studies 
could investigate obtaining preferences of adolescent respondents (of the general 
population or even the target population) and see whether these preferences 
differ from the earlier obtained ‘societal preferences’. In this way, we may obtain 
data from informants most closely related to the studied patients. 
A further methodological limitation of the current thesis, also applicable to the 
evaluation of other mental disorders, is that we did not explicitly address the 
handling of common co-morbidities in performing health economic evaluations 
and interpreting their outcomes. In mental health, co-morbidities occur 
frequently and may affect the outcomes of a treatment. Treatment of one disorder 
may for instance positively or negatively affect the symptoms of a secondary 
disorder. When this is the case, observed treatment outcomes may be affected by 
the (possibly overlapping and interacting) symptoms of disorders. Furthermore, 
the presence of co-morbidity may complicate treatment and/or prolong the 
time to recovery. Consequently, taking a broad view on treatment outcomes 
will increase the chance of comprehensively capturing broad effects, yet 
interpreting the results is not always straight-forward in the presence of common 
co-morbidities and interdependencies, and may require close collaboration of 
clinicians, researchers and policy makers.
Some observations regarding the data used in the different studies also need 
to be made here. In the early chapters, we would have preferred (randomized 
control) trial data as input for the health economic models, yet unfortunately 
that data was not available and additional data collection exceeded the scope of 
this dissertation. Also, we would have preferred a larger number of participants 
for our interview study among clinicians, as a larger and more diverse group of 
respondents may have provided a more representative sample of systemic family 
therapists. The current sample may have lead to a relatively strong focus on drug 
use as the majority of respondents worked with patients with addiction problems. 
Additionally, it might have been interesting to have obtained information from 
other stakeholders, such as patients, to take an even broader perspective on the 
relevant outcomes of the interventions. Practical limitations and restrictions were 
the main reasons for not doing so. Furthermore, the discrete choice experiment 
performed within this dissertation was web-based and proved to be a difficult 
exercise for many respondents. The large number of participants of the discrete 
choice experiment who did not answer the control questions correctly and who 
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were therefore excluded from the analysis may have biased the results as the 
educational level of included respondents was shown to be higher than of the 
excluded individuals. Performing the experiment in a face-to-face setting may 
have improved the understanding of the respondents and may therefore have 
diminished drop-out and affected results. 
Another noteworthy issue is that, in the current study, we obtained Dutch data 
only. Given this obvious limitation it may be interesting to investigate in future 
studies whether aspects like opinions of experts or societal weights for ASC T-ASI 
states differ in other countries. Differences may for instance occur, as substance 
use may be a more sensitive subject in some countries, responsibility of (young) 
individuals may be judged differently, importance of family relations may 
differ per country, etcetera. Consequently, this may affect what are considered 
important outcomes as well as the societal preference weights for these outcomes. 
Recommendations for research and policy
Notwithstanding the limitations noted in the previous paragraph, we express 
several recommendations for future research. Policymakers increasingly face 
(difficult) decisions concerning the allocation of scarce health care resources. It 
is important that these decisions be informed in the best possible way. Health 
economic analyses in the context of externalizing disorders in adolescents have 
shown to be scarce and of insufficient quality, and common outcome measures 
seem too limited to capture relevant outcomes of the interventions. We explored 
different ways to expand the scope of economic evaluation of interventions for 
externalizing disorders in adolescents. Besides using and enhancing the common 
methodology, we also provided an alternative to the conventional QALY measure 
aimed at covering broader effects more in line with clinical goals. 
Based on the findings of this dissertation, we suggest that economic evaluations 
of interventions for externalizing disorders in adolescents should, when 
performed according to conventional methodology, minimally include add-ons 
to account for broader elements of societal costs and benefits, without omissions 
or double-counting. These add-ons could be more limited additions to at least 
cover for instance the costs of additional educational support and spillover 
effects in terms of caregivers’ utility, medical costs and productivity losses, as 
was done in Chapter 2. Ideally, we would recommend future trials to include 
broader outcome measures, such as the ASC-T-ASI, alongside common health-
related quality of life measures. In this way, comparability with a wider range 
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of (medical) interventions would still be warranted based on the QALY outcome, 
yet one may also be able to use the more comprehensive ASC-T-ASI outcomes 
to make broader (systemic) effects visible and measurable, particularly useful 
in interpreting QALY results and when comparing with interventions in the 
same or a similar context. Directly investigating the needs and wishes of policy 
makers in this context, in terms of the type of information provided and the 
comparability of results, remains important as well. If comparability of outcomes 
of economic evaluations is compromised by using different utility measures in 
different contexts, this may pose less of a problem if appropriate ‘thresholds’ 
exist for these different outcome measures [16]. It would therefore be useful to 
define a threshold value for an improvement in functioning/wellbeing based on 
different preference-based outcome measures. This amount could be based on 
studies investigating how much people are willing to pay per point improvement 
on a relevant outcome measure. Such a threshold value is now increasingly 
investigated for QALY gains, but remains un(der)explored for other outcome 
measures, such as the ICECAP instruments, or the ASC T-ASI. If appropriate 
thresholds would exist, the issue of comparability of outcome measures is less 
problematic. We suggest future research on this topic such that outcomes can 
clearly be translated into policy advice.
Furthermore, we recommend future research to be directed at exploring different 
broad outcome measures, including the ASC T-ASI, further investigation their 
validity, sensitivity to change, and reliability, and confirming the current ASC 
T-ASI tariffs in larger samples. In addition, future research may be directed 
at obtaining preference scores in other countries to determine inter-country 
differences in societal preference scores, and obtaining preference scores in other 
samples (affected adolescents or a random sample of adolescents). Though this 
dissertation mainly focused on the effect side of the health economic evaluation 
of externalizing disorders in adolescents, various aspects connected to the cost 
side, such as inclusion of costs of crimes, incarceration, costs of lower level of 
education and earnings, etcetera, also warrant further investigation. 
In addition, the research presented in this thesis may be valuable in the context 
of other areas and interventions in the field of mental health. The use of the 
ASC T-ASI or a similarly broad and preference-based measure in addition to 
the conventional QALY measure, in an attempt to better account for broad and 
diverse treatment effects, would be interesting in other areas as well. More 
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research on relevant outcomes and outcome measures in other areas of (mental) 
health care remains important.    
General conclusion
When performing economic evaluations and attempting to assess the societal 
costs and benefits of interventions for externalizing disorders in adolescents, 
more suitable methodology is required. This dissertation has suggested the use 
of existing methodology, with (compared to common economic evaluations) 
additions and enhancements to better reflect the goals and outcomes of systemic 
interventions. In spite of our efforts, several questions remain unanswered. 
Yet, we have taken first steps in further raising awareness of this issue and in 
improving the methodology of economic evaluations in this field. 
While working on this dissertation, I was particularly fascinated by the challenge 
of making outcomes of mental health inventions measureable, especially since 
such outcomes are often not visible from the outside, and not measurable by a 
single scan or by analyzing a single drop of blood. Nonetheless, the effects of 
interventions can make a huge difference for the wellbeing of a large number 
of individuals, together with the different systems they belong to. Furthermore, 
I was intrigued by the differences in viewpoint of clinicians and economists in 
this area, and felt an urge to bring these worlds closer together so as to improve 
their mutual understanding. I hope that this dissertation may contribute to the 
goal of making health economic evaluations of mental disorders, particularly 
with regard to externalizing disorders, more meaningful and, as such, serve as 
a starting point towards bridging the gap between health economic concepts 
and clinical practice in this field.
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Summary
Mental disorders are common. Effective treatments for mental disorders need 
to demonstrate their cost-effectiveness to compete for scarce, collectively 
financed health care resources. However, estimating the overall burden of these 
disorders and the effect of relevant treatments on patients, their environment 
and society as a whole are complex and challenging tasks. This particularly 
applies to externalizing disorders in adolescents where treatments often involve 
the systems around the patients and where a wide variety of societal costs and 
effects occur. Economic evaluations of such treatments do not yet seem to capture 
these broad and multifaceted costs and effects sufficiently. In this dissertation, 
we explored various ways to expand the scope of existing economic evaluations 
of interventions for externalizing disorders in adolescents to account for these 
broader costs and effects.
We started out by performing a ‘conventional’ cost-utility analysis (CUA) of 
pharmacological interventions extended with elements to account for broader 
societal costs. We then examined the available literature on cost-effectiveness 
analyses (CEA) and CUAs of systemic family interventions. Based on the 
literature, we observed a lack of state-of-the art economic evaluations as well as 
low quality of existing analyses of treatments for substance use and delinquency. 
Subsequently, we performed a CEA of a systemic family intervention and 
introduced a broad, yet very basic outcome measure specific to delinquency (i.e., 
criminal activity free years). Such evaluation proved to be feasible, yet lacked 
the comparability of outcomes facilitated by cost utility analyses. Therefore, we 
next explored steps towards broader CUAs of systemic family interventions. To 
do so, we first performed interviews among clinicians to establish whether the 
common QALY measure adequately captures all goals and relevant effects of 
systemic interventions. We also investigated which outcome dimensions may be 
missing within the current methodology (e.g. when using the EQ-5D instrument). 
Clinicians indicated that the EQ-5D captured several relevant dimensions yet 
lacked others. In line with these findings we took steps towards developing a 
broader, more comprehensive outcome measure. We systematically searched for 
existing outcome measures with broad dimensions and suitable to be used to 
obtain societal preference weights. We identified a broad, established instrument, 
which already is accepted in the field, and covers the broader domains that 
interventions for externalizing disorders aim to affect. Finally, we obtained 
societal preference weights for an abbreviated version of this instrument, suitable 
for self-completion, to facilitate its use in health economic evaluation.
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Summary
We can conclude that when performing economic evaluations and attempting to 
assess the societal costs and benefits of interventions for externalizing disorders 
in adolescents, more suitable methodology is needed. In this dissertation, various 
health economic techniques were explored and adapted in this context. We have 
attempted to investigate how the broad effects of treatments for externalizing 
disorders can be included in economic evaluations and have shown that the 
existing methodology, together with extensions and a preference-based broad 
measure, can be valuable in attaining this goal. We have taken first steps in 
further raising awareness of this issue and in improving the methodology of 
economic evaluations in this field.
In spite of our efforts, several questions remain unanswered and some of the 
explored directions (such as using a new outcome measure) also raise new 
questions (e.g. regarding comparability of results with other interventions). 
Future research could further investigate these issues in order to improve the 
methodology of economic evaluations in the context of mental disorders in 
general and of externalizing disorders in adolescents in particular.
Binnenwerk werkbestand Saskia.indd   255 28-10-2019   12:39:05
256
Samenvatting
Psychische aandoeningen hebben een hoge prevalentie. Behandelingen van 
zulke aandoeningen dienen aantoonbaar effectief en doelmatig te zijn om in 
aanmerking te komen voor schaarse, collectief gefinancierde middelen. Echter, 
het is een uitdagende taak om de kosten en effecten van de diverse behandelingen 
op de patiënt, zijn omgeving en de maatschappij als geheel accuraat in te schatten. 
Dit is in het bijzonder het geval voor externaliserende psychische aandoeningen 
bij adolescenten waarbij vaak ‘het systeem rondom de patiënt’ (zoals familie, 
buurt en school) bij de behandeling betrokken wordt en waarbij een breed scala 
aan maatschappelijke kosten en effecten ontstaan. Economische evaluaties van 
dergelijke behandelingen lijken op dit moment deze brede en uiteenlopende 
maatschappelijke kosten en effecten veelal buiten beschouwing te laten. In dit 
proefschrift is getracht bij te dragen aan de verbreding van de reikwijdte van 
economische evaluaties van behandelingen voor externaliserende problematiek 
bij adolescenten, teneinde het meewegen van bredere maatschappelijke kosten 
en opbrengsten te bevorderen.
Allereerst is een conventionele kosten-utiliteiten analyse (KUA) van 
farmacotherapeutische interventies uitgevoerd, waaraan enkele elementen van 
bredere maatschappelijke kosten werden toegevoegd in de analyse. Vervolgens 
hebben wij de bestaande literatuur over kosteneffectiviteitsanalyses (KEAs) en 
kostenutiliteitsanalyses (KUAs) van systeeminterventies bij externaliserende 
problematiek bij adolescenten, met name middelengebruik en delinquentie, 
gereviewd. Hierbij kwam naar voren dat er een gebrek is aan economische 
evaluaties op dit terrein en dat de schaarse gepubliceerde evaluaties vaak 
te wensen over laten in termen van kwaliteit. Daarna hebben wij een KEA 
van systeeminterventies uitgevoerd en hierbij een brede, zeer eenvoudige 
uitkomstmaat, specifiek voor delinquentie geïntroduceerd (namelijk criminaliteit-
vrije-jaren). De evaluatie met behulp van deze uitkomstmaat bleek uitvoerbaar, 
echter werd noodzakelijkerwijs hierdoor de vergelijkbaarheid van de uitkomsten 
met andere evaluaties verminderd en maakt de uitkomstmaat geen onderscheid 
tussen verschillende vormen van criminaliteit en is deze beperkt qua inhoud.
Derhalve zijn in het proefschrift aansluitend eerste stappen gezet om bredere 
KUAs van systeeminterventies mogelijk te maken. Allereerst hebben wij daartoe 
interviews met clinici gehouden om informatie in te winnen over de vermeende 
geschiktheid van een veelgebruikte uitkomstmaat die het mogelijk maakt QALYs 
te berekenen, de EQ-5D, om doelen en relevante effecten van systeeminterventies 
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te meten. Verder hebben wij de vraag voorgelegd welke dimensies volgens 
hen ontbraken in een conventionele economische evaluatie, waarin het EQ-5D 
instrument als uitkomstmaat wordt gebruikt. Clinici gaven aan dat de EQ-5D 
meerdere belangrijke dimensies omvat, echter dat er ook een aantal belangrijke 
dimensies ontbraken. In het verlengde van deze bevindingen hebben wij stappen 
gezet richting de ontwikkeling van een bredere, meer omvattende uitkomstmaat. 
We hebben systematisch gezocht naar bestaande instrumenten met brede 
dimensies die geschikt zouden zijn voor het verkrijgen van maatschappelijke 
waarderingsscores. We hebben een breed, bestaand instrument geïdentificeerd, 
dat reeds geaccepteerd is in het veld en dat de bredere domeinen afdekt die 
van belang zijn voor interventies voor externaliserende problematiek. Tenslotte 
hebben we maatschappelijke gewichten voor een verkorte versie van het 
instrument (waarbij de patiënt het instrument zelf invult) verkregen om het 
gebruik in economische evaluaties beter mogelijk te maken.
We kunnen concluderen dat beter passende methodologie nodig is voor het 
uitvoeren van economische evaluaties van interventies gericht op het behandelen 
van externaliserende problematiek, indien het doel is om alle maatschappelijke 
kosten en effecten mee te wegen. Binnen dit proefschrift hebben we in deze 
context diverse economische technieken geëxploreerd en aanpassingen 
voorgesteld. We hebben gepoogd te onderzoeken hoe de brede effecten van 
interventies voor externaliserende problematiek meegenomen kunnen worden 
binnen economische evaluaties en laten zien dat de bestaande methodologie, met 
verschillende aanvullingen en een maatschappelijk gewaardeerde uitkomstmaat, 
waardevol kunnen zijn om dit doel te bereiken. Daarmee zijn eerste stappen 
gezet om het bewustzijn met betrekking tot deze onderwerpen te vergroten en 
om de methodologie in dit veld te verbeteren.
Ondanks deze resultaten blijven veel vragen onbeantwoord en ook roepen 
sommige van de genoemde mogelijkheden (zoals het gebruik van een 
nieuwe uitkomstmaat) nieuwe vragen op (bijvoorbeeld met betrekking tot 
de vergelijkbaarheid van de uitkomsten met andere interventies). Toekomstig 
onderzoek zou dieper op deze vraagstukken kunnen ingaan teneinde de 
methodologie van economische evaluaties in de context van geestelijke 
gezondheid nog verder te verbeteren.
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